NCTID:NCT02599389||dmc_oversight:Yes||primary_outcome_count:2||primary_outcome_list:Incremental cost per Qaly gained at 18 months|18 months after angioplasty|,Incremental cost per avoided stenosis relapse at 18 months|18 months after angioplasty|,||||secondary_outcome_count:9||secondary_outcome_list:New In-stent restenosis during follow-up|1 month, 6 months, 12 months and 18 months after angioplasty|,A major adverse event|1 month, 6 months, 12 months and 18 months after angioplasty|,Improvement in the walking procedure|Before and 12 months after angioplasty|,Clinical improvement|6 months, 12 months and 18 months after angioplasty|,Systolic blood pressure Index|6 months, 12 months and 18 months after angioplasty|,new treatment for the treated lesion|6 months, 12 months and 18 months after angioplasty|,revascularization, with restenosis of the treated lesion|6 months, 12 months and 18 months after angioplasty|,recurrence of clinical symptoms|6 months, 12 months and 18 months after angioplasty|,Blood ultrasonic doppler velocimetry|6 months, 12 months and 18 months after angioplasty|,||||arm_group_count:3||arm_group_list:Standard balloon|Angioplasty with use of standard balloons,Drug-coated balloons|Angioplasty with use of drug-coated balloons,Drug-coated balloons and laser|Angioplasty with use of drug-coated balloons in association with Excimer Laser,||||inclusion_exclusion: Inclusion Criteria: - Patient of age > 18 years - Patient with previously peripheral implanted stent(s) located in or extending to the popliteal artery - Patient who received this stent between 3-36 months before inclusion - Patient with one or more in-stent restenosis lesion(s) > 70% in the same arterial segment in association with clinical symptoms of claudication or an critical limb ischemia with Rutherford classification of 2, 3, 4 or 5 - Reference vessel diameter between 4 and 7 mm - Patient affiliated to a social security regimen - EC-approved consent form signed by the participant and the investigator (must be signed prior initiation of any study related intervention) Exclusion Criteria: - Life expectancy >18 months - Patient already included in this study (recruitment of the contralateral leg is not allowed) - Patient contraindicated for the use of antiplatelet therapy - Pregnant or breast-feeding women - Patient with a target limb infection being treated - Patient with a procoagulant blood disease - Patient with history of contrast agents allergies - Patient with intolerance to paclitaxel - Patient with severe renal impairment (GFR <30 ml / min / 1.73 m²) or patient with a creatinine clearance <15 ml / min - External compression of previously implanted stent - Patient participating in any clinical trial using another investigational drug or product which could interfere with the interpretation of the trial results. - Patient under trusteeship or guardianship Angiographic exclusion criteria : - Inflow (above) severe lesion >70% or occlusion untreated satisfactorily (residual lesion> 50%) before the management of the target lesion - Perforation, dissection or lesions on the arterial network access requiring an assumption prior to randomization - Stent fracture grade 4 or 5 at the target lesion ||mesh_term:||||
NCTID:NCT02710656||dmc_oversight:No||primary_outcome_count:1||primary_outcome_list:Efficacy measured by binary restenosis rate|Until 12 months after procedure|,||||secondary_outcome_count:7||secondary_outcome_list:Immediate procedural outcome of percutaneous balloon angioplasty|From start of procedure surgery until completion of procedure surgery (Percutaneous balloon angioplasty)|,Rutherford|Baseline until 12 months after procedure|,Mortality|Until 12 months after procedure|,Repeated target lesion revascularization (TLR) rate|Until 12 months after procedure|,Repeated target extremity revascularization (TER) rate|Until 12 months after procedure|,Minor and major amputation rate|Until 12 months after procedure|,Ankle-Brachial Index (ABI)|Baseline until 12 months after procedure|,||||arm_group_count:2||arm_group_list:Drug Coated Balloon (DCB) - Legflow®|Percutaneous balloon angioplasty performed with the investigational device, the paclitaxel eluting Legflow® balloon.,Standard PTA - POBA|Percutaneous balloon angioplasty performed with the clinical standard, that is, a non-drug eluting balloon (POBA, plain old balloon angioplasty).,||||inclusion_exclusion: Inclusion Criteria: 1. Patient must sign the informed consent form prior to the index-procedure. 2. Patient must be older than 18 years. 3. Patient with Rutherford 2, 3 and 4.. 4. Target lesion is an occlusion or ≥70% stenosis (visual estimate) located in SFA or popliteal artery (P1 -P2). 5. Maximum length of the target lesion is 13 cm. 6. Target lesion is TASC A, B or C. 7. Target lesion is a de novo lesion or restenotic lesion (previously POBA treated, in-stent restenosis is not allowed). 8. Inflow arteries are free from hemodynamically significant obstruction (i.e. ≥ 50% diameter stenosis). It is allowed to treat inflow lesions during the index-procedure if the result is ≤ 30% diameter stenosis (treatment with DCB or DES is not allowed). Treatment of a non-target lesion in the target vessel is allowed if the nontarget lesion is considered to be an inflow lesion. 9. Popliteal artery P3 segment (below knee popliteal artery) is free from hemodynamically significant obstruction (i.e. ≥ 50%). Treatment of a lesion in this segment is not allowed during the index-procedure. 10. At least 1 patent (< 50% diameter stenosis) below-the-knee vessel (anterior tibial artery, posterior tibial artery or peroneal artery) till the ankle as confirmed by baseline angiography. Exclusion Criteria: 1. Patient is already included in this study (recruitment of the contralateral leg is not allowed). 2. Patient has a known intolerance to antiplatelet therapy or contrast agent. 3. Patient with known sensitivity to Paclitaxel. 4. Patient is pregnant or patient intends to become pregnant within 1 year after the index-procedure. 5. Patient takes esomeprazole or omeprazole. 6. Patient with serum creatinine >2.0 mg/dL or renal dialysis. 7. Patient suffers from acute limb ischemia defined as any sudden decrease in limb perfusion causing a potential threat to limb viability. 8. Patient has a life expectancy <2 years. 9. Patient with Rutherford 0, 1 , 5 and 6. 10. Patient has a target lesion that is severely calcified (grade 3 and grade 4). 11. Patient with a TASC D lesion. 12. Patient has an acute thrombus or aneurysm in the target vessel. 13. Patient has a target lesion that cannot be crossed with a guidewire. 14. Target vessel has been treated previously with a DCB or a DES. 15. Treatment of outflow lesions during the index-procedure. 16. Patients with significant disease of all 3 infrapopliteal vessels (i.e. ≥ 50% diameter stenosis in each vessel). 17. Any scheduled surgery within 3 months after the index-procedure that would necessitate the discontinuation of clopidogrel. 18. Patients with previous bypass surgery involving the SFA. 19. Patient has cirrhosis of the liver. ||mesh_term:Atherosclerosis,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT01221610||dmc_oversight:Yes||primary_outcome_count:1||primary_outcome_list:Assessment of the 6 months late lumen loss in the target lesion measured by quantitative vascular angiography (QVA).|6 months|,||||secondary_outcome_count:5||secondary_outcome_list:6 months binary restenosis rate|6 months|,6 months and 12 months TLR rate|6 and 12 months|,6 months and 12 months change in mean ABI|6 and 12 months|,6 months and 12 months change in Rutherford class|6 and 12 months|,Major Adverse Event rate at 6 and 12 months (procedure- or device-related death or amputation, target lesion thrombosis and clinically driven TLR)|6 and 12 months|,||||arm_group_count:2||arm_group_list:Drug Releasing Balloon|Passeo-18 Lux Drug Releasing Balloon catheter,Standard PT A (POBA)|Uncoated Passeo-18 PTA catheter,||||inclusion_exclusion: Inclusion Criteria: 1. Age ≥ 50 years, 2. Informed consent signed by patient prior to randomization 3. Single or sequential de novo or restenotic lesions (stenosis ≥ 70% diameter reduction or occlusion) in the femoropopliteal arteries ≥ 30 mm and ≤ 200 mm long 4. Rutherford Class 2 - 5 in the target limb 5. Reference Vessel Diameter (RVD) 3 - 7 mm, based on visual estimation 6. Inflow free from flow-limiting lesion (< 50% stenosis) confirmed by angiography. Patients with flow-limiting inflow lesions (> 50% stenosis) can be included if lesion has been treated successfully before the index procedure 7. At least one non-occluded crural vessel (eg without significant stenosis) with angiographically documented run-off to the foot 8. Successful wire crossing of the lesion 9. Willingness to comply with all specified follow-up evaluations 10. Male or negative pregnancy test of women in childbearing age Exclusion Criteria: 1. Co-morbid conditions limiting life expectancy ≤ 1 year 2. Patient currently participating in another clinical trial 3. Lesions which are untreatable with PTA or other interventional techniques 4. The target stenosis is located distal to a stenosis ≥ 50% that cannot be pre-treated because the drug coating could get lost during crossing the proximal lesion 5. Thrombus in the target vessel, documented by angiography 6. Target lesion is severely calcified, documented by angiography 7. Prior bypass surgery of target vessel 8. Previously implanted stent in the target lesion 9. Treatment of bifurcation required 10. Planned amputation of the target limb 11. Flow-limiting (> 50% DS) Inflow lesion proximal to target lesion, left untreated 12. Failure to obtain <30% residual stenosis in a pre-existing haemodynamically significant (>50% DS) inflow lesion in the ipsilateral iliac or proximal SFA. (DEB or DES not allowed for the treatment of inflow lesion) 13. Additional hemodynamically relevant proximal and distal lesions with stenosis ≥ 50 %, except iliac arteries, are excluded. Iliac artery lesion treatments have to be successful with a residual stenosis ≤ 30 % 14. Haemorrhagic diathesis or another disorder such as gastrointestinal ulceration or cerebral circulatory disorders which restrict the use of platelet aggregation inhibitor therapy and anticoagulation therapy 15. Phenprocoumon intake 16. Impaired renal function (creatinine ≥ 2.0 - 2.5 mg/dl), according to investigator assessment 17. Known allergy to contrast media that cannot be adequately controlled with pre-medication 18. Allergy, intolerance or hypersensitivity to Paclitaxel structurally or related compounds and/or to the delivery matrix n-Butyryl tri-nhexyl citrate (BTHC) ||mesh_term:Atherosclerosis,Vascular Diseases,Peripheral Arterial Disease,Arteriosclerosis,||||
NCTID:NCT01867736||dmc_oversight:Yes||primary_outcome_count:2||primary_outcome_list:Safety: Major adverse event rate (MAE), defined as all cause death, major amputation of target extremity, target lesion thrombosis, target lesion revascularisation (TLR)and target vessel revascularization (TVR) at 30 days.|30 days|,Performance: Target lesion primary patency rate at 6 months assessed by quantitative vascular angiogram (QVA).|6 months|,||||secondary_outcome_count:12||secondary_outcome_list:Target lesion failure, assessed by target lesion revascularization (TLR) rate at 6 months and 12 months|6 and 12 months|,Target vessel revascularization (TVR) rate at 6 months and 12 months|6 and 12 months|,Binary re-stenosis rate at 6 months, assessed by QVA|6 months|,Major adverse event rate, defined as all cause death, major amputation of target extremity, target lesion thrombosis, TLR and TVR at 6 months and 12 months|6 and 12 months|,Change in mean ABI at discharge, 30 days, 6 months and 12 months|Discharge, 30 days, 6 months and 12 months|,Change in Rutherford classification at 30 days, 6 months and 12 months|30 days, 6 months and 12 months|,Quality of life evaluation, assessed by EQ5D questionnaire at baseline, 30 days, 6 months and 12 months|Baseline, 30 days, 6 months and 12 months|,Duplex based primary patency at 30 days, 6 months and 12 months|30 days, 6 months and 12 months|,Procedural success, defined as successful vascular access, completion of endovascular procedure and immediate morphologic success with a residual stenosis <30%.|Day 0|,Device success, defined as exact deployment according to Instructions For Use|Day 0|,Technical success, defined as device or procedural success without the occurrence of major adverse events during the hospital stay.|Participants will be followed for the duration of hospital stay, an expected average of 1-2 days|,Late Lumen Loss|6-months post-procedure|,||||arm_group_count:2||arm_group_list:Passeo-18 Lux DRB|Passeo-18 Lux Drug Releasing Balloon catheter,Standard PTA (POBA)|Uncoated Passeo-18 PTA balloon catheter,||||inclusion_exclusion: Inclusion Criteria: 1. Subject has provided written informed consent. 2. Subject is willing and able to comply with follow-up evaluations. 3. Subject is ≥ 18 years old. 4. Single or sequential de novo or restenotic lesions (stenosis ≥ 70% diameter reduction or occlusion) in the infrapopliteal arteries ≥ 30 mm. Lesions should not extend beyond the ankle joint. 5. A maximum of 2 different vessels can be treated: successful wire crossing is required for the first target vessel before randomization occurs. 6. Subject with PAD or critical limb ischemia according to the current guidelines in need for urgent revascularization to relieve symptoms and improve walking capacity. 7. Reference Vessel Diameter (RVD) 2 - 4 mm, based on visual estimation. 8. Inflow free from flow-limiting lesion confirmed by angiography. Patients with flow-limiting inflow lesions (> 50% stenosis) can be included if lesion(s) have been treated successfully before the index procedure, with a maximum residual stenosis of 30% per visual assessment. 9. At least one non-occluded crural vessel with angiographically documented run-off to the foot. 10. Successful wire crossing of the lesion. Exclusion Criteria: 1. Flow-limiting (> 50% DS) inflow lesion proximal to target lesion, left untreated. 2. Failure to obtain <30% residual stenosis in a pre-existing haemodynamically significant (>50% DS) inflow lesion (DEB or DES not allowed for the treatment of inflow lesions). 3. Infrapopliteal lesions extending beyond the ankle joint and involving crural vessels. 4. Acute thrombus in the target vessel (eg complication of inflow lesion treatment) documented by angiogram, if not treated successfully prior to enrolment). 5. Planned major amputation above the ankle of target limb, or any other planned major surgery within 30 days post-procedure. 6. Previous bypass surgery of target vessel. 7. Previously implanted stent in target lesion. 8. Haemorrhagic diathesis or coagulopathy or other disorders such as gastrointestinal ulcerations or cerebral disorders that would restrict prescription of dual anti-platelet therapy. 9. Subject with hepatic failure, deep vein thrombosis, thrombophlebitis, systemic lupus erythematous or subject is on immunosuppressant therapy. 10. Subject with acute MI ≤ 3 months. 11. Renal failure with a creatinine of ≥ 2,5 mg/dl, except patients currently on regular dialysis. 12. Phenprocoumon intake, except for patients who are treated for Arterial Fibrillation. For these patients Phenprocoumon treatment can be interrupted and re-started after treatment with Dual Antiplatelet Therapy for 4 weeks post procedure. 13. Known allergy to contrast media used for angiography that cannot be controlled by pre-medication with steroids and/or antihistaminica. 14. Allergy, intolerance or hypersensitivity to Paclitaxel or related compounds and/or to the delivery matrix n-Butyryl tri-n-hexyl citrate(BTHC). 15. Co- morbid conditions limiting life expectancy ≤ 1 year. 16. Patients that are under active treatment for cancer; Patients, who have been successfully treated for cancer in the past, can be included. 17. Subject is participating in another clinical device trial where the primary endpoint has not yet been reached. 18. Pregnant and/or breast-feeding females or females who intend to become pregnant during the time of the study. ||mesh_term:Atherosclerosis,Vascular Diseases,Peripheral Arterial Disease,Arteriosclerosis,||||
NCTID:NCT00696956||dmc_oversight:No||primary_outcome_count:1||primary_outcome_list:Primary endpoint: Late lumen loss (LLL) of the target lesion after 6 months (assessed by DSA)|after 6 months|,||||secondary_outcome_count:16||secondary_outcome_list:Interventional success rate (defined as reststenosis less than 50%)|up to 18 months|,Restenosis rate at 6 and 18 months (restenosis rate is defined as a diameter stenosis of ≥ 50% of reference diameter|up to 18 months|,Minimum lumen diameter (MLD) at 6 months|up to 18 months|,Target lesion revascularization recorded at 6, 12 and 18 months; target lesion revascularization is defined as any reintervention or artery bypass graft surgery involving the target lesion.|up to 18 months|,Target vessel revascularization recorded at 6, 12 and 18 months|up to 18 months|,Target limb revascularization recorded at 6, 12 and 18 months|up to 18 months|,Improvement of clinical stage at 6, 12 and 18 months|up to 18 months|,Change in ABI compared to pretreatment if vessels are compressible|up to 18 months|,Hospitalization (extra days due to complications of the index procedure) and hospitalization between the follow-up visits due to the index leg|up to 18 months|,Major amputations at the index limb|up to 18 months|,Mortality|up to 18 months|,LLL of stented segments at 6 months comparing the uncoated and the coated bal-loon group.|up to 18 months|,Subgroup analysis; primary endpoint and TLR|up to 18 months|,LLL, MLD and restenosis rate at 18 month follow-up determined by angiography|up to 18 months|,Subgroup analysis neuropathy and no neuropathy according to clinical improve-ment in patients classified Rutherford 5|up to 18 months|,Clinical benefit patients Rutherford 3 vs. Rutherford 4 and 5|up to 18 months|,||||arm_group_count:2||arm_group_list:A|Normal balloon for balloon angioplasty (Submarine, Ampherion Deep by Invatec),2|Paclitaxel coated balloon (same balloon like in the control group, but coated with 3 µg/mm2 Paclitaxel),||||inclusion_exclusion: Inclusion Criteria: - Age between 18 and 95 years, - peripheral vascular disease, Rutherford stage 3-5, diameter stenosis ≥ 70 %, ≥ 15 -150 mm length, up to 2 vessels to be treated Exclusion Criteria: - Disease associated with life-expectancy less than 18 months - Acute thrombus or aneurysm in the index limb/ vessel - Doubts in the willingness or capability of the patient to allow follow up examination ||mesh_term:Atherosclerosis,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT00930813||dmc_oversight:Yes||primary_outcome_count:1||primary_outcome_list:Angiographic Late Lumen Loss|6 months|,||||secondary_outcome_count:10||secondary_outcome_list:Safety - Device Related Adverse Events|30 days|,Primary Patency of Treated Segment|6, 12, 24 months|,Target Lesion Revascularization|6, 12, 24 months|,Target Vessel Revascularization|6, 12, 24 months|,Device Success|at procedure|,Procedural Success|at procedure|,Change in Ankle-brachial Index|pre-procedure, 6, 12 and 24 months|,Change in Walking Impairment Questionnaire (WIQ)|pre-procedure, 6, 12 and 24 months|,Change in Rutherford Grade|pre-procedure,6, 12 and 24 months|,Serum Paclitaxel Levels - in Subsets of Patients|0, 1, 3 hours and pre-discharge|,||||arm_group_count:2||arm_group_list:Lutonix Catheter|Paclitaxel coated Balloon Catheter,Standard uncoated Balloon Angioplasty Catheter|uncoated angioplasty balloon,||||inclusion_exclusion: Inclusion Criteria: Clinical Criteria - Male or non-pregnant female ≥18 years of age. - Rutherford Clinical Category 2-5 - Patient is willing to provide informed consent and comply with the required follow up visits, testing schedule, and medication regimen Angiographic Criteria - A single de novo or restenotic atherosclerotic lesion >70% in the SFA or popliteal artery that is ≥4 cm and ≤15 cm in total length. - Reference vessel diameter ≥4 mm and ≤ 6mm - Successful wire crossing of lesion - A patent inflow artery free from significant lesion (>50% stenosis) as confirmed by angiography (treatment of target lesion acceptable after successful treatment of inflow artery lesions) Exclusion Criteria: - Pregnant or planning on becoming pregnant in < 2yrs - Live expectancy of <2 years - Patient actively participating in another investigational device or drug study - History of hemorrhagic stroke within 3 months - Previous or planned surgical or interventional procedure within 30 days of index procedure - Chronic renal insufficiency with creatinine >2.5 mg/L - Prior surgery of the target lesion - Inability to take required study medications - Anticipated use of IIb/IIIa inhibitor prior to randomization - Lesion length is <4 cm or >15 cm or there is no normal proximal arterial segment in which duplex ultrasound velocity ratios can be measured - Known inadequate distal outflow - Significant inflow disease - Acute or sub-acute thrombus in target vessel - Severe lesion calcification - Acute vessel occlusion or sudden symptom onset - Use of adjunctive therapies (i.e. laser, atherectomy, cryoplasty, scoring/cutting balloon, etc.) - Prior participation in the current study ||mesh_term:Atherosclerosis,Vascular Diseases,Arteriosclerosis,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT01594684||dmc_oversight:No||primary_outcome_count:1||primary_outcome_list:Late Lumen Loss (LLL)|6 +/-2 months|,||||secondary_outcome_count:12||secondary_outcome_list:• Procedural success|after intervention|,Target lesion revascularization (TLR)|6, 12 and 24 months|,Target vessel revascularization (TVR)|6, 12 and 24 months|,Binary restenosis rate|6, 12 and 24 months|,Rutherford category|6, 12 and 24 months|,Ancle Brachial index (ABI)|6, 12 and 24 months|,Late lumen loss (LLL)|24 months|,Minimum lumen diameter (MLD)|12 and 24 months|,Hospitalization|6, 12 and 24 months|,safety|30days|,resteosis pattern|6 and 24 months|,Target lesion revascularization (TLR), clinical success and angiographic outcome (restenosis rate, late lumen loss) after second therapy|after intervention, 6, 12 and 24 months|,||||arm_group_count:3||arm_group_list:drug eluting balloon|treatment with drug eltuing balloon,uncoated balloon|treatment with uncoated balloon,double drug eluting balloon|if treatment fails 30 days or later,||||inclusion_exclusion: Inclusion Criteria: 1. In-stent restenosis or re-occlusion at the target lesion due to an interventional treatment > 3 months prior to enrollment. 2. Has evidence of ≥ 70% stenosis or occlusion in the SFA and/or popliteal confirmed by angiography that is 3-27 cm long. 3. Reference vessel diameter of 3 to 7 mm (reference vessel diameter = normal vessel diameter 1 cm proximal of the index lesion) 4. Patients (men and women) with PAD disease category 2 to 5 according to Rutherford classification. 5. Patient is eligible for an operative vascular intervention in case of complications during the procedure. 6. Female patients of child bearing potential must have a negative pregnancy test 7 days at theprior to the time of intervention. 7. Fully informed and signed consent must be obtained from each patient. 8. Patients must be willing and able to continue study participation following study procedure in order to ensure completion of all procedures and observations required by protocol. 9. Patient has evidence of at least one run off vessel that does not also require treatment for significant (≥ 50% stenosis or occlusion) stenosis during the index procedure to the ankle/foot of the limb to be treated. Treatment of infrapopliteal lesions must be staged at least 30 days before or after the index procedure. 10. If restnosis occurs in both arms 30 days or later (re-re-sternosis)- treament with two drug eluting balloons at the same location (double dose) Exclusion Criteria: 1. Patients with more than two lesions in the target vessel requiring treatment (if the distance between two lesions is less than 2 cm, the lesions should be counted as one lesion). The second lesion should also be treated with either coated or uncoated balloons (according to the randomization) 2. Guidewire cannot cross lesion and/or an intentional subintimal approach in the stented lesion is required. 3. Patients with stent fractures grade 2-4. 4. Inflow lesion (proximal to the study lesion) with flow limitation not being successfully treated prior to treatment of the study lesion. 5. Acute thrombosis of the study lesion requiring lysis or thrombectomy prior to the treatment of the study lesion. 6. Acutely occurring symptoms with a lyses or an operation as a therapeutic option within the last 6 weeks within the study limb. 7. Potential loss of leg due to critical or acute ischemia. 8. No patent distal run-off vessel. 9. Aneurysm in the blood vessel intended for intervention in this study. 10. Blood platelet count < 100.000/mm3 or >700.000/mm3, leukocyte count < 3.000/mm3. 11. Contra-indication to anticoagulation, or any anti-platelet agent (e.g. aspirin, heparin, clopidogrel, ticlopidine, abciximab), or paclitaxel. 12. Known intolerance or contra-indication (e.g. severe hepatic (with ALAT and/or ASAT > 3 times the normal reference range) or renal (creatinine > 1.1 mg/dl in women and >1.5 mg/dl in men) to contrast agents which cannot be adequately pre-treated, e.g. with adequate hydration. 13. Severe illnesses such as cancer, liver or renal diseases, myocardial insufficiency leading to protocol deviations and/or a reduced life expectancy of less than 2 years. 14. Manifest hyperthyreosis. 15. Latent hyperthyreosis without adequate therapy, e.g., previous blocking with Natriumperchlorat (Irenat®). 16. Significant gastrointestinal hemorrhage within the previous 6 months prior to study participation. 17. History of hemorrhagic diathesis or coagulopathy or rejection of blood transfusions. 18. Medical reason against double anti-platelet therapy in anti-coagulated patient, e.g., receiving coumadine. 19. Any severe medical condition that might interfere with the interpretation of the data or result in an unacceptable risk for the patient's participation in the study, according to the judgment of the clinical investigator. 20. Female patient who is pregnant or lactating. 21. Patient under 18 years of age. 22. Participation in another clinical study up to 30 days prior to study entry. 23. Previous participation in the same trialstudy (only one leg can be treated within the study). ||mesh_term:Paclitaxel,||||
NCTID:NCT02498080||dmc_oversight:No||primary_outcome_count:1||primary_outcome_list:binary restenosis rate|12-months|,||||secondary_outcome_count:4||secondary_outcome_list:clinically driven target lesion revascularization (CD-TLR) rate|12-months|,major amputations rate|12-months|,wound healing rate|12-months|,target vessel occlusion rate|12-months|,||||arm_group_count:2||arm_group_list:DEB PTA|Devices: paclitaxel drug eluting balloon PTA,standard PTA|devices: standard balloon PTA,||||inclusion_exclusion: Inclusion Criteria: - patients with CLI (Rutherford classes 4, 5, 6); - stenosis and/or complete occlusion of P3 popliteal artery segment; - stenosis and/or complete occlusion of at least 1 leg vessel >40 mm in length; - life-expectancy >12 months; - possibility to perform angiogram at 12-months follow-up. Exclusion Criteria: - life-expectancy <12 months; - iodinated contrast media or paclitaxel allergy; - impossibility to undergo dual antiplatelet therapy. ||mesh_term:Ischemia,||||
NCTID:NCT01558505||dmc_oversight:No||primary_outcome_count:1||primary_outcome_list:angiographic binary restenosis|12 months|,||||secondary_outcome_count:3||secondary_outcome_list:major amputation|24 motnhs|,target lesion revascularization|24 months|,vessel reocclusion|24 months|,||||arm_group_count:2||arm_group_list:standard PTA|conventional balloon angioplasty,Drug-eluting balloon angioplasty|paclitaxel-eluting balloon angioplasty,||||inclusion_exclusion: Inclusion Criteria: - age>18 years - angiographic stenosis>50% or occlusion of one below-knee vessel Exclusion Criteria: - allergy to Paclitaxel - contraindication for combined antiplatelet treatment - life expectancy <1 year - hypersensitivity or contraindication to one of the study drugs - lack of consent - need for amputation ||mesh_term:Ischemia,||||
NCTID:NCT03175744||dmc_oversight:Yes||primary_outcome_count:4||primary_outcome_list:Freedom from Major Adverse Limb Event (MALE)|30 days|,Freedom from Perioperative Death (POD)|30 days|,Patency|6 months|,Limb Salvage|6 months|,||||secondary_outcome_count:3||secondary_outcome_list:Clinically-driven target lesion revascularization|6 months|,Major adverse event rates|6 months|,Patency rate|6 months|,||||arm_group_count:2||arm_group_list:Stellarex DCB|Spectranetics Stellarex Drug Coated Balloon,PTA Catheter|Standard Uncoated Balloon Angioplasty Catheter,||||inclusion_exclusion: Inclusion Criteria: - Rutherford Clinical Category 4-5 - Life expectancy > 1 year - Significant stenosis ≥70% - Patent inflow artery - Target vessel(s) diameter between 2 and 4 mm - Target vessel(s) reconstitute(s) at the ankle Exclusion Criteria: - Pregnant or planning to become pregnant - History of stroke within 3 months - Planned major amputation - eGFR <30 - Acute limb ischemia - Prior stent placement in target lesion ||mesh_term:Ischemia,||||
NCTID:NCT02963649||dmc_oversight:No||primary_outcome_count:1||primary_outcome_list:Efficacy: Late lumen loss (LLL) at 9 months|9 Months|,||||secondary_outcome_count:6||secondary_outcome_list:Composite Safety Endpoint|9 Months|,Major Adverse Event (MAE) rate|through 3, 6, 9, 12, 24 and 36 months|,Status of wound healing|at 30 days, 3, 6, 9, 12, 24 and 36 months|,Thrombosis at the target lesion|through 30 days, 3, 6, 9, 12, 24 and 36 months|,Device success|at the time of procedure|,Clinical success|up to discharge visit|,||||arm_group_count:2||arm_group_list:drug-eluting balloon IN.PACT 014|product is indicated for PTA in patients with obstructive disease of peripheral arteries with paclitaxel drug - elution.,Standard angioplasty balloon|standard PTA balloon,||||inclusion_exclusion: Inclusion Criteria: 1. Age ≥18 years. 2. Subject has been informed of the nature of the study, agrees to participate and has signed an EC approved consent form. 3. Female subjects of childbearing potential have a negative pregnancy test ≤7 days before the procedure and are willing to use a reliable method of birth control for the duration of study participation; 4. Subject has documented chronic Critical Limb Ischemia (CLI) in the target limb prior to the study procedure with Rutherford Clinical Category 4 or 5 . 5. Life expectancy >1 year in the Investigator's opinion. 6. Reference Vessel Diameter (RVD) 2 - 4 mm, and confirmed by DUS assessment. 7. Presence of documented run-off to the foot 8. Inflow free from flow-limiting lesion confirmed by angiography. 9. Successful pre-dilatation of the (entire) target lesion. Exclusion Criteria: 1. Subject unwilling or unlikely to comply to the appropriate follow-up times for the duration of the study. 2. Prior stent(s) or bypass surgery within the target vessel(s) (including stents placed within target vessels during the index procedure prior to randomization. 3. Previous DCB of the target vessel within 6 months prior to index procedure. 4. Aneurysm in the target vessel. 5. Angiographic evidence of thrombus within target limb. 6. Recent MI or stroke < 30 days prior to the index procedure. 7. Heart failure with Ejection Fraction < 30%. 8. Impaired renal function (GFR <20 mL/min) and patients on dialysis. 9. Subject with vasculitis, systemic Lupus Erythematosus or Polymyalgia Rheumatica on active treatment. 10. Patient receiving systemic corticosteroid therapy. 11. Known allergies or sensitivities to heparin, aspirin (ASA), other anticoagulant/anti-platelet therapies which could not be substituted, and/or paclitaxel or an allergy to contrast media that cannot be adequately pre-treated prior to the index procedure. 12. The patient is currently enrolled in another investigational device or drug trial that is interfering with the endpoints of this study. ||mesh_term:Peripheral Arterial Disease,Peripheral Vascular Diseases,Ischemia,Paclitaxel,||||
NCTID:NCT01816412||dmc_oversight:Yes||primary_outcome_count:1||primary_outcome_list:Composite of freedom from all-cause peri-operative (≤30 day) death and freedom at 6 months from the following: index limb amputation (above or below the ankle), index limb re-intervention, and index-limb-related death.|6 months|,||||secondary_outcome_count:2||secondary_outcome_list:Safety|1, 3, 6, 12 and 24 months|,Efficacy|1, 3, 6, 12 and 24 months|,||||arm_group_count:2||arm_group_list:LDCB|Paclitaxel Coated Balloon,PTA|Standard Uncoated Balloon Angioplasty Catheter PTA Catheter,||||inclusion_exclusion: Inclusion Criteria: - Male or non-pregnant female ≥20 years of age; - Rutherford Clinical Category 2-4; - Length ≤15 cm; - ≥70% stenosis - Lesion location starts ≥1 cm below the common femoral bifurcation and terminates distally ≤2 cm below the tibial plateau AND ≥1 cm above the origin of the TP trunk; - A patent inflow artery as confirmed by angiography - At least one patent native outflow artery to the ankle Exclusion Criteria: - Life expectancy of < 2 years; - History of hemorrhagic stroke within 3 months; - Previous or planned surgical or interventional procedure within 2 weeks before or within 30 days after the index procedure; - History of MI, thrombolysis or angina within 2 weeks of enrollment; - Renal failure or chronic kidney disease - Severe calcification that renders the lesion un-dilatable ||mesh_term:Constriction, Pathologic,Paclitaxel,||||
NCTID:NCT02063672||dmc_oversight:Yes||primary_outcome_count:2||primary_outcome_list:Percentage of Participants With Primary Patency at 1 Year|12 Months|,Percentage of Participants Without Primary Safety Events|12 Months|,||||secondary_outcome_count:18||secondary_outcome_list:Percentage of Participants With Device Success|During the Index Procedure (90 mins)|,Percentage of Participants With Technical Success|During the Index Procedure (90 mins)|,Percentage of Participants With Procedural Success|During the Index Procedure (90 mins)|,Percentage of Participants With Primary Patency at 6 and 12 Months|6 months and 12 months|,Percentage of Participants With Secondary Patency at 6 Months and 12 Months|6 months and 12 months|,Percentage of Participants Without Clinically Driven Target Lesion Revascularization (TLR)|6 months and 12 months|,Percentage of Participants Without Target Lesion Revascularization (TLR)|6 months and 12 months|,Percentage of Participants With Sustained Clinical Benefit Compared to Baseline|6 months and 12 months|,Change of Rutherford Classification From Baseline|6 months and 12 months|,Change of Resting Ankle Brachial Index (ABI) From Baseline|6 months and 12 months|,Change in Walking Impairment Questionnaire From Baseline|6 months and 12 months|,Change in Quality of Life From Baseline|6 months and 12 Months|,Percentage of Participants Without Major Vascular Complications (≤30 Day)|30 Days|,Percentage of Participants Without All-Cause Death|1 month, 6 months, and 12 months|,Percentage of Participants Without Major Limb Amputation|1 month, 6 months, and 12 months|,Percentage of Participants Without Minor Limb Amputation|1 month, 6 months, and 12 months|,Percentage of Participants Without Target Vessel Revascularizations (TVR)|1 month, 6 months, and 12 months|,Percentage of Participants Without Any Target Limb Reinterventions|1 month, 6 months, and 12 months|,||||arm_group_count:2||arm_group_list:Lutonix DCB|Lutonix Paclitaxel Drug Coated Balloon,PTA Catheter|Standard Uncoated Balloon Angioplasty Catheter,||||inclusion_exclusion: Key Inclusion Criteria: 1. Male or non-pregnant female ≥18 years of age 2. Rutherford Clinical Category 2-4 3. Significant (≥ 50%) restenosis of a previous bare (not covered and not drug-eluting) nitinol stent(s) in the femoropopliteal artery 4. Lesion measures between 4 and 18 cm 5. Target vessel diameter between ≥4 and ≤6 mm and able to be treated with available device size matrix 6. A patent inflow artery free from significant lesion (≥50% stenosis) as confirmed by angiography 7. Successful crossing and predilatation of the target lesion with a guidewire 8. At least one patent native outflow artery to the ankle, free from significant (≥50%) stenosis as confirmed by angiography that has not previously been (nor planned to be) revascularized 9. No other prior vascular or surgical interventions within 2 weeks before and/or planned 30 days after the protocol treatment Key Exclusion Criteria: 1. Life expectancy of <1 year 2. Patient is currently participating in an investigational drug or other device study or previously enrolled in this study NOTE: Enrollment in another drug or device clinical trial during the follow up period is not allowed 3. History of stroke within 3 months 4. History of MI, thrombolysis or angina within 2 weeks of enrollment 5. Prior vascular surgery of the index limb, with the exception of remote common femoral patch angioplasty separated by at least 2 cm from the target lesion 6. Target lesion involves a previously placed covered stent or drug-eluting stent 7. Grade 4 or 5 stent fracture (mal-aligned components or trans-axial spiral configuration) in the restenotic stent 8. Inability to take required study medications or allergy to contrast that cannot be adequately managed with pre- and post-procedure medication 9. Known inadequate distal outflow (>50 % stenosis of distal popliteal and/or all three tibial vessels), or planned future treatment of vascular disease distal to the target lesion 10. Intended use of adjunctive treatment modalities (i.e. laser, atherectomy, cryoplasty, scoring/cutting balloon, stents, etc.) ||mesh_term:||||
NCTID:NCT01566461||dmc_oversight:Yes||primary_outcome_count:2||primary_outcome_list:Primary Patency|12 month|,Primary Safety Composite|12 month|,||||secondary_outcome_count:18||secondary_outcome_list:Major Adverse Event (MAE) Composite|12 month|,All-cause Death|12 month|,Target Vessel Revascularization (TVR)|12 month|,Target Lesion Revascularization (TLR)|12 month|,Time to First Clinically Driven Target Lesion Revascularization (CD-TLR)|12 month|,Major Target Limb Amputation|12 month|,Thrombosis at the Target Lesion|12 month|,Primary Sustained Clinical Improvement|12 month|,Secondary Sustained Clinical Improvement|12 month|,Duplex-defined Binary Restenosis (Peak Systolic Velocity Ratio (PSVR) >2.4)|12 month|,Duplex-defined Binary Restenosis (Peak Systolic Velocity Ratio (PSVR) >3.4)|12 month|,Quality of Life Assessment by EuroQol Group 5-Dimension Self-Report Questionnaire (EQ5D)|12 month|,Change in Walking Distance as Assessed by Six Minute Walk Test (6MWT)|From baseline to 12 month|,Walking Capacity Assessment by Walking Impairment Questionnaire (WIQ)|12 month|,Device Success|Day 1|,Procedural Success|Day 1|,Clinical Success|Day 1|,Days of Hospitalization Due to the Index Lesion|12 month|,||||arm_group_count:2||arm_group_list:Drug-Coated Balloon (DCB)|IN.PACT Admiral: Balloon Angioplasty,Standard PTA|Standard Percutaneous Balloon Angioplasty (PTA) Balloon: Balloon Angioplasty,||||inclusion_exclusion: Inclusion Criteria: - Age: > or equal to 18 years and < or equal to 85 years - Documented ischemia with Rutherford classification 2, 3, or 4 - Target lesion in the SFA and/or PPA - Angiographic evidence that target lesion consists of a single de novo or non-stented restenotic lesion or is a combination lesion that meets the following criteria: 1. 70 - 99% occlusion by visual estimate with lesion length > or equal to 4 cm and < or equal to 18 cm 2. 100% occlusion by visual estimate with lesion length < or equal to 10 cm 3. Combination lesions must have a total lesion length of > or equal to 4 cm and < or equal to 18 cm with an occluded segment that is < or equal to 10 cm (by visual estimate) - Target vessel diameter > or equal to 4 mm and < or equal to 7 mm - Angiographic evidence of adequate distal run-off to the ankle - Able to walk without assistive devices Exclusion Criteria: - Stroke or heart attack within 3 months prior to enrollment - Enrolled in another investigational drug, device or biologic study - Any surgical procedure or intervention performed within 30 days prior to or post index procedure - SFA or PPA disease in the opposite leg that requires treatment at the index procedure - Failure to successfully cross the target lesion - Angiographic evidence of severe calcification - Target lesion requires treatment with alternative therapies such as stenting, laser, atherectomy, cryoplasty, brachytherapy, re-entry devices) - Known allergies or sensitivity to heparin, aspirin, other anticoagulant/antiplatelet therapies, paclitaxel or contrast media that cannot be adequately pre-treated prior to index procedure - Chronic kidney disease ||mesh_term:Arterial Occlusive Diseases,Constriction, Pathologic,||||
NCTID:NCT01947478||dmc_oversight:Yes||primary_outcome_count:1||primary_outcome_list:Efficacy: Primary patency|12 month|,||||secondary_outcome_count:1||secondary_outcome_list:Primary safety endpoint|12 month|,||||arm_group_count:2||arm_group_list:MDT-2113 Drug-Eluting Balloon|Paclitaxel drug-eluting angioplasty balloon,Standard angioplasty balloon|Standard PTA balloon without Paclitaxel drug-elution,||||inclusion_exclusion: Inclusion Criteria: - Age: ≥ 20 years and ≤ 85 years - Documented ischemia with Rutherford classification 2, 3, or 4 - Able to walk without assistive devices - Target lesion is in the SFA and/or PPA above the knee - Target lesion consists of a single de novo or non-stented restenotic lesion (or tandem lesions) or is a combination lesion that meets the following criteria: 1. ≥ 70% and < 100% occluded with total lesion length ≥ 40 mm and ≤ 200 mm 2. 100% occluded with total lesion length ≤100 mm 3. Combination lesions must have total lesion length ≥40 mm and ≤200 mm with an occluded segment that is ≤ 100 mm in length (by visual estimates) - Reference vessel diameter ≥ 4 mm and ≤7 mm (by visual estimate) - Angiographic evidence of adequate distal run-off through the foot Exclusion Criteria: - Stroke or STEMI within the 3 months prior to enrollment - Either local or systemic thrombolytic therapy within the 48 hours prior to the index procedure - Inability to tolerate oral anticoagulation therapy (blood thinners such as warfarin) while on concomitant dual antiplatelet therapy (DAPT) - Known allergies or sensitivities to heparin, aspirin (ASA), other anticoagulant/antiplatelet therapies or to paclitaxel, or an allergy to contrast media that cannot be adequately pre-treated prior to the index procedure - Chronic renal insufficiency - Subject is enrolled in another investigational device, drug, or biologic study - Any major surgical procedure or intervention performed within the 30-day period prior to or post index procedure - Contralateral SFA/PPA disease requiring treatment in the same setting as index procedure - Failure to successfully cross the target lesion - Angiographic evidence of severe calcification - Target lesion known in advance of enrollment to require treatment with alternative therapy such as stenting, laser, atherectomy, cryoplasty, brachytherapy, re-entry devices, cutting balloons, scoring balloons; use of embolic protection devices is also prohibited ||mesh_term:Arterial Occlusive Diseases,Constriction, Pathologic,||||
NCTID:NCT01412541||dmc_oversight:Yes||primary_outcome_count:2||primary_outcome_list:Primary Safety - Percentage of Subjects With Composite of Freedom From All-cause Peri-operative (≤30 Day) Death and Freedom From the Following: Index Limb Amputation, Index Limb Re-intervention, and Index-limb-related Death at 12 Months.|12 months|,Primary Efficacy - Percentage of Subjects With Primary Patency of the Target Lesion at One Year.|12 months|,||||secondary_outcome_count:50||secondary_outcome_list:Secondary Efficacy #1 - Number of Devices With Device Success.|During the procedure|,Secondary Efficacy #1A - Number of Subjects With Technical Success.|During the procedure|,Secondary Efficacy #1B - Number of Subjects With Procedural Success.|During the procedure|,Secondary Efficacy #2 - Percentage of Subjects With Duplex Ultrasound Clinical Primary Patency [Freedom From Clinically Driven Target Lesion Revascularization (TLR) and Binary Restenosis] at 6 Months.|6 Months|,Secondary Efficacy #2 - Percentage of Subjects With Duplex Ultrasound Clinical Primary Patency [Freedom From Clinically Driven Target Lesion Revascularization (TLR) and Binary Restenosis] at 12 Months.|12 Months|,Secondary Efficacy #2A - Percentage of Subjects With Secondary Patency (Absence of Target Lesion Restenosis by Core Lab Adjudication) at 6 Months.|6 Months|,Secondary Efficacy #2A - Percentage of Subjects With Secondary Patency Rate at 12 Months (Defined by Core Lab Adjudication).|12 Months|,Secondary Efficacy #3 - Percentage of Subjects With Alternative Primary Patency Based on Alternative Definitions of Duplex Ultrasound Peak Systolic Velocity Ratio (DUS PSVR) <2.0 Through 6 Months.|6 Months|,Secondary Efficacy #3 - Percentage of Subjects With Alternative Primary Patency Based on Alternative Definitions of Duplex Ultrasound (DUS) Peak Systolic Velocity Ratio (PSVR) <2.0 Through 12 Months.|12 Months|,Secondary Efficacy #3A - Percentage of Subjects With Alternative Primary Patency Based on Alternative Definitions of Duplex Ultrasound (DUS) Peak Systolic Velocity Ratio (PSVR) <3.0 Through 6 Months.|6 Months|,Secondary Efficacy #3A - Percentage of Subjects With Alternative Primary Patency Based on Alternative Definitions of Duplex Ultrasound (DUS) Peak Systolic Velocity Ration (PSVR) <3.0 Through 12 Months.|12 Months|,Secondary Efficacy #4 - Percentage of Subjects With Alternative Primary Patency Based on Alternative Definitions of Suplex Ultrasound (DUS) Peak Systolic Velocity Ration (PSVR) <2.5 Through 6 Months.|6 Months|,Secondary Efficacy #4 - Percentage of Subjects With Alternative Primary Patency Based on Alternative Definitions of Duplex Ultrasound (DUS) Peak Systolic Velocity Ratio (PSVR) <2.5 Through 12 Months.|12 Months|,Secondary Efficacy #5 - Percentage of Subject With Freedom From Target Lesion Revascularization (TLR) Clinically-driven at 6 Months.|6 Months|,Secondary Efficacy #5 - Percentage of Subjects With Freedom From Target Lesion Revascularization (TLR) Clinically-driven at 12 Months.|12 Months|,Secondary Efficacy #5A - Percentage of Subjects With Freedom From Target Lesion Revascularization (TLR) Total (Clinical and DUS/Angiography - Driven) at 6 Months.|6 Months|,Secondary Efficacy #5A - Percentage of Subjects With Freedom From Target Lesion Revascularization (TLR) Total (Clinical and DUS/Angiography - Driven) at 12 Months.|12 Month|,Secondary Efficacy #6 - Percentage of Subjects With Change of Rutherford Classification From Baseline to 6 Months (%Improved).|Baseline and 6 Months|,Secondary Efficacy #6 - Percentage of Subjects With Change of Rutherford Classification From Baseline to 12 Months.|Baseline and 12 Months|,Secondary Efficacy #7 - Mean Difference Between the Baseline and 6 Months of Resting Ankle Brachial Index (ABI).|Baseline and 6 Months|,Secondary Efficacy #7 - Mean Difference Between the Baseline and 12 Months of Resting Ankle Brachial Index (ABI).|Baseline and 12 Months|,Secondary Efficacy #8 - Mean Differences Between the Total Walking Impairment Questionnaire Score From Baseline to 6 Months.|Baseline and 6 months|,Secondary Efficacy #8 - Mean Differences Between the Total Walking Impairment Questionnaire Score From Baseline to 12 Months.|Baseline and 12 Months|,Secondary Efficacy #9 - Mean of Subjects With Change in Six Minute Walk Test Distance From Baseline to 6 Months.|Baseline and 6 Months|,Secondary Efficacy #9 - Mean of Subjects With Change in Six Minute Walk Test Distance From Baseline Through 12 Months.|Baseline and 12 Months|,Secondary Efficacy #10 - Mean Change of the EuorQol (EQ-5D) Index From Baseline to 6 Months.|Baseline and 6 Months|,Secondary Efficacy #10 - Mean Change of the EuorQol (EQ-5D) Index From Baseline to 12 Months.|Baseline and 12 Months|,Secondary Efficacy #10A - Mean Change in Quality of Life Physical and Mental Component of SF-36 v2 From Baseline to 6 Months.|Baseline and 6 Months|,Secondary Efficacy #10A - Mean Change in Quality of Life Physical Component and Mental Component of SF-36 v2 From Baseline to 12 Months.|Baseline and 12 Months|,Secondary Safety #1 - Percentage of Subjects With Freedom From All-cause Death, Index Limb Amputation Above the Ankle and Target Vessel Revascularization (TVR) (VIVA Safety Endpoint).|30 days|,Secondary Safety #2 - Percentage of Subjects With Composite of Freedom From All-cause Perioperative (≤30 Day) Death and Freedom From the Following at 1 Month: Index Limb Amputation, Index Limb Re-intervention, and Index-limb-related Death at 1 Month.|1 Month|,Secondary Safety #2 - Percentage of Subjects With Composite of Freedom From All-cause Perioperative (≤30 Day) Death and Freedom From the Following at 6 Months: Index Limb Amputation, Index Limb Re-intervention, and Index-limb-related Death.|6 Months|,Secondary Safety #3 - Percentage of Subjects With All-cause Death at 1 Month.|1 month|,Secondary Safety #3 - Percentage of Subjects With All-cause Death at 6 Months.|6 Months|,Secondary Safety #3 - Percentage of Subjects With All-cause Death at 12 Months.|12 Months|,Secondary Safety #4 - Percentage of Subjects With Amputation (Above the Ankle)-Free Survival (AFS) 1 Month.|1 Month|,Secondary Safety #4 - Percentage of Subjects With Amputation (Above the Ankle)-Free Survival (AFS) 6 Months.|6 Months|,Secondary Safety #4 - Percentage of Subjects With Amputation (Above the Ankle)-Free Survival (AFS) 12 Months.|12 Months|,Secondary Safety #5 - Percentage of Subjects With Target Vessel Revascularization (TVR) at 1 Month.|1 Month|,Secondary Safety #5 - Percentage of Subjects With Target Vessel Revascularization (TVR) at 6 Months.|6 Months|,Secondary Safety #5 - Percentage of Subjects With Target Vessel Revascularization (TVR) at 12 Months.|12 Months|,Secondary Safety #6 - Percentage of Subjects With Reintervention for Treatment of Thrombosis of the Target Vessel or Embolization to Its Distal Vasculature at 1 Month.|1 Month|,Secondary Safety #6 - Percentage of Subjects With Reintervention for Treatment of Thrombosis of the Target Vessel or Embolization to Its Distal Vasculature at 6 Months.|6 Months|,Secondary Safety #6 - Percentage of Subjects With Reintervention for Treatment of Thrombosis of the Target Vessel or Embolization to Its Distal Vasculature at 12 Months.|12 Months|,Secondary Safety #7 - Percentage of Subjects With Major Vascular Complications at 1 Month.|1 Month|,Secondary Safety #7 - Percentage of Subjects With Major Vascular Complications at 6 Months.|6 Months|,Secondary Safety #7 - Percentage of Subjects With Major Vascular Complications at 12 Months.|12 Months|,Secondary Safety #8 - Percentage of Subjects With Readmission for Cardiovascular Events at 1 Month.|1 Month|,Secondary Safety #8 - Percentage of Subjects With Readmission for Cardiovascular Events at 6 Months.|6 Months|,Secondary Safety #8 - Percentage of Subjects With Readmission for Cardiovascular Events at 12 Months.|12 Months|,||||arm_group_count:2||arm_group_list:Moxy Drug Coated Balloon|Paclitaxel coated balloon catheter,Standard Uncoated Angioplasty Balloon|PTA Catheter,||||inclusion_exclusion: Clinical Inclusion Criteria: 1. Male or non-pregnant female ≥18 years of age; 2. Rutherford Clinical Category 2-4; 3. Patient is willing to provide informed consent, is geographically stable and comply with the required follow up visits, testing schedule and medication regimen; Angiographic Lesion Inclusion Criteria: 4. Length ≤15 cm; 5. Up to two focal lesions or segments within the designated 15 cm length of vessel may be treated (e.g. two discrete segments, separated by several cm, but both falling within a composite length of <15 cm); 6. ≥70% stenosis by visual estimate; 7. Lesion location starts ≥1 cm below the common femoral bifurcation and terminates distally ≤2 cm below the tibial plateau AND ≥1 cm above the origin of the TP trunk; 8. de novo lesion(s) or non-stented restenotic lesion(s) >90 days from prior angioplasty procedure; 9. Lesion is located at least 3 cm from any stent, if target vessel was previously stented; 10. Target vessel diameter between ≥4 and ≤6 mm and able to be treated with available device size matrix; 11. Successful, uncomplicated (without use of a crossing device) antegrade wire crossing of lesion; 12. A patent inflow artery free from significant lesion (≥50% stenosis) as confirmed by angiography (treatment of target lesion acceptable after successful treatment of inflow artery lesions); NOTE: Successful inflow artery treatment is defined as attainment of residual diameter stenosis ≤30% without death or major vascular complication. 13. At least one patent native outflow artery to the ankle, free from significant (≥50%) stenosis as confirmed by angiography that has not previously been revascularized (treatment of outflow disease is NOT permitted during the index procedure); 14. Contralateral limb lesion(s) cannot be treated within 2 weeks before and/or planned 30 days after the protocol treatment in order to avoid confounding complications; 15. No other prior vascular interventions within 2 weeks before and/or planned 30 days after the protocol treatment. Exclusion Criteria: Patients will be excluded if ANY of the following conditions apply: 1. Pregnant or planning on becoming pregnant or men intending to father children; 2. Life expectancy of <5 years; 3. Patient is currently participating in an investigational drug or other device study or previously enrolled in this study; NOTE: Enrollment in another clinical trial during the follow up period is not allowed. 4. History of hemorrhagic stroke within 3 months; 5. Previous or planned surgical or interventional procedure within 2 weeks before or within 30 days after the index procedure; 6. History of myocardial infarction (MI), thrombolysis or angina within 2 weeks of enrollment; 7. Rutherford Class 0, 1, 5 or 6; 8. Renal failure or chronic kidney disease with modification in diet in renal disease glomerular filtration rate (MDRD GFR) ≤30 ml/min per 1.73 m2 (or serum creatinine ≥2.5 mg/L within 30 days of index procedure or treated with dialysis); 9. Prior vascular surgery of the index limb, with the exception of remote common femoral patch angioplasty separated by at least 2 cm from the target lesion; 10. Inability to take required study medications or allergy to contrast that cannot be adequately managed with pre- and post-procedure medication; 11. Anticipated use of IIb/IIIa inhibitor prior to randomization; 12. Ipsilateral retrograde access; 13. Composite lesion length is >15 cm or there is no normal proximal arterial segment in which duplex flow velocity can be measured; 14. Significant inflow disease. Successful treatment of inflow disease allowed prior to target lesion treatment; 15. Known inadequate distal outflow (>50 % stenosis of distal popliteal and/or all three tibial vessels), or planned future treatment of vascular disease distal to the target lesion; 16. Sudden symptom onset, acute vessel occlusion, or acute or sub-acute thrombus in target vessel; 17. Severe calcification that renders the lesion un-dilatable; 18. Use of adjunctive treatment modalities (i.e. laser, atherectomy, cryoplasty, scoring/cutting balloon, etc.). ||mesh_term:Arterial Occlusive Diseases,Constriction, Pathologic,||||
NCTID:NCT00987324||dmc_oversight:No||primary_outcome_count:1||primary_outcome_list:Percent in-segment diameter stenosis at follow-up angiography|6-8 months|,||||secondary_outcome_count:4||secondary_outcome_list:In-segment minimal luminal diameter|6-8 months|,In-segment binary angiographic restenosis|6-8 months|,Combined incidence of death or myocardial infarction|1 and 2 years|,Incidence of thrombosis|1 and 2 years|,||||arm_group_count:3||arm_group_list:Paclitaxel-eluting stent|Paclitaxel-eluting stent (Taxus),Plain Balloon|plain balloon angioplasty,Paclitaxel-eluting balloon|SeQuent Please,||||inclusion_exclusion: Inclusion Criteria: 1. Patients with ischemic symptoms or evidence of myocardial ischemia in the presence of ≥ 50% restenosis after prior implantation of LES in native coronary vessels. 2. Written, informed consent by the patient or her/his legally-authorized representative for participation in the study. 3. In women with childbearing potential a negative pregnancy test is mandatory. Exclusion Criteria: 1. Age < 18 years. 2. Cardiogenic shock. 3. Acute ST-elevation myocardial infarction within 48 hours from symptom onset. 4. Target lesion located in the left main trunk or bypass graft. 5. Target lesion located in small vessel (vessel size < 2.0 mm). 6. Malignancies or other comorbid conditions (for example severe liver, renal and pancreatic disease) with life expectancy less than 12 months or that may result in protocol non-compliance. 7. Severe renal insufficiency (glomerular filtration rate ≤ 30 ml/min). 8. Contraindications to antiplatelet therapy, paclitaxel, stainless steel, cobalt, chrome. 9. Pregnancy (present, suspected or planned) or positive pregnancy test. 10. Previous enrollment in this trial. 11. Patient's inability to fully comply with the study protocol. ||mesh_term:Heart Diseases,Ischemia,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT01495533||dmc_oversight:Yes||primary_outcome_count:1||primary_outcome_list:late lumen loss in-segment|6 months|,||||secondary_outcome_count:2||secondary_outcome_list:Procedural Success|participants will be followed for the duration of hospital stay, an expected average of 2 days|,Major adverse cardiovascular events|6 months|,||||arm_group_count:2||arm_group_list:uncoated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a AngioSculpt(R) scoring balloon (no drug coating),drug coated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a drug coated AngioSculpt(R) scoring balloon (paclitaxel 3.0 µg/mm²),||||inclusion_exclusion: Inclusion Criteria: - >18 years of age - clinical evidence of stable or unstable angina or a positive functional study - patients with ≤ 2 primary in-stent restenosis (ISR) lesions (≥ 70% diameter stenosis) within previously placed bare metal stents (BMS) Exclusion Criteria: - acute myocardial infarction within the past 72 hours - chronic renal insufficiency with serum creatinine levels >2.0 mg per deciliter% - known hypersensitivity or contraindications to aspirin, heparin, clopidogrel, ticlopidine or paclitaxel, and sensitivity to contrast media not amenable to premedication - concomitant medical illness associated with a life-expectancy of less than two years - stented segment length ≥30 mm, vessel diameter <2.5 mm, diameter stenosis <70% ||mesh_term:Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT01239953||dmc_oversight:Yes||primary_outcome_count:1||primary_outcome_list:Minimal lumen diameter|Late angiographic follow-up (6-9 months)|,||||secondary_outcome_count:1||secondary_outcome_list:Combined clinical and angiographic end-points|6-9 months, 1 year and 3 years|,||||arm_group_count:2||arm_group_list:Paclitaxel-eluting balloon|Paclitaxel-eluting balloon (SeQuent Please, B. Braun),Everolimus-eluting stent|Everolimus-eluting stent (Xience Prime, Abbott Vascular),||||inclusion_exclusion: Inclusion Criteria: PATIENT: - Age between 20 and 85 years - Signed informed consent - Acceptance of late angiographic control (6-9 months) - Angina and / or objective evidence of ischemia LESION: - In-Stent restenosis (> 50% visual) any bare metal stent - Knowledge of prior stent location Exclusion Criteria: PATIENT: - Inclusion in another clinical research protocol - Women of childbearing age - Severe associated systemic disease (including renal or liver failure) - Severe depression of left ventricular ejection fraction (LVEF <25%) - Disease that affects life expectancy - Recent myocardial infarction ( <7 days) - Time of implantation of the previous BMS <1 month - Severe difficulties expected for late angiographic study LESION: - Angiographic failure during implementation of initial stent(residual stenosis> 50%) - Image of large thrombus in-stent (> vessel diameter) - Tortuosity or Ca + + with very severe difficulties during prior stent deployment - Vessel diameter <2 mm (visual estimate) - Restenosis only "outside" the stent (The edge of the stent is not affected) - Completely occlusive restenosis (100%, TIMI 0) - Very diffuse restenosis (> 30 mm length) ||mesh_term:Sirolimus,Paclitaxel,Albumin-Bound Paclitaxel,Everolimus,||||
NCTID:NCT01239940||dmc_oversight:Yes||primary_outcome_count:1||primary_outcome_list:Minimal lumen diameter|Late angiographic follow-up (6-9 months)|,||||secondary_outcome_count:1||secondary_outcome_list:Combined clinical and angiographic end-points|6-9 months, 1 year and 3 years|,||||arm_group_count:2||arm_group_list:Paclitaxel-eluting balloon|Paclitaxel-eluting balloon (SeQuent Please, B. Braun),Everolimus-eluting stent|Everolimus-eluting stent (Xience Prime, Abbott Vascular),||||inclusion_exclusion: Inclusion Criteria: PATIENT: - Age between 20 and 85 years - Signed informed consent - Acceptance of late angiographic control (6-9 months) - Angina and / or objective evidence of ischemia LESION: - In-Stent restenosis (> 50% visual) any drug-eluting stent - Knowledge of prior stent location Exclusion Criteria: PATIENT: - Inclusion in another clinical research protocol - Women of childbearing age - Severe associated systemic disease (including renal or liver failure) - Severe depression of left ventricular ejection fraction (LVEF <25%) - Disease that affects life expectancy - Recent myocardial infarction ( <7 days) - Time of implantation of the previous DES <1 month - Severe difficulties expected for late angiographic study LESION: - Angiographic failure during implementation of initial stent(residual stenosis> 50%) - Image of large thrombus in-stent (> vessel diameter) - Tortuosity or Ca + + with very severe difficulties during prior stent deployment - Vessel diameter <2 mm (visual estimate) - Restenosis only "outside" the stent (The edge of the stent is not affected) - Completely occlusive restenosis (100%, TIMI 0) - Very diffuse restenosis (> 30 mm length) ||mesh_term:Sirolimus,Paclitaxel,Albumin-Bound Paclitaxel,Everolimus,||||
NCTID:NCT01255956||dmc_oversight:No||primary_outcome_count:3||primary_outcome_list:Incidence of repeated restenosis angiographically evidenced|at 9 months|,Neointimal volume assessed by intravascular ultrasound (IVUS)|at 9 months|,Late lumen loss and neointimal volume assessed by optical coherence tomography (OCT)|at 9 months|,||||secondary_outcome_count:6||secondary_outcome_list:Incidence of repeated target lesion revascularization (TLR)|at 9 months|,Incidence of repeated target vessel revascularization (TVR)|at 9 months|,Incidence of death|at 9 months|,Incidence of myocardial infarction|at 9 months|,Incidence of brain stroke|at 9 months|,Incidence of in-stent thrombosis|at 9 months|,||||arm_group_count:2||arm_group_list:Rapamycin eluting stent|Patients treated with rapamycin eluting stent (n=100),Paclitaxel eluting balloon catheter|Patients treated with paclitaxel eluting balloon catheter (n=100),||||inclusion_exclusion: Inclusion Criteria: - at least 18 years of age - symptomatic restenosis in bare metal stent implanted in native coronary artery - angina pectoris - ischemia evidenced by non-invasive diagnostic tests - angiographically evidenced in-stent restenosis > 50% assessed by quantitative coronary angiography (QCA) - vessel diameter > 2,5 mm Clinical exclusion criteria: - myocardial infarction within less than past 72 hours - heart failure with left ventricular ejection fraction (LVEF) < 30% - chronic renal failure with significant impairment of glomerular filtration (creatinine > 2 mg/dl) - hypersensitivity or contraindication to acetylsalicylic acid, clopidogrel, heparin, abciximab, rapamycin, paclitaxel - hypersensitivity to contrast - other diseases that may cause significant deterioration in long-term prognosis - acute or chronic inflammatory diseases - patients who are unwilling to consent for participation in the study Angiographic exclusion criteria: - significant stenosis in left main coronary artery (LM) - multivessel disease qualifying for coronary artery bypass grafting (CABG) - anatomical localization and morphology that preclude optimal percutaneous intervention intervention's (PCI) result or intravascular ultrasound (IVUS) or optical coherence tomography performance - vessel diameter < 2,5 mm - restenotic lesion length > 30 mm ||mesh_term:Sirolimus,Paclitaxel,Albumin-Bound Paclitaxel,Everolimus,||||
NCTID:NCT00485030||dmc_oversight:Yes||primary_outcome_count:1||primary_outcome_list:Binary in-segment angiographic restenosis|at 9 months angiographic follow-up|,||||secondary_outcome_count:4||secondary_outcome_list:The composite of death, myocardial infarction, and target-vessel revascularization|in-hospital, 1 month, and 9 months after index procedure|,stent thrombosis|in-hospital, 1 month, and 9 months after index procedure|,Late luminal loss|at 8 month angiographic follow-up|,Procedural success defined as achievement of a final diameter stenosis of <30% by QCA using any percutaneous method, without the occurrence of death, Q wave MI, or repeat revascularization of the target lesion|during the hospital stay|,||||arm_group_count:2||arm_group_list:Cypher|sirolimus-eluting stent,Xience-V|everolimus-eluting stent,||||inclusion_exclusion: Inclusion Criteria: 1. The patient must be at least 18 years of age. 2. Restenosis after drug-eluting stents (>50% by visual estimate) 3. Lesion length ≥ 10 mm (diffuse type ISR) 4. Patients with stable (CCS class 1 to 4) or acute coronary syndromes (unstable angina pectoris Braunwald class IB, IC, IIB, IIC, IIIB, IIIC or NSTEMI) or patients with atypical chest pain or without symptoms but having documented myocardial ischemia, amenable to stent-assisted percutaneous coronary intervention 5. The patient or guardian agrees to the study protocol and the schedule of clinical and angiographic follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site. Exclusion Criteria: 1. The patient has a known hypersensitivity or contraindication to any of the following medications: - Heparin - Aspirin - Both Clopidogrel and TIclopidine - Sirolimus eluting stent - Stainless steel and/or - Contrast media (patients with documented sensitivity to contrast which can be effectively pre-medicated with steroids and diphenhydramine [e.g. rash] may be enrolled. Patients with true anaphylaxis to prior contrast media, however, should not be enrolled). 2. Systemic (intravenous) Sirolimus use within 12 months. 3. Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study. 4. History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia), or will refuse blood transfusions. 5. Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months. 6. Current known current platelet count <100,000 cells/mm3 or Hgb <10 g/dL. 7. Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment). 8. Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period. 9. Patients with EF<30%. 10. Acute MI patients within symptom onset < 12 hours needing primary angioplasty 11. Creatinine level 3.0mg/dL or dependence on dialysis. 12. Severe hepatic dysfunction (AST and ALT 3 times upper normal reference values). 13. Patients with left main stem stenosis and left main in-stent restenosis created by DES(>50% by visual estimate) ||mesh_term:Sirolimus,Everolimus,||||
NCTID:NCT01093300||dmc_oversight:Yes||primary_outcome_count:1||primary_outcome_list:Late luminal loss in the analysis segment|9 months|,||||secondary_outcome_count:7||secondary_outcome_list:Late luminal loss in the inflation/in-stent segment|9 months|,Target lesion/vessel revascularization, myocardial infarction|1, 2 years|,Periprocedural myocardial infarction|3 days|,% diameter stenosis in the analysis segment & in the inflation/in-stent segment|9 months|,Neointimal volume, % neointimal volume, % volume obstruction|9 months|,Time interval from device insertion to initiation of deployment|0 days|,Stent thrombosis|1, 2 years|,||||arm_group_count:2||arm_group_list:Paclitaxel-eluting balloon catheter|Paclitaxel-eluting balloon catheter use for treatment of ISR lesion,Everolimus-eluting stent|Everolimus-eluting stent use for treatment of ISR lesion,||||inclusion_exclusion: Inclusion Criteria: - Age at least 18y - Significant ISR lesion (>50% by visual estimate) of previously stented de novo coronary artery - Evidence of myocardial ischemia (e.g., stable, unstable angina, recent infarction, silent ischemia, positive functional study or a reversible changes in the electrocardiogram (ECG) consistent with ischemia) or ISR with diameter stenosis > 70% - Written, informed consent - Target lesion(s) located in a native coronary artery within a previously stented lesion with previous stent diameter of ≥ 2.5 mm and ≤ 4.00 mm - Target lesion(s) amenable for percutaneous coronary intervention Exclusion Criteria: - Hypersensitivity to aspirin, clopidogrel, heparin, sirolimus, paclitaxel or radiocontrast media - Systemic sirolimus use within 12 months - Female of childbearing potential - History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia) - Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months - Non-cardiac co-morbid conditions present with life expectancy <1 year or that may result in protocol non-compliance - Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period - ISR of left main coronary artery - Restenosis of two stented bifurcation lesion ||mesh_term:Sirolimus,Paclitaxel,Albumin-Bound Paclitaxel,Everolimus,||||
NCTID:NCT02924857||dmc_oversight:Yes||primary_outcome_count:2||primary_outcome_list:True Drug Coated Balloon Success|12 months|,Freedom from Major Adverse Events|12 months|,||||secondary_outcome_count:3||secondary_outcome_list:By Angiographic Core Lab Review (Acute)|1 hour|,By Duplex Ultrasound Core Lab Review|6, 12 & 24 months|,By Clinical Assessment|1, 6, 12, & 24 months|,||||arm_group_count:2||arm_group_list:Test Group (Chocolate Touch)|The diameter of the Chocolate Touch should correspond to the diameter of the vessel for treatment with a balloon to artery ratio of 1.1:1.The Chocolate Touch must be inflated to at least nominal pressure. Maintain balloon inflation for a minimum of 2 minutes. The balloon may be inflated as long as required to achieve optimal angioplasty outcome.If delivery is attempted and failed, a new Chocolate Touch should be used for subsequent attempts after pre-dilatation.,Control Group (Lutonix Drug Coated Balloon)|Never inflate the Lutonix® Drug Coated Balloon (DCB)prior to reaching the target lesion.The Lutonix® Catheter should be advanced to the target site as fast as possible (i.e. 30 seconds) and immediately inflated to appropriate pressure to ensure full wall apposition (balloon to artery ratio of >1:1).If the deployment of the Lutonix® Catheter exceeds 3 minutes, the catheter requires placement with a new unit.Maintain balloon inflation for a minimum of 2 minutes (120 seconds). The balloon may be inflated as long as required by standard of care to achieve a good angioplasty outcome.,||||inclusion_exclusion: Inclusion Criteria: 1. Minimum of 18 years of age 2. Intermittent claudication or ischemic rest pain (Rutherford 2-4) 3. Life Expectancy >2 years 4. Patient has agreed to follow-up requirements and given informed consent 5. Lesion successfully crossed with a guidewire 6. Lesion in the superficial femoral or popliteal artery 7. Target lesion >70% stenosis 8. Reference Vessel Diameter between 3.5 & 6.0mm and within treatment range of Chocolate Touch to be used 1.1:1 at Target Lesion 9. Target Lesion <18cm that consists of no more than two adjacent lesions (<25mm apart) and is able to be completely covered with inflation of no more than two assigned balloons 10. Angiographic evidence of distal run-off demonstrated by at least one patent tibial vessel without evidence of significant (>70%) stenosis from origin to to ankle 11. In-flow vessel without significant stenosis (<70%) or successful treatment (<30% residual stenosis with no complications) of a diseased iliac vessel Exclusion Criteria: 1. Acute limb ischemia, or patient indicated for thrombolytic therapy 2. Planned surgery within 30 days including interventions on the non-target limb 3. Target Limb concurrent interventions involving a re-entry device, atherectomy, laser, or ablation procedures, the use of a drug eluting stent, or, treatment with any other drug coated balloon 4. Myocardial infarction or stroke within 30 days prior to the procedure 5. Known intolerance to required medications, contrast media, nitinol, or Paclitaxel 6. Known impaired Renal Function that could have an impact on contrast tolerance with Glomerular filtration rate (GFR) ≤ 30 ml/min per 1.73 m^2 and/or elevated serum creatinine >2.5mg/dL (220µmol/L) 7. Known bleeding disorder or uncontrolled hypercoagulable disorder 8. Non-atherosclerotic lesion (e.g. vasculitis or Berger's disease) 9. Female who is pregnant or intends to be pregnant during study 10. Patient is enrolled in another clinical study or was previously enrolled in this study 11. Presence of perforation, dissection or other injury at access site or in target vessel at time of enrollment 12. Severe Calcification at the target lesion (defined as angiographic evidence of dense calcification present on both sides of the vessel wall on two orthogonal views and that extends >5 continuous cm in length) 13. Previous bypass graft or stent at target vessel, OR, iliac stent that cannot permit crossing by the treatment balloon within the introducer sheath ||mesh_term:Intermittent Claudication,Ischemia,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT02561299||dmc_oversight:No||primary_outcome_count:1||primary_outcome_list:Device success (per each DCB used during the index procedure), defined as the ability to achieve successful delivery and deployment of the DCB to the target lesion as described per Instructions for Use (IFU)|Index Procedure|,||||secondary_outcome_count:5||secondary_outcome_list:Late Lumen Loss (LLL) of the target lesion by Quantitative Vascular Angiography (QVA)|6 Month|,Patency of the target lesion by Duplex Ultrasound (DUS) post-procedure|6 Month and 12 Month|,Freedom from clinically driven target lesion revascularization|30 Day, 3 Month, 6 Month, 12 Month|,Freedom from unplanned, unavoidable major amputation of the index limb|30 Day, 3 Month, 6 Month, 12 Month|,Change in Rutherford Category|30 Day, 3 Month, 6 Month, 12 Month|,||||arm_group_count:2||arm_group_list:OA with adjunctive DCB angioplasty|Lesion preparation with Peripheral Orbital Atherectomy System followed by drug-coated balloon angioplasty,DCB angioplasty|014 Drug Coated Balloon angioplasty,||||inclusion_exclusion: Inclusion Criteria: - Subject's age ≥ 18 years - Rutherford Clinical Category 3 - 5 - Lesions [except in-stent restenosis (ISR)] of the distal popliteal (POP segment below the anatomical knee joint), anterior tibial, posterior tibial, tibial peroneal trunk, and peroneal arteries with ≥ 70 % diameter stenosis (DS) by angiography - Presence of clearly visible calcification in two views (both sides of vessel at the same location) evaluated angiographically- [Computerized tomography (CT) angio images may substitute to confirm distribution of calcium, if available as standard of care] - Length of calcium ≥ 25 % of total lesion length or ≥ 2 cm total length - Target lesion length up to 20 cm Exclusion Criteria: - Subject or subject's legal representative is not willing to sign an Ethics Committee approved informed consent form or comply with the study protocol requirements - Contraindicated by either device, per Instructions For Use - Presence of inflow lesion (≥ 50 % DS) or inflow not successfully treated (≥ 50% DS and/or unresolved significant angiographic complication) - Compromised outflow distal to the target lesion (≥ 70 % DS) or presence of lesion(s) or occlusion(s) located from 5 cm above the ankle to below the ankle joint space - Subject has more than 2 target vessels requiring treatment - The guide wire cannot be passed across the target lesion(s) and/or guide wire position distal to target lesion(s) outside vessel lumen - Presence of significant (≥ 70 % DS) lesion(s) or occlusion(s) not meeting the study criteria which were not successfully treated during the index procedure (≥ 50 % DS and/or significant angiographic complication) - Subject has planned amputation (including minor) of the index limb or previous major amputation of the contralateral limb - Creatinine > 2.5 mg/dL, unless on dialysis - Subject has any significant medical condition which, in the Investigator's opinion, may interfere with the subject's optimal participation in the study - Subject is participating in an investigational drug or device study that has the potential to clinically interfere with the study outcome measures - Subject is pregnant or planning to become pregnant within the study period - Subject has an unresolved severe systemic infection - Subject has an anticipated life span of less than one year - Subjects with known hypersensitivity to paclitaxel or paclitaxel related compounds - Subjects who cannot receive recommended anti-platelet and/or anticoagulant therapy - Pre-dilatation of the target lesion prior to randomization and OA treatment ||mesh_term:Vascular Calcification,||||
NCTID:NCT01858428||dmc_oversight:Yes||primary_outcome_count:2||primary_outcome_list:Patency at 12 Month Post-procedure|12 months|,Freedom From Device and Procedure-related Death and Target Limb Major Amputation and Clinically-driven Target Lesion Revascularization|30 Days and 12 months|,||||secondary_outcome_count:13||secondary_outcome_list:Major Adverse Event (MAE) Rate in the Hospital and at 1, 6, 12, 24, 36, 48 and 60 Months Post-procedure|1, 6, 12, 24, 36, 48 and 60 months|,Rate of Vascular Access and Bleeding Complications|in-hospital and 1, 6, 12 and 24 months|,Rate of Clinically-driven Target Lesion Revascularization|6, 12, 24, 36, 48 and 60 months|,Rate of Target Lesion Revascularization|6, 12, 24, 36, 48 and 60 months|,Rate of Target Limb Major Amputation|1, 6, 12, 24, 36, 48 and 60 months|,Mortality Rate|6, 12, 24, 36, 48 and 60 months|,Rate of Occurrence of Arterial Thrombosis of the Treated Segment|1, 6, 12, 24, 36, 48 and 60 months|,Patency Rate and Freedom From Clinically-driven TLR|6, 24 and 36 months|,Lesion Success of Achieving a Final In-lesion Residual Diameter Stenosis of ≤50%|procedure, Day 0|,Technical Success of Achieving a Final In-lesion Residual Diameter Stenosis of ≤50%|procedure, Day 0|,Per Subject Clinical Success Achieving no Major Adverse Events During the Procedure|procedure, Day 0|,Per Subject Procedural Success Achieving no Major Adverse Events During the Procedure|procedure, Day 0|,Change in Ankle-brachial Index (ABI) From Pre-procedure|6, 12, 24 and 36 months|,||||arm_group_count:2||arm_group_list:Bare PTA|The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA).,Drug-Coated PTA|The CVI Paclitaxel-coated PTA Catheter is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.,||||inclusion_exclusion: Inclusion Criteria: - Subjects with symptomatic leg ischemia, requiring treatment of the Superficial Femoral Artery (SFA) or popliteal artery. Exclusion Criteria: - Known intolerance to study medications, paclitaxel or contrast agents that in the opinion of the investigator cannot be adequately pre-treated ||mesh_term:Peripheral Arterial Disease,Peripheral Vascular Diseases,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT00472472||dmc_oversight:Yes||primary_outcome_count:1||primary_outcome_list:angiographic late lumen loss|6 months|,||||secondary_outcome_count:1||secondary_outcome_list:binary restenosis rate; major adverse events|18 months|,||||arm_group_count:2||arm_group_list:1|PTA,2|PTA with Paccocath,||||inclusion_exclusion: Inclusion Criteria: - Rutherford stage 1, 2, 3, 4 oder 5 - Occlusion or Stenosis of Superficial femoral and/or popliteal artery - Successful guide wire passage of the lesion - Patient suitable of vascular surgery in case of complication - Written consent - Patient is willing to take part in follow up examinations within the study Exclusion Criteria: - Acute ischemia - Distal run off less than one vessel - Pregnancy - Hyperthyroidism - Thrombocytes <100.000/mm3 or >700.000/mm3, Leucocytes <3.000/mm3 - Life expectancy less than two years - Patients not willing to enter the study ||mesh_term:Peripheral Arterial Disease,Peripheral Vascular Diseases,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT02965677||dmc_oversight:No||primary_outcome_count:1||primary_outcome_list:clinically driven target lesion revascularization (CD-TLR)|12 month post procedure|,||||secondary_outcome_count:15||secondary_outcome_list:Procedural Success|at 0-30 days|,Device Success|at 0-30 days|,Clinical Success|at 0-30 days|,Change in Rutherford classification measured|at 0-30 days, 6 months and 12 months post procedure|,Change in ABI measure|at 0-30 days, 6 months and 12 months post procedure|,Walking capacity assessment by Walking Impairment Questionnaire (WIQ)|at 0-30 days, 6 months and 12 months post procedure|,Walking distance assessment by Six Minute Walk Test (6MWT)|0-30 days, 6 months and 12 months post procedure compared with baseline|,Quality of life assessment by EQ5D|at 0-30 days, 6 months and 12 months post procedure compared with baseline|,Target lesion revascularization (TLR)|0-30 days, 6 months and 12 months post procedure|,Target vessel revascularization (TVR)|at 0-30 days, 6 months and 12 months post procedure|,Thrombus at the target lesion site|0-30 days, 6 months and 12 months post procedure|,Target limb amputation rates|at 0-30 days, 6 months and 12 months post procedure|,Major Adverse Event (MAE) rate which including all cause death, CD-TLR and major target limb amputation.|at 0-30 days, 6 months and 12 months post procedure|,Clinical-driven target vessel revascularization (CD-TVR) rates|at 0-30 days, 6 months and 12 months post procedure|,Clinical-driven target lesion revascularization (CD-TLR) rates|at 0-30 days, 6 months and 12 months post procedure|,||||arm_group_count:2||arm_group_list:LEGFLOW OTW group|in this group subject will be treated by Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW) and followed up,Admiral Xtreme|in this group subject will be treated by Peripheral Balloon Dilatation Catheter (Admiral Xtreme) and followed up,||||inclusion_exclusion: Inclusion Criteria: 1. Age ≥ 18 years and ≤ 85 years. 2. De novo or restenotic lesions in the femoral popliteal artery due to atherosclerosis, which located in the superficial femoral artery and/or proximal popliteal artery (arterial segment starting at least 1cm beyond the common femoral artery bifurcation to the distal P1 segment of the popliteal artery at the level of the proximal edge of the patella). And the patients are suitable for endovascular therapy with LEGFLOW OTW or Admiral Xtreme. 3. Rutherford class 2 to 5. 4. Target lesion length ≤ 200mm. 5. Target lesion stenosis ≥ 70% or total occlusion, and it can be passed with common manipulation. 6. Reference vessel diameter ≥ 4mm and ≤ 8mm by visual estimate. 7. Target lesion consists of a single of de novo or restenotic lesion, or a adjacent lesion or a combination lesion or multiple lesion which meets the following criteria: - adjacent lesion: (1) lesion space ≤ 30mm; (2) total lesion length (include lesion space) ≤ 200mm; (3) can be treated as a single lesion. - Combination lesion: combination lesion is defined as not a chronic total occlusion (CTO), but may include a part of total occlusion (100% stenosis). The total lesion length ≤ 200mm. - Multiple lesion: (1) lesion space > 30mm; (2) total lesion length (include lesion space) ≤ 200mm; (3) can be treated as multiple lesions. 8. Angiographic evidence of adequate distal run-off to the foot (at least one native calf vessel is patent, defined as < 50% diameter stenosis), whether or not this outfolw was re-established by previous intervention. 9. If subject has ipsilateral/contralateral iliac disease that requires treatment during the procedure, the iliac lesions must meet all the following criteria: - Iliac lesion or occlusion is ≤ 100mm in length; - must be treated before the target lesion (superficial femoral artery/proximal popliteal artery). - must be successfully treated before target lesion treatment; success is defined as: (1) residual stenosis < 30%; (2) free of dissection which can limit blood flow; (3) no occurrence of thrombus, embolization, or other SAE. 10. Life expectancy more than one year. 11. Understands the study objective and is willing to participate and provide the informed consent form, and is willing to comply with specified follow-up evaluations at the specified time points. Exclusion Criteria: 1. Women of childbearing age with negative pregnancy test before procedure, and breastfeeding women. 2. Stroke or STEMI within 30 days prior to the procedure. 3. Either local or systemic thrombolytic therapy within 6 weeks prior to the procedure. 4. Any major surgical operation (operation class ≥ 3) or interventional therapy within 30 days prior to the procedure. 5. Any major selective surgical operation (operation class ≥ 3) or interventional therapy within 30 days prior to the procedure. 6. Restenotic lesions after DCB or bypass surgery. 7. Target limb has been previously treated with bypass surgery. 8. Guidewire must be passed through from the distal part of limb. 9. Known allergies or sensitivities to contrast agent, paclitaxel, anti-platelet, anticoagulants or thrombolytic drugs. 10. Known allergies or sensitivities to heparin, including those patients who have had a previous incidence of heparin-induced thrombocytopenia (HIT) type II. 11. Aneurysm located at the target vessel. 12. Acute or sub-acute thrombosis in the target vessel. 13. Angiographic evidence of severe calcification (defined as dense circumferential calcification that makes the target lesion non-dilatable and/or calcificatin that is present on both sides of the vessel wall and that extends more than 5 cntinuous centimeters in length within the target lesion prior to contrast injection or digital subtraction angiography). 14. The bilateral lower limb must be treated in one procedure. 15. Uncorrected bleeding disorder. 16. Renal insufficiency (serum creatinine >2.5mg/dL or renal dialysis). 17. Stenosis or occlusions due to non-atherosclerosis, such as thrombotic occlusive vasculitis or vasculitis. 18. Septicemia or bacteremia. 19. Patients with severe disease (such as severe chronic obstructive pulmonary disease, malignant tumor, dementia, etc.) or patient's physical condition may affect the compliance with this study. 20. Pre-dilation resulted in a major (≥ Grade D) flow-limiting dissection or residual stenosis > 70%. 21. Major distal amputation (above the transmetatarsal) in the study limb or non-study limb. 22. Patients who have participated in another investigational drug or device trial that has not completed the primary endpoint. ||mesh_term:Peripheral Arterial Disease,Peripheral Vascular Diseases,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT01247402||dmc_oversight:Yes||primary_outcome_count:1||primary_outcome_list:primary patency rate|6 months|,||||secondary_outcome_count:1||secondary_outcome_list:severe adverse events|30 day|,||||arm_group_count:2||arm_group_list:Paclitaxel eluting balloon|Freeway 0.035 Paclitaxel eluting balloon (3 microgram Paclitaxel/mm2),Standard balloon angioplasty|standard balloon angioplasty,||||inclusion_exclusion: Inclusion Criteria: All criteria 1-6 should apply for inclusion. 1. Age > 50 years 2. Patient legally authorized to provide written informed consent 3. Patient willing and likely to comply with the follow up schedule 4. Patient symptomatic Rutherford-Becker 2-5 (Fontaine II-IV) 5. In-stent restenosis in the SFA and P1 segment of the popliteal artery (PA) 6. Tibial run-off of at least 1 artery which however may be stenotic but amenable to PTA Exclusion Criteria: 1. Patients unable to give informed consent 2. Patients enrolled in another study with any investigational drug or device 3. Major surgical procedures (not including minor amputations) within 30 days prior to this study or planned within 30 days of entry into this study 4. Pregnancy 5. Patients with any known allergy, hypersensitivity or intolerance to radiologic contrast media, ASA, Clopidogrel or Ticlopidine, Paclitaxel 6. Life expectancy of < 1 years ||mesh_term:Peripheral Arterial Disease,Peripheral Vascular Diseases,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT03884257||dmc_oversight:Yes||primary_outcome_count:2||primary_outcome_list:freedom from clinically-driven target lesion revascularization (CD-TLR) at 12 months post-procedure|12 months post-procedure|,Safety composite of death, major amputation, and target vessel revascularization (CD-TVR)|12 months post-procedure|,||||secondary_outcome_count:15||secondary_outcome_list:acute device success|Index procedure|,acute procedural success|index procedure|,freedom from all causes of death, freedom from major target limb amputation and freedom from CD-TVR through 30 days|1 month post-procedure|,Sustained clinical improvement|6 and 12 months post-procedure|,freedom from major adverse events|6 and 12 months post-procedure|,primary patency rate|6 and 12 months post-procedure|,freedom from target lesion revascularisation|6 and 12 months post-procedure|,freedom from target vessel revascularisation|6 and 12 months post-procedure|,freedom from binary restenosis|6 and 12 months post-procedure|,freedom from major target limb amputation|6 and 12 months post-procedure|,freedom from thrombosis at target lesion|6 and 12 months post-procedure|,change in walking impairment questionnaire score from baseline to 6 and 12 months|6 and 12 months post-procedure|,change in target limb rutherford class from baseline to 6 and 12 months|6 and 12 months post-procedure|,change in target limb resting ABI or TBI from baseline to 6 and 12 months|6 and 12 months post-procedure|,freedom from all causes of death|6 and 12 months post-procedure|,||||arm_group_count:2||arm_group_list:Passeo-18 Lux treatment group|These patients will be treated with the Passeo-18 Lux (Biotronik).,IN.PACT Admiral treatment group|These patients will be treated with the IN.PACT Admiral (Medtronic).,||||inclusion_exclusion: Inclusion Criteria: - Subject is ≥18 years - Subject has Rutherford classification 2, 3 or 4 - Subject has provided written informed consent and is willing to comply with study follow- up requirements - De novo stenotic or occlusive lesion(s) or non-stented restenotic or occlusive lesion(s) occurring >90 days after prior plain old balloon (POBA) angioplasty or >180 days after prior DCB treatment - Target lesion is located between the ostium of the SFA and the end of the P1 segment of the popliteal artery - Target vessel diameter ≥4mm and ≤7mm - Target lesion must be stenotic lesion ≤180mm in length (one long lesion or tandem lesions) by investigator's visual estimate or a total occlusion ≤120mm in length by investigator's visual estimate. Note: tandem lesions must have a total length of ≤180mm by visual estimate and be separated by ≤30mm - Target lesion must have angiographic evidence of ≥70% stenosis by investigator's visual estimation - Successful, uncomplicated crossing of the target lesion occurs when the tip of the guide wire is distal to the target lesion without the occurrence of flow-limiting dissection or perforation and is judged by visual inspection to be within the true lumen. Subintimal dissection techniques may be used if re-entry occurs above the knee (ATK) and without the use of re-entry devices - Target lesion is located at least 30mm from any stent, if target vessel was previously stented - After pre-dilatation, the target lesion is ≤50% residual stenosis, absence of a flow-limiting dissection and treatable with available device matrix - A patent inflow artery free from significant stenosis (≥50% stenosis) as confirmed by angiography - At least one patent native outflow artery to the ankle or foot, free from significant stenosis (≥50% stenosis) as confirmed by angiography Exclusion Criteria: - Acute limb ischemia - Patient underwent an intervention involving the target vessel within the previous 90 days - Patient underwent any lower extremity percutaneous treatment in the ipsilateral limb using a paclitaxel-eluting stent or DCB within the previous 90 days - Patient underwent a percutaneous transluminal angioplasty (PTA) of the target lesion using a DCB within the previous 180 days - Women who are pregnant, breast-feeding or intend to become pregnant - Patient has life expectancy of less than 1 year - Patient has a known allergy to contrast medium that cannot be adequately pre-medicated - Patient is allergic to all antiplatelet treatments - Patient is receiving immunosuppressant therapy - Patient has platelet count <100.000/mm3 or >700.000/mm3 - Patient has history of gastrointestinal haemorrhage requiring a transfusion within 3 months prior to the study procedure - Patient is diagnosed with coagulopathy that precludes treatment with systemic anticoagulation and/or dual antiplatelet therapy (DAPT) - Patient has history of stroke within the past 90 days - Patient has history of myocardial infarction within the past 30 days - Patient is participating in an investigational drug or medical device study that has not completed primary endpoint(s) evaluation or that clinically interferes with the endpoints from this study, or patient is planning to participate in such study prior to the completion of this study - Patient has had any major (e.g. cardiac, peripheral, abdominal) surgical procedure or intervention unrelated to this study within 30 days prior to the index procedure or has planned major surgical procedure or intervention within 30 days of the index procedure - An intervention in the contralateral limb, planned within 30 days post-index procedure - Patient had previous bypass surgery of the target lesion - Patient had previous treatment of the target vessel with thrombolysis or surgery - Patient is unwilling or unable to comply with procedures specified in the protocol or has difficulty or inability to return for follow-up visits as specified by the protocol - Target lesion involves an aneurysm or is adjacent to an aneurysm (within 5mm) - Target lesion requires treatment with alternative therapy such as stenting, laser, atherectomy, cryoplasty, brachytherapy or re-entry devices - Significant target vessel tortuosity or other parameters prohibiting access to the target lesion - Presence of thrombus in the target vessel - Iliac inflow disease requiring treatment, unless the iliac artery disease is successfully treated first during the index procedure. Success is defined as ≤30% residual diameter stenosis without death or major complications - Presence of an aortic, iliac or femoral artificial graft ||mesh_term:Peripheral Arterial Disease,Peripheral Vascular Diseases,||||
NCTID:NCT02129634||dmc_oversight:No||primary_outcome_count:1||primary_outcome_list:Primary patency of the treated (index) site at 6 months|6 months|,||||secondary_outcome_count:10||secondary_outcome_list:Limb-salvage rate|at 3, 6 and 12 months|,Primary patency of the treated (index) site|at 3 months|,Clinical categorisation of the treated ischemic leg|at 3, 6 and 12 months|,Minor amputation|at 3, 6 and 12 months|,Infrapopliteal surgical bypass of the trial leg|at 3, 6 and 12 months|,Infrapopliteal endovascular re-intervention of the trial leg|at 3, 6 and 12 months|,Primary patency of treated femoropopliteal sites|From the date of randomization until the date of end of primary patency of treated femoropopliteal sites (asscessed up to 12 months)|,Peri-procedural complications|(within 30 days)|,Death|From the date of randomization until the date of death from any cause (asscessed up to 12 months)|,Incremental cost-effectiveness ratio (ICER)|at 3 month, 6 month and 12 month|,||||arm_group_count:2||arm_group_list:CB-PTA arm|After successful crossing of the trial lesion, a conventional angioplasty balloon with a diameter matching the trial vessel is advanced over the guidewire and is inflated at the trial lesion site, according to the normal practice of the operator. Comparisons of pre- and post-angioplasty percentage stenosis will be made in the same angiographic projection(s).,DEB-PTA arm|After successful crossing of the trial lesion, angioplasty with a conventional angioplasty balloon is performed before DEB-PTA. This is because the paclitaxel coating may be scrapped off the balloon if the DEB is used to cross the trial lesion. A conventional angioplasty balloon with a diameter matching the trial vessel is advanced over the guidewire and is inflated at the trial lesion site, according to the normal practice of the operator. A DEB with a diameter matching the trial vessel and lesion length is then advanced over the 0.018 inch guidewire and inflated at the trial lesion site for 60 seconds. If the lesion length is longer than the length of the balloon, a second inflation with another DEB will be required. The maximal total lesion length of the treated lesions will not exceed 20cm. Comparisons of pre- and post-angioplasty percentage stenosis will be made in the same angiographic projection(s).,||||inclusion_exclusion: Inclusion Criteria: - Written informed consent - Age > 21 years - If female patient with child bearing potential, patient may not be pregnant at the study entry and must utilize reliable birth control for the duration of her participation into the study - Patient is willing and able to comply with the specified follow-up evaluation - Critical Limb Ischaemia, Rutherford category 4 (ischaemic rest pain), 5 (minor tissue loss) or 6 (major tissue loss) - Stenosis (>50% luminal loss) or occlusion of infra-genicular arteries (defined as: distal to the infra-popliteal artery), including the tibiofibular trunk, the anterior tibial artery, the posterior tibial artery and the peroneal artery - Infragenicular arterial lesions with length of <20cm - At least one crural (anterior tibial, posterior tibial or peroneal) artery with expected unobstructed runoff to ankle level after treatment - Successful guidewire crossing of the trial lesion Exclusion Criteria: - Acute limb ischaemia - Subacute limb ischaemia which requires thrombolysis as first treatment modality - Previous major amputation of the affected limb (at or above the level of the ankle) - Concurrent iliac or femoropopliteal artery disease not suitable for endovascular or surgical revascularisation - Concurrent iliac or femoropopliteal artery occlusion of >10cm, even if suitable for surgical or endovascular revascularization - Patients without (expected) distal runoff to the index site - Revascularization involving the same site within 30 days prior to the index procedure or planned revascularization of the same limb within 30 days of the index procedure - Previous implanted stent at the index site - Life expectancy of less than 6 months - Factors making clinical follow-up very difficult or impossible - Known allergy to paclitaxel - Known allergy to contrast media - Patients on Warfarin or any other anti-coagulants - Known allergy to anti-platelet drugs (Aspirin/ Clopidogrel) (or) unable to tolerate dual anti-platelet drugs therapy - Active history of gastritis and other bleeding tendencies precluding use of dual anti-platelet therapy - Known heparin induced thrombocytopenia (HIT type 2) - Patient unable or unwilling to tolerate contrast media - eGFR less than 50 ml/min/1.73m2 unless patient is on dialysis. - If the patient has significant heart disease and Left Ventricular Ejection Fraction Percentage (LVEF%) is less than 35 %. - Either PT/PTT of >1.5 times the median of normal that cannot be corrected for the time of the procedure (or ) INR >1.6 that cannot be corrected for the time of the procedure - Thrombocytopenia of platelet count <50,000 /µL (50 X 109/L) which cannot be corrected for the time of the procedure ||mesh_term:Peripheral Arterial Disease,Peripheral Vascular Diseases,Ischemia,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT02772224||dmc_oversight:No||primary_outcome_count:2||primary_outcome_list:Restenosis rate|12 months|,Peak systolic velocity ratio|12 months|,||||secondary_outcome_count:3||secondary_outcome_list:Rutherford scale|Immediately after procedure|,ABI value|Immediately after procedure|,Residual stenosis|Immediately after procedure|,||||arm_group_count:2||arm_group_list:Drug eluting balloon angioplasty|Paclitaxel coated balloon angioplasty,Conventional balloon angioplasty|Conventional balloon angioplasty,||||inclusion_exclusion: Inclusion Criteria: 1. Patients with Peripheral vascular disease with or without diabetes. 2. Rutherford class 2-6. 3. Target lesions with a diameter reduction of at least 50% on angiography, and without past history of any intervention. 4. Target vessel with 2.0--10.0mm in diameter and having a lesion of about 4cm-20cm in length. 5. Written informed consent signed by the patients or representatives Exclusion Criteria: 1. Previous bypass surgery or stent placement at the ipsilateral lower limb 2. History of intolerance to antiplatelet therapy, heparin, or contrast media. 3. Bleeding diathesis; 4. Active systemic bacterial infection; 5. Severely impaired renal function (serum creatinine level > 2.5 mg/dL. 6. Expected survival time of less than 24 months ||mesh_term:Peripheral Arterial Disease,Peripheral Vascular Diseases,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT01556542||dmc_oversight:No||primary_outcome_count:1||primary_outcome_list:angiographic binary restenosis|12 months|,||||secondary_outcome_count:3||secondary_outcome_list:major amputation|24 months|,target lesion revascularization|24 months|,vessel reocclusion|24 months|,||||arm_group_count:2||arm_group_list:standard PTA|nitinol stent implantation,DEB|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation,||||inclusion_exclusion: Inclusion Criteria: - age>18 years - intermittent claudication(Fontane III or IV) - angiographic stenosis>50% or occlusion of superficial femoral-popliteal artery>40mm - at least one below-knee vessel to the ankle Exclusion Criteria: - allergy to Paclitaxel - contraindication for combined antiplatelet treatment - life expectancy <1 year - hypersensitivity or contraindication to one of the study drugs - lack of consent ||mesh_term:Peripheral Arterial Disease,Peripheral Vascular Diseases,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT02033135||dmc_oversight:No||primary_outcome_count:1||primary_outcome_list:Maximal walking distance|24 months|,||||secondary_outcome_count:3||secondary_outcome_list:Ankle brachial pressure indices|24 months|,Quality of life|24 months|,Cost of the treatment|24 months|,||||arm_group_count:2||arm_group_list:Angioplasty with Zilver PTX|Angioplasty and stenting with a polymer free paclitaxel-eluting stent (Zilver-PTX) plus unsupervised exercise therapy, smoking cessation advice and best medical therapy.,Best medical treatment|Unsupervised exercise therapy, smoking cessation advice and best medical therapy.,||||inclusion_exclusion: Inclusion Criteria: - Patient has signed and dated the informed consent. - Patient has 1- 2 documented stenotic or occluded atherosclerotic lesions (up to 18 cm long) of the above-the-knee femoropopliteal artery, that meet all of the inclusion criteria and none of the exclusion criteria. - Reference vessel (the above-the-knee femoropopliteal artery) diameter of 4 mm to 9 mm. - Taget lesion(s) should be accessible for stenting, as imaged with angiography (digital subtraction, MRI or CTI), i.e. proximal cm of SFA must be open - Patient has a de novo or restenotic lesion(s) with >50% stenosis documented angiographically and no prior stent in the target lesion. - Patient has symptoms of peripheral arterial disease classified as Rutherford Category 2 (moderate claudication) or 3 (severe claudication) lasting for at least 3 months. (Positive Claudication Questionnaire) - Exercise therapy, smoking cessation advise and best medical therapy must have been implemented at least 3 months ago and without significant clinical effect. - Patient has a resting ABI <0.9 or an abnormal exercise ABI (decrease of more than 0.15) if resting ABI is normal. Patient with incompressible arteries (ABI >1.2) must have a TBI <0.8. - Patient agrees to return for a clinical status assessment and duplex ultrasound at 6 weeks, 6 months, 12 months, and at 24 months. Exclusion Criteria: - Patient is pregnant, breast-feeding or under 18 years of age. - Patient unable to understand and sign informed consent forms - Patient is simultaneously participating in another investigational drug or device study. - Patient has any planned surgical or interventional procedure within 30 days after the study procedure. - Patient in whom antiplatelet and/or anticoagulant therapy is contraindicated. - Patient has known hypersensitivity or contraindication to aspirin, antiplatelet medication, contrast dye, paclitaxel or nitinol. - Patient 2-3 patent crural vessel runoff with <50% stenosis throughout its course. - Activity limited by co-morbid condition other than claudication, for example: severe coronary artery disease; angina pectoris; chronic lung disease; neurological disorder such as hemiparesis; arthritis, or other musculoskeletal conditions including amputation and BMI > 40 - Other active significant medical problems such as cancer, known chronic renal disease (serum creatinine greater than 2.0 mg/dl within 60 days or renal replacement therapy), known chronic liver disease or anaemia, active substance abuse, or known history of dementia ||mesh_term:Atherosclerosis,Peripheral Arterial Disease,Peripheral Vascular Diseases,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT02812966||dmc_oversight:No||primary_outcome_count:1||primary_outcome_list:Primary patency (Peak systolic velocity ratio<=2.4)|12 months|,||||secondary_outcome_count:1||secondary_outcome_list:Target lesion revascularization rate|12 months|,||||arm_group_count:2||arm_group_list:Lutonix DCB|Lutonix 035 Drug coated Balloon PTA Catheter,IN.PACT DCB|IN.PACT Admiral Paclitaxel-Coated PTA Balloon Catheter,||||inclusion_exclusion: Inclusion Criteria: 1. Patient is willing and able to provide informed consent, willing and agrees to comply with regular follow up visits, testing, medication regimen compliance any another treatments deemed necessary for treatment of vascular disease. 2. Male or non-pregnant female 3. Age greater >=18 years of age 4. Patients with moderate to severe claudication or ischemic rest pain as defined by Rutherford 2-4 class symptoms 5. >=1 tibial run-off vessel at baseline 6. Angiographic criteria - >=70% stenosis (via visual angiographic estimate in the superficial femoral artery and/or popliteal arteries as appropriate) - 4-7mm vessel diameter - <=15cm for planned treatment segment length. - Planned treatment segments are to no further proximal than 1 cm from the bifurcation of the common femoral artery and no further distal than the 1 cm above the tibioperoneal trunk. - Lesions treated within the target vessel are either De Novo lesions or not previously stented restenotic segments of the superficial femoral artery and/or popliteal artery that are greater than 90 days from prior angioplasty procedure - If the target vessel was previously stented the treated lesion must be at least 3 cm from the previously placed stent - Lesion must be able to be treated with either drug coated balloon device based on the sizes specifications of both devices - Successful, uncomplicated crossing must be possible within the treated lesion either with or without a crossing device - Inflow artery must be free from significant occlusive disease (< 50%) as confirmed by visual estimation by angiography otherwise the inflow artery must be treated beforehand. - At least 1 patent vessel outflow from the target vessel treated must be present by angiography Exclusion Criteria: 1. Unable to meet clinical criteria to have peripheral angioplasty and follow-up treatment (lab values and pregnancy test) 2. Contra-indicated to either DCB 3. < 18 years of age at time of consent and/or index procedure 4. Pregnant or Breast feeding 5. In-stent restenosis within the target lesion 6. Previously stented target lesion/vessel. 7. Target lesion/vessel previously treated with drug-coated balloon <12 months prior to randomization/enrollment. 8. Perforated vessel as evidenced by extravasation of contrast media prior to consent or enrollment. 9. Presence of other hemodynamically significant outflow lesions in the target limb requiring intervention <=30 days of consent or randomization. 10. Presence of aneurysm in the target vessel. 11. Major amputation in the target limb. 12. Subjects who have undergone prior surgery of the SFA/PPA in the target limb to treat atherosclerotic disease. 13. Use of atherectomy, laser or other debulking devices in the target limb SFA/PPA during the index procedure. 14. Acute ischemia and/or acute thrombosis of the SFA/PPA prior to consent or randomization. 15. Known hypersensitivity or contraindication to contrast dye that, in the opinion of the local investigator, cannot be adequately pre-medicated. 16. Known hypersensitivity/allergy to the investigational stent system or protocol related therapies. 17. On dialysis or on an immunosuppressant therapy. 18. Concomitant renal failure (including serum creatinine >2.0 mg/dL.) 19. Occurrence of myocardial infarction (MI) or cerebrovascular accident (CVA) <=6 months prior to consent. 20. Platelet count <80,000 mm3 or >600,000 mm3 or history of bleeding diathesis. 21. Unstable angina pectoris at the time of consent or randomization. 22. Septicemia at the time of consent or randomization. 23. Moderate to severely calcified lesions. ||mesh_term:Peripheral Arterial Disease,Peripheral Vascular Diseases,||||
NCTID:NCT00776906||dmc_oversight:n/a||primary_outcome_count:1||primary_outcome_list:Evaluation of Late Lumen Loss|6 months|,||||secondary_outcome_count:0||secondary_outcome_list:||||arm_group_count:2||arm_group_list:1|PTX-coated balloon,2|Bare balloon,||||inclusion_exclusion: Key Inclusion Criteria: - Age >18 years. - Able to provide informed consent. - Has at least one de novo or restenotic lesion(s) with > 70% stenosis documented angiographically of the SFA or popliteal artery. If more than one lesion requires intervention, only one should be treated as a study lesion. Key Exclusion Criteria: - Has significant stenosis (> 50%) or occlusion of inflow tract (proximal ipsilateral, iliofemoral, or aortic lesions) not successfully treated before this procedure. - Lack of at least one patent runoff vessel with < 50% stenosis throughout its course. - Lesions in target area requiring atherectomy (or ablative devices), cutting balloons, cryoplasty balloons, or any other advanced device to facilitate angioplasty balloon or stent delivery. ||mesh_term:Peripheral Arterial Disease,Peripheral Vascular Diseases,||||
NCTID:NCT02923193||dmc_oversight:Yes||primary_outcome_count:1||primary_outcome_list:Procedural success is defined as residual stenosis ≤30% without flow-limiting dissection (≥ grade D) prior to DCB or stenting by angiographic core lab.|Peri-Procedural|,||||secondary_outcome_count:6||secondary_outcome_list:Primary patency defined as freedom from clinically-driven target lesion revascularization (TLR) and freedom from restenosis determined by duplex ultrasound or angiogram greater than or equal to 50% stenosis.|Peri-Procedural|,Composite of new-onset Major Adverse Events (MAEs)|Within 30 days, 6, 12 and 24 months post procedure|,Primary patency|30 days, 6, 12 and 24 months|,Clinical Success ABI|30 days, 6, 12 and 24 months|,Clinical Success Rutherford Category|30 days, 6, 12 and 24 months|,Clinical Success Quality of Life|30 days, 6, 12 and 24 months|,||||arm_group_count:2||arm_group_list:Lithoplasty System followed by DCB|Shockwave Lithoplasty® Peripheral Lithoplasty System is a lithotripsy-enhanced, low-pressure balloon dilatation of calcified, stenotic peripheral arteries in patients who are candidates for percutaneous therapy. lithoplasty,Medtronic IN.PACT (DCB)|Medronic IN.PACT Drug Coated Balloon (DBS) is indicated for percutaneous transluminal angioplasty (PTA) in patients with obstructive disease of peripheral arteries, including patients with in-stent restenosis (ISR) and arteriovenous (AV) access to help maintain hemodialysis access in patients with end-stage renal disease.,||||inclusion_exclusion: Randomized Study Arm Eligibility Criteria General Inclusion Criteria 1. Subject is able and willing to comply with all assessments in the study. 2. Subject or subject's legal representative have been informed of the nature of the study, agrees to participate and has signed the approved consent form. 3. Age of subject is greater than or equal to 18. 4. Rutherford Clinical Category 2, 3, or 4 of the target limb. 5. Estimated life expectancy >1 year. 6. Subject is a suitable candidate for angiography and endovascular intervention in the opinion of the investigator or per hospital guideline. 7. Subject is intended to undergo treatment with Lithoplasty followed by DCB, or DCB with standard balloon pre-dilatation. Angiographic Inclusion Criteria 8. Target lesion that is located in a native, de novo superficial femoral artery (SFA) or popliteal artery (popliteal artery extends to and ends proximal to the ostium of the anterior tibial artery). 9. Target lesion reference vessel diameter is between 4.0mm and 7.0mm by visual estimate. 10. Target lesion is ≥70% stenosis by investigator via visual estimate. 11. Target lesion length is ≤180mm for lesions 70-99% stenosed. Target lesion can be all or part of the 180mm treated zone. 12. Chronic total occlusion, lesion length is ≤100mm of the total ≤180 mm target lesion. 13. Subject has at least one patent tibial vessel on the target leg with runoff to the foot, defined as no stenosis >50%. 14. Calcification is at least moderate defined as presence of fluoroscopic evidence of calcification: 1) on parallel sides of the vessel and 2) extending > 50% the length of the lesion if lesion is ≥50mm in length; or extending for minimum of 20mm if lesion is <50mm in length. General Exclusion Criteria 1. Rutherford Clinical Category 0, 1, 5 and 6. 2. Subject has active infection requiring antibiotic therapy. 3. Planned target limb major amputation (above the ankle). 4. History of prior endovascular or surgical procedure on the index limb within the past 30 days or planned within 30 days of the index procedure. 5. Subject has a known coagulopathy or has bleeding diatheses, thrombocytopenia with platelet count less than 100,000/microliter. 6. Subject in whom antiplatelet or anticoagulant therapy is contraindicated. 7. Subject has known allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately pre-treated. 8. Subject has known allergy to urethane, nylon, or silicone. 9. Myocardial infarction within 60 days prior to enrollment. 10. History of stroke within 60 days prior to enrollment. 11. History of thrombolytic therapy within two weeks of enrollment. 12. Subject has acute or chronic renal disease defined as serum creatinine of >2.5 mg/dL or >220 umol/L, or on dialysis. 13. Subject is pregnant or nursing. 14. Subject is participating in another research study involving an investigational agent (pharmaceutical, biologic, or medical device) that has not reached the primary endpoint. 15. Subject has other medical, social or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment, and the procedures and evaluations pre- and post-treatment. 16. The use of specialty balloons, re-entry or atherectomy devices. Angiographic Exclusion Criteria 17. In-stent restenosis within 10mm of the target zone. 18. Lesions within 10mm of the ostium of the SFA or within 10mm of the ostium of the anterior tibial artery. 19. Evidence of aneurysm or thrombus in target vessel. 20. No calcium or mild calcium in the target lesion. 21. Target lesion within native or synthetic vessel grafts. 22. Subject has significant stenosis (>50% stenosis) or occlusion of inflow tract before target treatment zone (e.g. iliac or common femoral) not successfully treated. 23. Subject requires treatment of a peripheral lesion on the ipsilateral limb distal to target site at the time of the index procedure. 24. Failure to successfully cross the guidewire across the target lesion; successful crossing defined as tip of the guidewire distal to the target lesion in the absence of flow limiting dissections or perforations. Subjects who do not meet the inclusion/exclusion criteria for the randomized study may satisfy the eligibility criteria for the observational study. Observational Study Eligibility Criteria Inclusion Criteria 1. Subjects intended to be treated with the Shockwave Medical Peripheral Lithoplasty® System for de-novo or restenotic lesions of the femoral, ilio-femoral, popliteal, and infra-popliteal arteries. 2. Subjects presenting with claudication or CLI by Rutherford Clinical Category 2,3,4,5, or 6 of the target limb. 3. Age of subject is > 18. 4. Subject or subject's legal representative have been informed of the nature of the study, agrees to participate, and has signed the approved study consent form. 5. Calcification is at least moderate, defined as presence of fluoroscopic evidence of calcification: 1) on parallel sides of the vessel and 2) extending > 50% the length of the lesion if lesion is ≥50mm in length; or extending for minimum of 20mm if lesion is <50mm in length. Exclusion Criteria 1. Subjects with any medical condition that would make him/her an inappropriate candidate for treatment with Shockwave Medical Peripheral Lithoplasty® System as per Instructions for Use (IFU) or investigator's opinion. 2. Subject is already enrolled in other investigational (interventional) studies that would interfere with study endpoints. ||mesh_term:Peripheral Arterial Disease,Peripheral Vascular Diseases,||||
NCTID:NCT02936622||dmc_oversight:n/a||primary_outcome_count:1||primary_outcome_list:The percent diameter stenosis within the study lesion evaluated by conventional angiography.|6 months|,||||secondary_outcome_count:0||secondary_outcome_list:||||arm_group_count:3||arm_group_list:Stent 1|Zilver® PTX Stent,Stent 2|Zilver® Paclitaxel-Eluting Peripheral Stent with slower-dissolving polymer-free paclitaxel coating,Stent 3|Zilver® Paclitaxel-Eluting Peripheral Stent with higher-dose polymer-free paclitaxel coating,||||inclusion_exclusion: Inclusion Criteria: - One de novo or restenosed artherosclerotic lesion with ≥ 50% diameter stenosis - Symptoms of peripheral arterial disease (Rutherford 2-4) Exclusion Criteria: - Pregnant, breastfeeding, or planning to become pregnant in the next 5 years - Less than 18 years old - Medical condition or disorder that would limit life expectancy to less than 12 months or that may cause noncompliance with the protocol or confound the data analysis - Previous stent in the study vessel ||mesh_term:Peripheral Arterial Disease,Peripheral Vascular Diseases,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT01175850||dmc_oversight:Yes||primary_outcome_count:2||primary_outcome_list:Primary Patency|12 Month|,Primary Safety Composite|12 month|,||||secondary_outcome_count:17||secondary_outcome_list:Major Adverse Events (MAE) Composite|12 month|,All-cause Death|12 month|,Target Vessel Revascularization (TVR)|12 month|,Target Lesion Revascularization (TLR)|12 month|,Time to First Clinically Driven Target Lesion Revascularization (CD-TLR)|12 month|,Major Target Limb Amputation|12 month|,Thrombosis at the Target Lesion|12 month|,Primary Sustained Clinical Improvement|12 month|,Secondary Sustained Clinical Improvement|12 month|,Duplex-defined Binary Restenosis (Peak Systolic Velocity Ratio (PSVR) >2.4).|12 month|,Duplex-defined Binary Restenosis (Peak Systolic Velocity Ratio >3.4).|12 month|,Change From Baseline in Quality of Life Assessment by EuroQol Group 5-Dimension Self Report Questionnaire (EQ5D) at Month 12|Baseline to 12 month|,Change From Baseline in Walking Capacity Assessment by Walking Impairment Questionnaire (WIQ) at 12 Months|12 month|,Device Success|Day 1|,Procedural Success|Day 1|,Clinical Success|Day 1|,Days of Hospitalization Due to the Index Lesion|12 month|,||||arm_group_count:2||arm_group_list:Drug-Coated Balloon (DCB)|IN.PACT Admiral: Balloon Angioplasty,Standard PTA|Standard Percutaneous Transluminal Angioplasty (PTA) Balloon: Balloon Angioplasty,||||inclusion_exclusion: General Inclusion Criteria: - Age ≥18 years and ≤85 years - Patient or patient's legal representative is informed of the nature of the study, agrees to participate and has signed an EC approved consent form Angiographic Inclusion Criteria: - Target vessel is the superficial femoral artery and/or proximal popliteal artery (above the knee) General Exclusion Criteria: - Patient unwilling or unlikely to comply with follow-up schedule - Stroke or STEMI within 3 months prior enrolment Angiographic Exclusion Criteria: - Acute or sub-acute thrombus in the target vessel ||mesh_term:Peripheral Arterial Disease,Peripheral Vascular Diseases,||||
NCTID:NCT02625740||dmc_oversight:No||primary_outcome_count:2||primary_outcome_list:Number of patients with Freedom from clinically driven target lesion revascularization (TLR) and significant restenosis|6 months follow up|,Number of device and procedure related deaths and major adverse clinical events|1 months follow-up|,||||secondary_outcome_count:4||secondary_outcome_list:Percentage of Intraoperative Technical success|Intraoperative|,Number of participants with Clinically driven target lesion revascularization|12 months follow up|,Number of participants with clinical improvement|12 months follow up|,Number of Death and major adverse clinical events|12 months follow up|,||||arm_group_count:2||arm_group_list:Study group|After crossing the lesion with a guidewire, patients will be treated with intravascular high intensity, low-frequency ultrasound followed by local administration of liquid mixture of Paclitaxel and Iopromide-370 with predetermined dosage of 1.0 µg/mm,Control group|After crossing the lesion with a guidewire, patients will be treated with drug eluting ballon angioplasty with the In.Pact Admiral ballon (Medtronic),||||inclusion_exclusion: Inclusion Criteria: - Rutherford category ≥4 - femoral-popliteal lesion ≥10cm - successful intraluminal recanalization without need of a stent to obtain a satisfactory angiographic result - at least one patent below the knee vessel - patients older than 18 years Exclusion Criteria: - Rutherford category < 4 - pregnancy - known allergies to study medications and materials - need of sub-intimal approach to perform the recanalization - target vessel stent release ||mesh_term:Peripheral Arterial Disease,Peripheral Vascular Diseases,Ischemia,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT01858363||dmc_oversight:Yes||primary_outcome_count:2||primary_outcome_list:Primary Efficacy Endpoint|12 months|,Primary Safety Endpoint|30-Days and 12-Months|,||||secondary_outcome_count:0||secondary_outcome_list:||||arm_group_count:2||arm_group_list:Paclitaxel-coated balloon|Subjects with de novo occluded/stenotic or re-occluded/restenotic lesions will be randomly assigned to treatment with a Paclitaxel-coated balloon or bare balloon.,Bare balloon|Subjects with de novo occluded/stenotic or re-occluded/restenotic lesions will be randomly assigned to treatment with a Paclitaxel-coated balloon or bare balloon.,||||inclusion_exclusion: Inclusion Criteria: - Symptomatic leg ischemia requiring treatment of the superficial femoral or popliteal arteries - Rutherford clinical category 2, 3 or 4 - Male or non-pregnant female at least 18 years Exclusion Criteria: - Co-existing clinically significant aneurismal disease of the abdominal aorta, iliac or popliteal arteries - Significant gastrointestinal bleeding or any coagulopathy that would contraindicate the use of anti-platelet therapy - Known intolerance of study medications, paclitaxel or contrast agent - Active participation in another investigational device or drug study ||mesh_term:Peripheral Arterial Disease,Peripheral Vascular Diseases,Intermittent Claudication,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT01366482||dmc_oversight:Yes||primary_outcome_count:1||primary_outcome_list:Target Lesion Percent Stenosis|1 year|,||||secondary_outcome_count:0||secondary_outcome_list:||||arm_group_count:3||arm_group_list:Drug-eluting balloon|Subjects are randomized to have a lesion treated with a paclitaxel-coated balloon Intervention: Cotavance Drug-Eluting Balloon,Plaque excision + drug-eluting balloon|Subjects are randomized to have a lesion treated with plaque excision (PE) followed by treatment with a paclitaxel-coated balloon Intervention: SilverHawk/TurboHawk + Cotavance Drug-Eluting Balloon,Severely Ca++ Group|Subjects with a severely calcified lesion will be assigned to a non-randomized arm and treated with plaque excision followed by a drug-eluting balloon Intervention: SilverHawk/TurboHawk + Cotavance Drug-Eluting Balloon,||||inclusion_exclusion: Inclusion Criteria: - Rutherford Clinical Category 2-4 - At least 18 years of age - Is able and willing to provide written informed consent prior to study specific procedures Exclusion Criteria: - Has a life expectancy of less than 24 months - Is pregnant, of childbearing potential not taking adequate contraceptive measures, or nursing - Has one or more of the contraindications listed in the SilverHawk/ TurboHawk or Cotavance IFUs ||mesh_term:Peripheral Arterial Disease,Peripheral Vascular Diseases,Intermittent Claudication,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT02004951||dmc_oversight:No||primary_outcome_count:1||primary_outcome_list:Freedom from in-stent restenosis at 1 year|1 year|,||||secondary_outcome_count:0||secondary_outcome_list:||||arm_group_count:2||arm_group_list:Misago RX (Misago RX, Terumo Corp., Tokyo|The Misago RX is a peripheral stent (Misago RX, Terumo Corp., Tokyo, Japan) indicated to treat iliac and femoropopliteal arteries. The Misago RX is a flexible self-expanding nitinol stent that is delivered via a RX monorail delivery catheter.,Zilver PTX (Cook Medical, Bloomington, IN, USA)|Zilver PTX (Cook Medical, Bloomington, IN, USA) is a nitinol stent with a polymer-free paclitaxel coating designed to treat the above- the-knee femoropopliteal arteries. The anti-proliferative drug is the paclitaxel, a cytotoxic drug. The Zilver PTX stent is delivered via a over-the-wire system.,||||inclusion_exclusion: Inclusion criteria - Patient ≥18 years - Patient has a history of symptomatic peripheral arterial disease (Rutherford classification: 2-5) - Lesion is eligible for treatment with a maximum of 2 stents per lesion (treatment of both legs is not permitted) - Patient is affiliated to the Social Security or equivalent system - Patient has been informed of the nature of the study, agrees to its provisions (and only for swiss centers, has signed the informed consent form prior to any study related procedure) - Patient agrees to undergo all protocol required follow-up examinations and requirements at the investigational site - Reference vessel diameter 4 to 7-mm determined by CT scan (RVD obtained from averaging 5-mm segments proximal and distal to the lesions) - Target lesion has a pre-procedure percent diameter stenosis of ≥ 50% DS - De novo atherosclerotic lesions (stenosis and/or occlusion) of the superficial femoral artery, the proximal popliteal artery (P1), or both. The treatment area in the SFA and popliteal artery extended from 1 cm below the origin of the profunda femoris artery to 3 cm above the proximal margin of the intercondylar fossa of the femur. - Target lesion (single or multiple) has a maximal total length =14-cm and a minimal length = 2-cm - At least 1 patent runoff vessel (<50% DS throughout its course). The inflow artery(ies) cannot be treated using a drug eluting stent or drug coated balloon. Exclusion Criteria - Asymptomatic lesion - Restenosis - No atheromatous disease - Untreated >50% DS of the inflow tract - Resting ankle brachial index (ABI) unavailable - Female of child bearing potential - Patient has received, or is on the waiting list for a major organ transplant - Patient has a history of coagulopathy or will refuse blood transfusions - Patient is receiving or scheduled to receive anticancer therapy for malignancy within 1 year prior to or after the procedure - Severe concomitant disease with life expectation < one year - Known allergy to paclitaxel - Contraindication to Aspirin or Clopidogrel and Ticlopidin (the patient must be able to receive Dual Anti-Platelet Treatment for 2 months after the procedure) - Patient has an infected wound or osteomyelitis on the ipsilateral extremity or foot. - Patient has had prior major amputation to the ipsilateral (target) extremity - Patient is not able to give informed consent (and only for swiss centers) - Patient is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints Note: Trials requiring extended follow-up for products that were investigational, but have become commercially available since then, are not considered investigational trials - Patient has previously had, or requires, bypass surgery, endarterectomy or other vascular surgery on any vessel of the ipsilateral extremity - In the Investigator's opinion patient has (a) co-morbid condition(s) that could limit the patient's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study - Target lesion lies within or adjacent to an aneurysm - Patient with an allergy to contrast agent - Patient with a severe allergy to metal - Surgery or endovascular intervention of the target member within 14 days preceding the BATTLE procedure ||mesh_term:Peripheral Arterial Disease,Peripheral Vascular Diseases,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT02962141||dmc_oversight:No||primary_outcome_count:1||primary_outcome_list:Primary patency rate of the target lesion|at 6 month post procedure|,||||secondary_outcome_count:8||secondary_outcome_list:Device Success|intraoperative|,Technical Success|intraoperative|,Clinical Success|at 1 month|,Procedural Success|at 1 month|,MAE rates (death or stroke)|at 1 month, 3 months, 6 months, and 12 months post procedure.|,The diameter stenosis rate in target lesion|at 6 months post procedure|,Clinical-driven Target Lesion Revascularization (CD-TLR)|in1st, 3rd, 6th, 12th month post operation|,Clinical-driven Target Shunt Revascularization (CD-TSR)|in 1st, 3rd, 6th, 12th month post operation|,||||arm_group_count:2||arm_group_list:APERTO OTW group|in the APERTO OTW group the subject will be treated with APERTO OTW balloon (Paclitaxel Releasing Peripheral Balloon Dilatation Catheter),OHICHO II group|in the OHICHO II group the subject will be treated with OHICHO II balloon (Balloon Dilatation Catheter),||||inclusion_exclusion: Inclusion criteria: Patients must meet all of the following criteria: - Age ≥ 18 years and ≤ 75 years, male or female. - Patient or legally authorized representative can understand the purpose of this clinic trial. He or She volunteers to participate in this trial and can provide written informed consent, and is willing to accept the scheduled follow-up in specific time points. - Angiography, ultrasound or clinical diagnosis shows that patients have hemodialysis access dysfunction due to stenosis lesions. - Patients with indications of the percutaneous endovascular therapy, that is, the AVF stenosis is related to hemodynamics and ≥ 50%, and with any of the following clinical and physiological abnormalities (referred to NKF-K/DOQI guideline definitions): 1. Thrombosis in the AVF; 2. Elevated venous pressure during dialysis 3. Obvious abnormality in recirculation measurements 4. Abnormal physical examination findings 5. Unexplained decreases in dialysis dose 6. Decreased access flow - Target lesion is a de novo or restenosis. The number of target lesions is 1. - Target lesion consists of a single lesion or a multiple lesions with target lesion length ≤ 40 mm. - Target lesion(s) is located in the reflux vein which is from the anastomosis of native arteriovenous fistula (AVF) to the distal end of subclavian vein, except the anastomosis of native AVF. - If patient has non-target lesion, it must be successfully treated using PTA before treating target lesion. - Reference vessel diameter of target lesion ≥ 4.0 mm and ≤ 7.0 mm by visual estimate (determined by angiography or DUS). - Hemodialysis access previously used (mature AVF) can no longer be successfully used due to insufficient shunt flow volume caused by local lumen stenosis. Exclusion criteria: Patients will be excluded if any of the following conditions applies: - Patients who have participated in another investigational drug or device trial. - Patients who have been enrolled in this trial previously. - Women of childbearing age with negative pregnancy test before procedure, and breastfeeding women. - Any major surgical procedure (such as thoracotomy, craniotomy, etc.) within 30 days prior to the procedure. - Any planned major surgical procedure (such as thoracotomy, craniotomy, etc.) within 30 days of entry into this study - Immature AVF, which cannot be used for Dialysis or has not been used successfully due to insufficient lumen diameter to ensure successfully puncture and insufficient shunt flow volume. - Patients with AVG. - AVF has been previously implanted with stent. - Lesion in AVF has been previously treated with DEB. - Target lesion is located in the anastomosis of native AVF. - Known allergies or intolerance to Paclitaxel or contrast medium. - Life expectancy < 1 year - Patients with comitans systemic lupus erythematosus and ANCA associated vasculitis. ||mesh_term:Peripheral Arterial Disease,Peripheral Vascular Diseases,Arteriovenous Fistula,Fistula,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT03241459||dmc_oversight:Yes||primary_outcome_count:2||primary_outcome_list:Primary Lesion Patency|12 months|,Safety composite of death, amputation, and target vessel revascularization (TVR)|12 months|,||||secondary_outcome_count:17||secondary_outcome_list:Device Success|Day 0|,Technical Success|Day 0|,Procedure Success|72 hours|,Clinical Success|30 days|,Primary Lesion Patency|24 months|,Target Vessel Patency|12 months, 24 months|,Sustained Clinical Improvement|6 months, 12 months, 24 months|,Clinically-driven TLR|6 months, 12 months, 24 months, 36 months, 48 months, and 60 months|,Historical MAEs|6 months, 12 months, 24 months, 36 months, 48 months, and 60 months|,Major amputation|6 months, 12 months, 24 months, 36 months, 48 months, and 60 months|,Thrombosis|6 months, 12 months, 24 months, 36 months, 48 months, and 60 months|,Rutherford Class|Screening, 1 month, 6 months, 12 months, and 24 months|,PARC Class|Screening, 1 month, 6 months, 12 months, and 24 months|,Ankle Brachial Index (ABI)|Screening, 6 months, 12 months, and 24 months|,Walking Impairment Questionnaire (WIQ)|Screening, 1 month, 12 months, and 24 months|,Six Minute Walk Test (6MWT)|Screening, 12 months, and 24 months|,Peripheral Artery Questionnaire (PAQ)|Screening, 1 month, 12 months, and 24 months|,||||arm_group_count:2||arm_group_list:Surmodics SurVeil DCB|Surmodics SurVeil Drug-Coated Balloon is an investigational device coated with paclitaxel.,Medtronic IN.PACT Admiral DCB|Surmodics SurVeil Drug-Coated Balloon is an investigational device coated with paclitaxel.,||||inclusion_exclusion: Inclusion Criteria: - Subject is ≥18 years. - Subject has target limb Rutherford classification 2, 3 or 4. - Subject has provided written informed consent and is willing to comply with study follow-up requirements. - De novo lesion(s) or non-stented restenotic lesion(s) occurring >90 days after prior plain old balloon (POBA) angioplasty or >180 days after prior DCB treatment. - Target lesion location starts ≥10 mm below the common femoral bifurcation and terminates distally at or above the end of the P1 segment of the popliteal artery. - Target vessel diameter ≥4 mm and ≤7 mm. - Target lesion must have angiographic evidence of ≥70% stenosis by operator visual estimate. - Chronic total occlusions may be included only after successful, uncomplicated wire crossing of target lesion via an anterograde approach and without the use of subintimal dissection techniques. - Target lesion must be ≤180 mm in length (one long lesion or multiple serial lesions) by operator visual estimate. Note: combination lesions must have a total lesion length of ≤180 mm by visual estimate and be separated by ≤30 mm. - Target lesion is located at least 30 mm from any stent, if target vessel was previously stented. - Successful, uncomplicated (without use of a crossing device) wire crossing of target lesion. Successful crossing of the target lesion occurs when the tip of the guide wire is distal to the target lesion without the occurrence of flow-limiting dissection or perforation and is judged by visual inspection to be within the true lumen. - After pre-dilatation, the target lesion is ≤70% residual stenosis, absence of a flow limiting dissection and treatable with available device matrix. - A patent inflow artery free from significant stenosis (≥50% stenosis) as confirmed by angiography. - At least one patent native outflow artery to the ankle or foot, free from significant stenosis (≥50% stenosis) as confirmed by angiography. Exclusion Criteria: - Subject has acute limb ischemia. - Subject underwent percutaneous transluminal angioplasty (PTA) of the target limb using plain old balloon angioplasty (POBA) or a stent within the previous 90 days. - Subject underwent any lower extremity percutaneous treatment using a paclitaxel-eluting stent or a DCB within the previous 90 days. - Subject underwent PTA of the target lesion using a DCB within the previous 180 days. - Subject has had prior vascular intervention in the contralateral limb within 14 days before the planned study index procedure or subject has planned vascular intervention in the contralateral limb within 30 days after the index procedure. - Subject is pregnant, breast-feeding or intends to become pregnant during the time of the study. - Subject has life expectancy less than 2 years. - Subject has a known allergy to contrast medium that cannot be adequately pre-medicated. - Subject is allergic to ALL antiplatelet treatments. - Subject has impaired renal function (i.e. serum creatinine level ≥2.5 mg/dL). - Subject is dialysis dependent. - Subject is receiving immunosuppressant therapy. - Subject has known or suspected active infection at the time of the index procedure. - Subject has platelet count <100,000/mm3 or >700,000/mm3. - Subject has history of gastrointestinal hemorrhage requiring a transfusion within 3 months prior to the study procedure. - Subject is diagnosed with coagulopathy that precludes treatment with systemic anticoagulation and/or dual antiplatelet therapy (DAPT). - Subject has history of stroke within the past 90 days. - Subject has a history of myocardial infarction within the past 30 days. - Subject is unable to tolerate blood transfusions because of religious beliefs or other reasons. - Subject is incarcerated, mentally incompetent, or abusing drugs or alcohol. - Subject is participating in another investigational drug or medical device study that has not completed primary endpoint(s) evaluation or that clinically interferes with the endpoints from this study, or subject is planning to participate in such studies prior to the completion of this study. - Subject has had any major (e.g. cardiac, peripheral, abdominal) surgical procedure or intervention unrelated to this study within 30 days prior to the index procedure or has planned major surgical procedure or intervention within 30 days of the index procedure. - Subject had previous bypass surgery of the target lesion. - Subject had previous treatment of the target vessel with thrombolysis or surgery. - Subject is unwilling or unable to comply with procedures specified in the protocol or has difficulty or inability to return for follow-up visits as specified by the protocol. - Target lesion has severe calcification (as defined by the PARC classification of calcification). - Target lesion involves an aneurysm or is adjacent to an aneurysm (within 5 mm). - Target lesion requires treatment with alternative therapy such as stenting, laser, atherectomy, cryoplasty, brachytherapy, re-entry devices, or subintimal dissection techniques. - Significant target vessel tortuosity or other parameters prohibiting access to the target lesion. - Presence of thrombus in the target vessel. - Iliac inflow disease requiring treatment, unless the iliac artery disease is successfully treated first during the index procedure. Success is defined as ≤30% residual diameter stenosis without death or major complications. - Presence of an aortic, iliac or femoral artificial graft. ||mesh_term:Vascular Diseases,Peripheral Arterial Disease,Peripheral Vascular Diseases,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT02962232||dmc_oversight:No||primary_outcome_count:1||primary_outcome_list:Target lesion restenosis determined by CTA|6 month post procedure|,||||secondary_outcome_count:9||secondary_outcome_list:device success rate|at 0-30 days|,operation success rate|at 0-30 days|,clinical success rate|at 0-30 days|,change of the Rutherford score|in day 0-30, 6th month, 12th month post operation|,change of the life equality by EQ5D|in day 0-30, 6th month, 12th month post operation compares to baseline|,target limb ulcer healing rate|in day 0-30, 6th month, 12th month post operation|,target lesion revascularization rate|in day 0-30, 6th month, 12th month post operation|,target limb upper amputation and lower amputation rate|in day 0-30, 6th month, 12th month post operation|,major adverse event rate including all cause death, target limb upper amputation and target lesion revascularization|in day 0-30, 6th month, 12th month post operation|,||||arm_group_count:2||arm_group_list:LEGFLOW OTW group|in the LEGFLOW OTW group the subject will be treated by the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW),AMPHIRION DEEP group|in the AMPHIRION DEEP group the subject will be treated by PTA catheter (AMPHIRION DEEP),||||inclusion_exclusion: Inclusion Criteria: - age from 18 to 85 years (include 18 and 85 year); - critical limb ischemia subjects (Rutherford classification from 3 to 6) - expective survival more than 1 year; - can understand the study objective, self willing enrolls and sign the informed consent, and accept scheduled followed up at the specific time. Angiographic inclusive criteria: - reference vessel diameter 2.0-3.5mm; - stenosis or occlusion in arterial vasculature below the knee shall have distal outflow; - target lesion stenosis ≥70% or occlusion, length ≤270mm; - if subject has ipsilateral / contralateral iliac lesions, the iliac lesion shall meet all the following criteria: - iliac lesion or occlusion length ≤100mm and - shall be treated earlier than the target lesion and - shall be treated successfully. the successful treatment standard: 1) residual stenosis <30%; 2) without flow limiting dissection 3) without thrombosis, embolism or any other serious adverse events Exclusion Criteria: - subjects currently participate in other drugs or medical devices clinical study and have not reach the primary endpoint; - childbearing aged women whose pregnancy test before intervention operation is not negative, and lactating mothers; - subjects with renal function insufficiency (serum creatinine> 2.5mg / dL or in renal dialysis); - subjects have known be allergy or contraindication to the contrast agent, paclitaxel, heparin, antiplatelet, anticoagulant or thrombolytic agents; - subjects plan to a major amputation (over metatarsal level); - stroke subjects within 3 months or stroke subjects with severe hemiplegia and aphasia associated sequelaes over 3 months before the intervention operation; - subjects with acute myocardial infarction, thrombolytic therapy or angina within 30 days before the intervention operation; - subjects whose target lesion limb have gangrene (the gangrene range over the metatarsophalangeal joint); - target lesion is a stenosis or occlusion that have prior been treated by scaffold implantation, DEB, ordinary balloon catheter or bypass graft; - lesions and /or occlusion locate or extend to popliteal artery or below ankle joint; - subjects requiring be intervention in bilateral lower limb; - the stenosis lesion of ipsilateral femoral artery or ipsilateral popliteal artery have a diameter stenosis ≥50% untreated before the intervention operation; - ipsilateral femoral artery or ipsilateral popliteal artery has single or adjacent lesion length ≥15cm, or ipsilateral femoral artery or ipsilateral popliteal artery has multiple lesion and one of these multiple lesion length ≥10cm or occlusion; - - adjacent lesion: 1) interval no more than 30 mm, 2) can be treated as a single lesion; - - multiple lesion: 1) interval no more than 30 mm, 2) need to be treated as multiple lesion; - the residual stenosis still ≥30%, even when the length <15cm and stenosis ≥50% single or adjacent lesion in ipsilateral femoral artery or ipsilateral popliteal artery has been treated, or when each lesion length <10cm and stenosis ≥50% multiple lesion in ipsilateral femoral artery or ipsilateral popliteal artery has been treated; - DES and /or DEB has been used in the inflow vessel of lesions treatment; - subject has no patency vessel below the ankle artery before the intervention operation; - target vessel aneurysm; - acute or subacute thrombosis in target vessel; - angiography shows severe calcification in the target lesion (before contrast injection or digital subtraction angiography, intensive annular calcifications that make target lesion not expansion and / or a calcification within the target lesion and locate on either sides of the vessel wall whose continuous length over than 5cm); - lesions that the guild wire cannot pass through; - subjects need be treated by thrombus endarterectomy, percutaneous transluminal plaque circumcision or laser treatment device indicate by intraoperative angiography; ||mesh_term:Peripheral Arterial Disease,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT02701543||dmc_oversight:Yes||primary_outcome_count:2||primary_outcome_list:Patency rate|1 year|,Composite of freedom from device and procedure-related death through 12 months post procedure as well as freedom from both target limb major amputation and clinically-driven target vessel revascularization|1 year|,||||secondary_outcome_count:5||secondary_outcome_list:Target Lesion Revascularization (TLR) rate|6,12,24 months|,Walking capacity|6,12,24 months|,binary restenosis|6,12,24 months|,improvement shift in Rutherford classification|6,12,24 months|,secondary Safety|60 months|,||||arm_group_count:2||arm_group_list:Ranger Drug Eluting Balloon|Intervention with Over the Wire (OTW) Percutaneous transluminal angioplasty (PTA )balloon catheter with a semi-compliant balloon coated with a formulation of 2μg/mm2 paclitaxel and acetyl tri-n-butyl citrate (ATBC) as carrier substance,In Pact Drug Eluting Balloon|Intervention with Over the Wire (OTW) peripheral balloon catheter. The balloon surface is coated with a formulation of 3μg/mm2 paclitaxel and urea as carrier substance.,||||inclusion_exclusion: Inclusion Criteria: 1. Subject age ≥ 18 2. Subject has been informed of the nature of the study, agrees to participate, and has signed a Medical Ethics Committee approved consent form Subject understands the duration of the study, agrees to attend follow-up visits, and agrees to complete the required testing Rutherford category 2-4. 3. Subject has a de novo or restenotic lesion with ≥ 70% stenosis documented angiographically and no prior stent in the target lesion. 4. Target lesion length is ≤ 30cm 5. Target lesion is at least 1cm below the origin of the profunda femoris and does not exceed the medial femoral epicondyle. 6. Multiple lesions with max. 3cm healthy vessel segment in between lesions can be considered at the discretion of the operator as one lesion. Total lesion length should not exceed 30 cm. 7. Reference vessel diameter (RVD) ≥ 4 mm and ≤ 6.5 mm by visual estimation. 8. Patency of at least one (1) infrapopliteal artery to the ankle (< 50% diameter stenosis) in continuity with the native femoropopliteal artery. 9. A guidewire has successfully traversed the target treatment segment. Exclusion Criteria: 1. Failure to successfully cross the target lesion 2. Angiographic evidence of severe calcification 3. Presence of fresh thrombus in the lesion. 4. Presence of aneurysm in the target vessel/s 5. Presence of a stent in the target lesion 6. Prior vascular surgery of the target lesion. 7. Stroke or heart attack within 3 months prior to enrollment 8. Any surgical procedure or intervention performed within 30 days prior to or post index procedure 9. Superficial femoropopliteal Artery or Proximal popliteal artery disease in the opposite leg that requires treatment at the index procedure 10. Target lesion requires treatment with alternative therapies such as stenting, laser, atherectomy, cryoplasty, brachytherapy, re-entry devices 11. Enrolled in another investigational drug, device or biologic study 12. Life expectancy of less than one year 13. Known allergies or sensitivity to heparin, aspirin, other anticoagulant/ antiplatelet therapies, paclitaxel or contrast media that cannot be adequately pre-treated prior to index procedure 14. Rutherford classification of 0, 1, 5 or 6. ||mesh_term:Peripheral Arterial Disease,Paclitaxel,||||
NCTID:NCT03421561||dmc_oversight:No||primary_outcome_count:2||primary_outcome_list:Target vessel patency at 24 months post-procedure|24 months post-procedure|,Freedom from target limb major amputation and clinically-driven target lesion revascularization through 24 months post-procedure|24 months post-procedure|,||||secondary_outcome_count:12||secondary_outcome_list:Major adverse event (MAE) rate at 24, 36, 48 and 60 months post-procedure, defined as a composite rate of cardiovascular death, target limb major amputation and clinically-driven target lesion revascularization (TLR)|24, 36, 48 and 60 months post-procedure|,Rate of clinically-driven target lesion revascularization|24, 36, 48 and 60 months post-procedure|,Rate of clinically-driven target vessel revascularization|24, 36, 48 and 60 months post-procedure|,Rate of target limb major amputation|24, 36, 48 and 60 months post-procedure|,Mortality rate|24, 36, 48 and 60 months post-procedure|,Rate of occurrence of arterial thrombosis of the treated segment|24, 36, 48 and 60 months post-procedure|,Patency rate defined as the absence of target lesion restenosis as determined by duplex ultrasound (PSVR ≤ 2.5) and freedom from clinically-driven TLR|24 and 36 months post-procedure|,Change in ankle-brachial index (ABI) from pre-procedure|24 and 36 months post-procedure|,Change in walking impairment questionnaire (WIQ) from pre-procedure|24 and 36 months post-procedure|,Change in walking distance from pre-procedure|24 and 36 months post-procedure|,Change in Rutherford-Becker classification from pre-procedure|24 and 36 months post-procedure|,Change in EQ-5D from pre-procedure|24 and 36 months post-procedure|,||||arm_group_count:2||arm_group_list:DCB Subjects|The Stellarex DCB is a commercially available PTA balloon catheter (EverCross™ 0.035" PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.Basic Catheter SpecificationsGuidewire: 0.035"Balloon Length: 40/80/120 mmSheath Compatibility: greater than or equal to 6 FrenchBalloon Diameter: 4/5/6 mmShaft length: 135 cm The nominal dose density of paclitaxel on the Stellarex DCB is 2.0 μg/mm2. Indications The Stellarex 0.035" OTW Drug-coated Angioplasty Balloon is indicated for percutaneous transluminal angioplasty (PTA), after appropriate vessel preparation, of de novo or restenotic lesions up to 180 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-6 mm.,PTA Subjects|The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA).Basic Catheter SpecificationsGuidewire: 0.035"Balloon Length: 40/80/120 mmSheath Compatibility: greater to or equal to 6 FrenchBalloon Diameter: 4/5/6 mmShaft length: 135 cm Indications The EverCross Balloon Catheter is intended to dilate stenosis in the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries, and to treat obstructive lesions of native or synthetic arteriovenous dialysis fistulae. This device is also indicated for stent post-dilation in the peripheral vasculature. For additional information refer to the EverCross Instructions for Use.,||||inclusion_exclusion: Inclusion Criteria - From ILLUMENATE Pivotal IDE population TP-1397E Study subjects must fulfill the following clinical criteria: 1. Symptomatic leg ischemia, requiring treatment of the superficial femoral artery (SFA) and/or popliteal artery. 2. Greater than or equal to 18 years of age. 3. Willing to provide written informed consent, and capable and willing to comply with all required follow-up evaluations within the defined follow-up visit windows. 4. Will not undergo other planned vascular interventions within 14 days before and/or 30 days after the protocol treatment (successful treatment of ipsilateral and contralateral iliac permitted prior to enrollment). 5. Life expectancy >1 year. 6. Rutherford-Becker classification of 2, 3 or 4. Study Subjects must fulfill the following angiographic criteria: 7. De novo or restenotic lesion (except for in-stent restenotic lesion) >70% within the SFA and/or popliteal artery in a single limb. 8. Single lesion which is ≥3 cm and ≤18cm in length (by visual estimation). NOTE: Tandem lesions can be treated. A tandem lesion is defined as two distinct lesions with 3 cm or less of healthy vessel separating the two diseased areas. The total cumulative length of the tandem lesions, including the healthy vessel, must not exceed 18 cm. 9. Lesion is treatable by no more than two (2) study devices. 10. Successful wire crossing of the lesion. The guidewire advancement should not be indicative of the presence of fresh thrombus in the lesion. 11. Target reference vessel diameter is ≥4 mm and ≤6 mm (by visual estimation). 12. Inflow artery is patent, free from significant lesion stenosis (≥50% stenosis is considered significant) as confirmed by angiography. Treatment of a target lesion is acceptable after successful treatment of inflow artery lesion(s). NOTE: Successful inflow artery treatment is defined as attainment of residual diameter stenosis <30% without death or major vascular complication. 13. Target limb with at least one patent (less than 50% stenosis) tibio-peroneal run-off vessel confirmed by baseline angiography or prior magnetic resonance (MR) angiography or computed tomography (CT) angiography (within 45 days prior to index procedure). NOTE: treatment of outflow disease is NOT permitted. Exclusion Criteria - Subject with any of the following clinical criteria should be excluded: 1. Females who are pregnant, lactating, or intend to become pregnant, or males who intend to father children during study participation. 2. Known aortic aneurysm(s) > 5 cm. 3. Contraindication to dual anti-platelet therapy. 4. Known intolerance to study medications, paclitaxel or contrast agents that in the opinion of the investigator cannot be adequately pre-treated. 5. Current participation in an investigational drug or another device study. 6. History of hemorrhagic stroke within 3 months. 7. Previous or planned surgical or interventional procedure within 14 days before or 30 days after the index procedure (successful treatment of ipsilateral and contralateral iliac permitted prior to enrollment). 8. Prior endovascular treatment of target lesion by percutaneous transluminal angioplasty or any other means of previous endovascular treatment (e.g. stents/stent grafts, cutting balloon, scoring balloon, cryoplasty, thrombectomy, atherectomy, brachytherapy or laser devices) within six months of the index procedure, or any previous placement of a bypass graft proximal to the target lesion. 9. Treatment of lesions in the contralateral limb with the CVI Paclitaxel-coated PTA Catheter. 10. Use of the CVI Paclitaxel-coated PTA Catheter in other than a single treatment session. 11. Chronic renal insufficiency (dialysis dependent, or serum creatinine >2.5 mg/dL within 30 days of index procedure). Subject with any of the following angiographic criteria should be excluded: 12. Significant contralateral or ipsilateral common femoral disease that requires intervention during the index procedure. 13. No normal proximal arterial segment of the target vessel in which duplex ultrasound velocity ratios can be measured. 14. Known inadequate distal outflow. 15. Acute or sub-acute thrombus in the target vessel. 16. Aneurysmal target vessel. 17. Use of adjunctive therapies (i.e. laser, atherectomy, cryoplasty, scoring/cutting balloons, brachytherapy) during the index procedure in the target lesion or target vessel. 18. Treatment of the contralateral limb during the same procedure or within 30 days following the study procedure (exclusive of the iliac arteries which can be treated prior to enrollment). 19. Presence of concentric calcification that precludes PTA pre-dilation. 20. Prior stent placement in the target vessel. 21. Residual stenosis of greater than 70%, stent placement or flow-limiting (Grade D or greater) dissection following pre-dilation. ||mesh_term:Peripheral Arterial Disease,Paclitaxel,||||
NCTID:NCT01728441||dmc_oversight:Yes||primary_outcome_count:2||primary_outcome_list:Peak Systolic Velocity Ratio (PSVR)|12 months|,target lesion revascularization (TLR)|12 months|,||||secondary_outcome_count:9||secondary_outcome_list:Major Adverse Events (MAEs)|6, 12 and 24 months|,All cause death|6, 12 and 24 months|,Target vessel revascularization (TVR)|6, 12 and 24 months|,Clinically-driven target lesion revascularization (TLR)|6, 12 and 24 months|,Major target limb amputation within 6, 12 and 24 months. Major target limb Major target limb amputation|6, 12 and 24 months|,Sustained clinical improvement|6, 12 and 24 months|,Binary restenosis|6, 12 and 24 months|,Walking capacity|6, 12 and 24 months|,Procedural success|6, 12 and 24 months|,||||arm_group_count:2||arm_group_list:Paclitaxel Eluting Stent|Patients randomized to treatment with paclitaxel eluting stent will receive the Zilver® PTX® stent.Primary stenting should be performed covering the full lesion. Post-dilatation is at the investigator's discretion.,Paclitaxel Eluting Balloon|For patients randomized to treatment with drug eluting balloon (DEB), angioplasty (ballooning) should be performed covering the full lesion.,||||inclusion_exclusion: Inclusion Criteria: - Subject age ≥ 18 - Subject has been informed of the nature of the study, agrees to participate, and has signed a Medical Ethics Committee approved consent form. - Subject understands the duration of the study, agrees to attend follow-up visits, and agrees to complete the required testing. - Rutherford category 2-5. - Subject has a de novo or restenotic lesion with ≥ 70% stenosis documented angiographically and no prior stent in the target lesion. - Target lesion is at least 1cm below the origin of the profunda femoris and does not exceed the medial femoral epicondyle. - A single target lesion (stenotic areas separated by more than 3 cm with ≤ 30% stenosis might, at the decision of the investigator, be considered as 2 lesions). - Reference vessel diameter (RVD) ≥ 4 mm and ≤ 6.5 mm by visual assessment. - Patency of at least one (1) infrapopliteal artery to the ankle (< 50% diameter stenosis) in continuity with the native femoropopliteal artery. - A guidewire has successfully traversed the target treatment segment. Exclusion Criteria: Clinical exclusion criteria - Inability to obtain informed consent. - Life expectancy < 12 months. - Pregnancy, suspected pregnancy, or breastfeeding during study period (patients of childbearing potential must have negative serum pregnancy test 7 days prior to treatment). - Presence of one or more of the following co-morbid factors: hemodialysis dependence, renal insufficiency with a serum creatinine ≥ 2.5 mg/dl, cerebrovascular accident (CVA) within 1 month of procedure or any CVA resulting in unresolved walking impairment, and/or myocardial infarction (MI) within 1 month of procedure. - Any evidence of hemodynamic instability prior to procedure/randomization. - Coagulopathy or clotting disorders. - Present or suspected systemic infection or osteomyelitis affecting target limb. - Contraindication to contrast media or any study-required medication (antiplatelets, anticoagulants, thrombolytics, etc). - Hypersensitivity to nitinol and/or paclitaxel. - Enrollment into another study. - Intervention of the target lesion less than 90 days prior of the study procedure. Anatomic Exclusion Criteria: - Untreated external iliac artery inflow lesion (study allows for successful treatment prior to study treatment procedures). - Total occlusion uncrossable by a conventional guidewire. - Acute occlusive intraluminal thrombosis of the proposed lesion site. - Evidence of an aneurysm at the target lesion site. - Perforation in the target vessel as evidenced by the extravasation of contrast. ||mesh_term:Peripheral Arterial Disease,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT01960647||dmc_oversight:No||primary_outcome_count:1||primary_outcome_list:Rate of clinically driven target lesion revascularization|6 months|,||||secondary_outcome_count:10||secondary_outcome_list:Technical success|Baseline|,Clinical success|Baseline|,Procedural success|Baseline|,Ankle Brachial index improvement|6, 12, 24 months|,Change in Rutherford classification|6, 12, 24 months|,Walking improvement|6, 12 ,24 months|,Rate of minor and major complications|6,12, 24 months|,Rate of target lesion revascularization|12, 24 months|,Late lumen loss|6 months|,Patency rate|6, 12, 24 months|,||||arm_group_count:2||arm_group_list:Uncoated PTA balloon catheter|Dilatation with uncoated PTA balloon catheter,Freeway Paclitaxel balloon catheter|Dilatation with Freeway Paclitaxel (3 µg/mm2) coated balloon catheter,||||inclusion_exclusion: Inclusion Criteria: - Male or non-pregnant female (> 18 years of age) with symptomatic ischemia, requiring treatment of SFA or PI segment ( 2-5 of Rutherford classification) - Single and/or multiple de novo occluded, stenotic or reoccluded, restenotic lesion(s) of > 70% , ≤ 15 cm in total length and vessel diameter ≥ 4mm and ≤ 7mm (by visual estimation). - Patient provides a signed informed consent and complies with the follow up visits - Successful wire crossing of lesion - At least one patent (less than 50% stenosis) tibioperoneal run-off vessel Exclusion Criteria: - Gastrointestinal bleeding or coagulopathy contraindicating use of anti-platelet therapy - Known intolerance contraindications to study medications and contrast agents, non-controllable with medication. - Patient actively participating in another device or drug study - History of hemorrhagic stroke within 3 months - Previous or planned surgical or intervention procedure within 30 days of index procedure - Significant untreated inflow disease or no normal arterial segment proximal of lesion in which duplex ultrasound velocity ratios can be measured - Acute or sub-acute thrombus in target vessel - Use of adjunctive therapies (i.e. laser, atherectomy, cryoplasty, scoring/cutting balloon) - Patients with in-stent restenosis or prior surgery of the target lesion - Patients with abdominal aortic, iliaca or popliteal aneurysm (AAA) with ≥ 4cm diameter ||mesh_term:Peripheral Arterial Disease,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT01969630||dmc_oversight:No||primary_outcome_count:1||primary_outcome_list:angiographic binary restenosis|12 months|,||||secondary_outcome_count:1||secondary_outcome_list:Composite of all cause mortality, major amputation and target lesion revascularization.|12 months|,||||arm_group_count:2||arm_group_list:PEB|PEB angioplasty plus provisional nitinol stent implantation,PES|Systematic PES angioplasty,||||inclusion_exclusion: Inclusion Criteria: - intermittent claudication or critical limb ischemia - de novo stenosis ≥ 50% or occlusion of at least 40 mm in length located in femoropopliteal arteries - presence of a clear healthy segment between the lesion in superficial femoral and common femoral artery and between popliteal and tibioperoneal trunk - presence of at least 1 patent tibial vessel with distal run-off (below-the-knee artery was considered patent if free from obstructive lesions determining angiographic stenosis >70%) Exclusion Criteria: - life expectancy <1 year - contraindication for combined antiplatelet therapy or known allergy to nickel or paclitaxel - need for major amputation (MA) at the time of enrolment - Failure to recanalize intended below-the-knee arteries in CLI patients at risk of major amputation ||mesh_term:Peripheral Arterial Disease,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT02279784||dmc_oversight:No||primary_outcome_count:1||primary_outcome_list:number of events of angiographic binary restenosis|12 months|,||||secondary_outcome_count:3||secondary_outcome_list:number of events of target lesion revascularization|12 months|,number of events of death|12 months|,frequency of major amputation|12 months|,||||arm_group_count:2||arm_group_list:Freeway|angioplasty with Freeway drug-eluting balloon,Lutonix|angioplasty with Lutonix drug-eluting balloon,||||inclusion_exclusion: Inclusion Criteria: - age>18 years - angiographic stenosis>50% or occlusion of one below-knee vessel Exclusion Criteria: - allergy to Paclitaxel - contraindication for combined antiplatelet treatment - life expectancy <1 year - hypersensitivity or contraindication to one of the study drugs - lack of consent - need for amputation ||mesh_term:Peripheral Arterial Disease,||||
NCTID:NCT02517827||dmc_oversight:Yes||primary_outcome_count:1||primary_outcome_list:Primary patency|12 month|,||||secondary_outcome_count:2||secondary_outcome_list:Primary patency|24 month|,target lesion revascularisation|6, 12, and 24 month|,||||arm_group_count:2||arm_group_list:Endovascular procedure|Common femoral artery (target lesion) to be treated with directional atherectomy and paclitaxel-coated balloon angioplasty. Optional: stentimplantation.,Surgery|Common femoral artery (target lesion) to be treated with open, surgical endarterectomy,||||inclusion_exclusion: Inclusion Criteria: 1. Subject must be between 21 and 85 years old; 2. Female of childbearing potential must have a negative pregnancy test within 10 days prior to index procedure and utilize reliable birth control until completion of the 12-month angiographic evaluation; 3. Clinical diagnosis of symptomatic peripheral artery disease defined by Rutherford 2, 3, or 4; 4. Common femoral artery (CFA) stenosis (including CFA bifurcation) >70% (visual estimate) or occlusion; Additional non-target lesion(s) in remaining non-target vessel(s), except ipsilateral iliac arteries, can be treated at the physician´s discretion; 5. At least one vessel outflow (infrapopliteal arteries) to the foot (without stenosis >50%). 6. Endovascular Procedure: successful target lesion crossing of the guidewire (guidewire located intraluminally); 7. Non-target lesion interventions (TASC A and B) to restore adequate blood flow, in the same index procedure are allowed. This intervention must be prior to the treatment of the study lesion and successful; 8. Willing to comply with the specified follow-up evaluation; 9. Written informed consent prior to any study procedures. Exclusion Criteria: 1. Ipsilateral significant (>50%) stenosis of the iliac arteries. 2. Significant (>50%) stenosis of all infrapopliteal arteries, no patent artery to the foot. 3. Angiographic evidence of thrombus within target vessel; 4. Thrombolysis within 72 hours prior to the index procedure; 5. In-Stent restenosis or restenosis of the native common femoral artery. 6. Aneurysm in the abdominal aorta or iliac arteries; 7. Concomitant hepatic insufficiency, thrombophlebitis, deep venous thrombus, coagulation disorder or receiving immunosuppressant therapy; 8. Recent MI or stroke < 30 days prior to the index procedure; 9. Life expectancy less than 24 months; 10. Known or suspected active infection at the time of the index procedure; 11. Known or suspected allergies or contraindications to aspirin, clopidogrel bisulfate (Plavix) and ticlopidine (Ticlid), heparin, or contrast agent; 12. Any significant medical condition which, in the investigator´s opinion, may interfere with the subject´s optimal participation in the study; 13. The subject is currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study. ||mesh_term:Peripheral Arterial Disease,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT03064126||dmc_oversight:Yes||primary_outcome_count:2||primary_outcome_list:Primary Lesion Patency|12 months|,Major Adverse Events (MAEs)|12 months|,||||secondary_outcome_count:15||secondary_outcome_list:Technical Success of angioplasty procedure|Day 0|,Procedural Success of angioplasty procedure|Day 0|,Clinical Success rate assessment|Day 0|,Major Adverse Events (MAE) assessment|1 month, 6 months, 12 months, 24 months, 36 months, 48 month and 60 months|,Assessment of Death occurrence from any cause|1 month, 6 months, 12 months, 24 months, 36 months, 48 months and 60 months|,Clinically-driven Target Vessel Revascularization (TVR) rates|6 months, 12 months, 24 months, 36 months, 48 months and 60 months|,Clinically-driven Target Lesion revascularization (TLR) rates|6 months, 12 months, 24 months, 36 months, 48 months and 60 months|,Rate of Primary Sustained Clinical Improvement as assessed by changes in Rutherford Classification|1 month, 6 months, 12 months, 24 months and 36 months|,Rate of Secondary Sustained Clinical Improvement as assessed by changes in Rutherford Classification|1 month, 6 months, 12 months, 24 months and 36 months|,Rate of Hemodynamic Improvement as assessed by changes in Ankle Brachial Index (ABI)|1 month, 6 months, 12 months, 24 months, and 36 months|,Target Lesion Restenosis rate|1 month, 6 months, 12 months, 24 months, and 36 months|,Walking Improvement assessed by change in Six Minute Walk Test (6MWT)|Screening, 6 months and 12 months|,Walking Improvement assessed by change in Walking Impairment Questionnaire (WIQ)|1 month, 6 months, 12 months, 24 months and 36 months|,Patient Utility Values by change in EQ-5D|1 month, 6 months, 12 months, 24 months and 36 months|,Changes in healthcare utilization over time rates|Index Procedure (Day 0), 1 month, 6 months, 12 months, 24 months, 36 months, 48 months and 60 months|,||||arm_group_count:2||arm_group_list:RANGER™ Paclitaxel Coated Balloon|RANGER™ Paclitaxel Coated Balloon Catheter angioplasty in the SFA/PPA at the index procedure.Subjects will be randomized 3:1 to the drug coated or standard angioplasty balloon.,Standard Balloon Angioplasty|Standard Balloon Catheter angioplasty in the SFA/PPA at the index procedure. Subjects will be randomized 3:1 to the drug coated or standard angioplasty balloon.,||||inclusion_exclusion: Inclusion Criteria: 1. Subject (or Legal Guardian) is willing and able to provide consent before any study-specific tests or procedures are performed and agree to attend all required follow-up visits; 2. Subject at least 20 years of age; 3. Chronic symptomatic lower limb ischemia defined as Rutherford classification 2, 3, or 4; 4. Target lesion is in the native SFA and/or PPA down to the P1 segment; 5. Patent popliteal and infrapopliteal arteries, i.e., single vessel runoff or better with at least one of three vessels patent (less than 50 % stenosis) to the ankle or foot; 6. Reference vessel diameter ≥ 4 mm and ≤ 8 mm by visual estimate; 7. Angiographic evidence that target lesion consists of a single de novo, non-stented and non-atherectomy treated or restenotic lesion (or tandem lesions or a combination lesion as defined below) that is: - ≥ 70%-99% stenotic with total lesion length up to 180 mm by visual estimate. - Occluded with total lesion length ≤ 100 mm by visual estimate. - If lesion is restenotic, most recent PTA treatment must be > 3 months prior to enrollment. Exclusion Criteria: 1. Life expectancy, documented in the Investigator's opinion, of less than 12 months; 2. Hemorrhagic stroke or cardiac event (e.g. STEMI, unstable angina) within 6 months prior to enrollment; 3. Known allergies or sensitivities to heparin, aspirin, other anticoagulant/antiplatelet therapies, and/or paclitaxel; 4. Known hypersensitivity or contraindication to contrast dye that, in the opinion of the investigator, cannot be adequately pre-medicated; 5. Chronic renal insufficiency with serum creatinine > 2.0 mg/dL within 30 days of index procedure or treatment with dialysis; 6. Platelet count < 80,000 mm 3 or > 600,000 mm 3 or history of bleeding diathesis; 7. Receiving immunosuppressive therapy; 8. Septicemia at the time of enrollment; 9. Any major intervention planned within 30 days post index procedure; 10. Presence of other hemodynamically significant outflow lesions in the target limb requiring intervention within 30 days of enrollment; 11. Failure to successfully cross the target lesion with a guidewire; 12. Failure to successfully pre-dilate the target vessel; 13. Patient has lesion that requires the use of adjunctive primary treatment modalities (i.e. laser, atherectomy, scoring/cutting balloon, other debulking devices, etc.) during the index procedure; 14. History of major amputation in the target limb; 15. Target lesion or vessel has ever been previously treated with stent (e.g. in-stent restenosis) or surgery. Target lesion or vessel has been treated with atherectomy or a DCB in the past 12 months; 16. Pregnant or breast feeding; 17. Presence of aneurysm in the target vessel; 18. Acute ischemia and/or acute thrombosis of the SFA/PPA prior to enrollment; 19. Patient has significant inflow disease which cannot be treated prior to the target lesion treatment; 20. Patient has perforated targeted vessel as evidenced by extravasation of contrast media; 21. Patient has severe calcification that renders the lesion undilatable; 22. Current participation in another investigational drug or device clinical trial that has not completed the primary endpoint at the time of randomization/enrollment or that clinically interferes with the current trial endpoints. ||mesh_term:Atherosclerosis,Peripheral Arterial Disease,Arterial Occlusive Diseases,Plaque, Atherosclerotic,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT02013193||dmc_oversight:Yes||primary_outcome_count:1||primary_outcome_list:in-segment late lumen loss|six months|,||||secondary_outcome_count:20||secondary_outcome_list:technical success|during index procedure, less 1 hour|,procedural success|within 24 hours of index procedure|,primary patency|six months|,primary patency|twelve months|,assisted primary patency|six months|,assisted primary patency|twelve months|,secondary patency|six months|,secondary patency|twelve months|,binary restenosis rate|six months|,binary restenosis rate|twelve months|,clinical success|pre-discharge, estim. 1-2 days post-index procedure|,clinical success|six months|,clinical success|twelve months|,hemodynamic success|pre-discharge, estim. 1-2 days post-index procedure|,hemodynamic success|six months|,hemodynamic success|twelve months|,change in quality of life|six months|,change in quality of life|twelve months|,change in quality of life|24 months|,change in quality of life|36 months|,||||arm_group_count:2||arm_group_list:Ranger(TM) Paclitaxel-coated balloon|Index lesion treated with Ranger(TM) Paclitaxel-coated PTA balloon catheter (Ranger DCB),uncoated PTA balloon|Index lesion treated with an uncoated standard PTA dilatation balloon catheter selected upon investigator´s discretion,||||inclusion_exclusion: Inclusion Criteria: - Subjects must be age 18 or older - Subject is willing and able to provide informed consent - Subject is available to attend all required follow-up visits - Subject has a clinically significant symptomatic leg ischemia requiring treatment - Subject has a Rutherford clinical category of 2-4 - If the index lesion is restenotic, the prior PTA must have been >30 days prior to treatment in the current study - Only one lesion per limb can be treated under this protocol. - Successful intraluminal wire crossing of the target lesion - Index lesion is a clinically and hemodynamically significant stenotic or restenotic lesion located in the native nonstented superficial femoral artery or proximal popliteal artery - Degree of stenosis 70% or more, by visual assessment - Lesion length between 20 mm and 150 mm - At least one patent infrapopliteal artery to the foot of the index limb Exclusion Criteria: - Subjects who have undergone prior vascular surgery of the femoropopliteal artery in the index limb to treat atherosclerotic disease - History of major amputation in the same limb as the target lesion - Presence of aneurysm in the target vessel - Acute ischemia and/or acute thrombosis in any artery of the lower limbs - Acute Myocardial Infarction within 30 days before the index procedure - Persistent, intraluminal thrombus of the proposed target lesion post-thrombolytic therapy - Known hypersensitivity or contraindication to contrast dye that cannot be adequately pre-medicated - Known allergies against Paclitaxel or other components of the used medical devices - Intolerance to antiplatelet, anticoagulant, or thrombolytic medications that would be administered during the trial - Platelet count <100,000 mm3 or >600,000 mm3 - Concomitant renal failure with a serum creatinine >2.0 mg/dL - Receiving dialysis or immunosuppressant therapy - Life expectancy of less than one year - Women of child-bearing potential must agree to use a reliable method of contraception from the time of screening through 12 months after the index procedure. - Woman who is pregnant or nursing. - Previously planned stenting of the index lesion - Use of adjunctive therapies (debulking, laser, cryoplasty, re-entry devices) - Planned or expected procedures (cardiac, aorta, peripheral) within 30 days after the index procedure - Presence of outflow lesions requiring intervention within 30 days of the index procedure - Perforated vessel as evidenced by extravasation of contrast media - Heavily calcified target lesions resistant to PTA - Current participation in another drug or device trial that has not completed the primary endpoint, that may potentially confound the results of this trial, or that would limit the subject's compliance with the follow-up requirements - Current participation in any study using drug-coated/drug-eluting technologies - Current participation in any study using drug-coated/drug-eluting technologies - Target lesion with in-stent restenosis (any stent or stent-graft) ||mesh_term:Atherosclerosis,Peripheral Arterial Disease,Intermittent Claudication,Arteriosclerosis,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT02145065||dmc_oversight:Yes||primary_outcome_count:1||primary_outcome_list:Angiographic late lumen loss|6 months|,||||secondary_outcome_count:7||secondary_outcome_list:Safety - Device related adverse events|30 days, 6 months|,Critical limb ischemia|30 days, 6 months|,Device Success|at procedure|,Target Lesion Revascularization|6, 12, 24 months|,Target vessel revascularization|6, 12, 24 months|,Primary patency of treated segment|6, 12, 24 months|,Treated limb amputation|30 days, 6 months|,||||arm_group_count:2||arm_group_list:Plain Balloon Angioplasty|Plain Balloon Angioplasty,microcrystalline Paclitaxel Coated Balloon (PAK)|plain balloon angioplasty followed by mcPCB dilation,||||inclusion_exclusion: Inclusion Criteria: - Age > 18 y.o. - Claudication in Rutherford Class 1-5, - Lesion in the femoropopliteal artery defined as >50% and < 99% diameter stenosis with length of up to 10 cm in vessel diameter of 3-7 mm - Chronic total occlusions of length less than 100 mm - Ability to cross the lesions with a guidewire. Exclusion Criteria: - Critical acute or chronic limb ischemia - Acute coronary syndrome - Chronic kidney disease stage III-V - Restenotic lesion - Femoropopliteal graft - Known allergy to clopidogrel or aspirin - History of stroke within past 6 months - Age > 80 y.o. - Life expectancy < 2 years ||mesh_term:Peripheral Arterial Disease,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT01305070||dmc_oversight:No||primary_outcome_count:1||primary_outcome_list:Duplex-ultrasound determined recurrent restenosis in the superficial femoral artery (SFA)|6 month|,||||secondary_outcome_count:8||secondary_outcome_list:Recurrent restenosis within the stent at 12 month|12 month|,Clinically driven target lesion revascularization (TLR) at 6 and 12 month|6 and 12 month|,Recurrent stenosis >= 70% within the stent at 6 and 12 month|6 and 12 month|,Clinical and hemodynamic parameters|at 1, 6 and 12 month|,Primary angiographic success rate|12 month|,Major adverse vascular events (MAVE)|12 month|,Death|12 month|,Impact of "bail-out" stent-in-stent placement on 6-and 12-month end points|6 and 12 month|,||||arm_group_count:2||arm_group_list:Standart balloon angioplasty|Admiral Xtreme, Invatec,Paclitaxel-eluting balloon arm|In.Pact Admiral, Invatec,||||inclusion_exclusion: Inclusion Criteria: 1. Age > 21 years old. 2. Patient must sign informed consent form. 3. Patient must agree to participate in the study and comply with follow-up requirements. 4. Clinically, all patients must be in Rutherford category 2 to 4. Angiographic Inclusion Criteria: 5. Planned angioplasty of in-stent restenoses (degree of stenosis 70-100%) within the SFA. The target lesion must not extend beyond the stent margins. In cases of two or more stenotic regions within the stented segment, these are considered separate lesions if there is a nonstenotic or only mildly stenotic (< 30%) segment of at least 2 cm in length between them. Otherwise, they are considered a single lesion. In case of separate lesions, only the proximal lesion will be taken as the target lesion! 6. The length of the in-stent lesion should be at least 1 cm and maximally 20 cm (measurement by radiopaque ruler). 7. The degree of target lesion stenosis must be determined by pre-interventional duplex ultrasound. 8. The target lesion region starts at the origin of the SFA and ends distally at the femoropopliteal crossover (crossing by SFA of medial rim of femur in the PA projection). 9. Patency (< 50% stenosis) of popliteal artery and at least 1 infragenicular artery. Exclusion Criteria: General: 1. Patient is currently participating in another clinical trial. 2. Pregnancy or pregnancy planned during study duration. 3. Life expectancy less than 1 year. 4. Co-morbidities preventing study participation. 5. Severe coagulation disorders. 6. Current treatment with anticoagulants other than aspirin, ticlopidine, clopidogrel or prasugrel. 7. Active gastric ulcer or gastrointestinal bleeding. 8. Thrombotic occlusion of the target vessel within previous 4 weeks. 9. Treatment of target lesion with laser or atherectomy devices. 10. Dialysis dependency. 11. Manifest hyperthyreosis. 12. Known allergy against contrast agent that cannot be adequately controlled by usual premedication. 13. Known heparin intolerance. 14. Known paclitaxel intolerance. Angiographic: 15. Target lesion extends into the popliteal artery. 16. Symptomatic untreated inflow lesion > 50% in ipsilateral iliac arteries. Pretreatment of iliac stenoses is possible. 17. SFA lesions > 50% stenosis proximal and/or distal to the target lesion that require treatment. 18. Target lesion extends beyond the stent margins. ||mesh_term:Vascular Diseases,Peripheral Vascular Diseases,Peripheral Arterial Disease,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT00471289||dmc_oversight:No||primary_outcome_count:1||primary_outcome_list:The primary endpoint will be primary patency of the treated site at 6 months. Primary patency is defined as <50% loss of luminal diameter at the treated site on CT arteriography (CTA) without re-intervention in the interim.|6 months|,||||secondary_outcome_count:13||secondary_outcome_list:Primary patency of the treated sites at 3, 6 and 12 months after intervention assessed by duplex sonography (binary patency, <50% stenosis defined as PSV ratio <2.0)|3, 6, 12 months|,Clinical evaluation of the treated ischemic leg at 3, 6 and 12 months.|3, 6, 12 months|,Major amputation (at or above the ankle) of the trial leg at 3, 6 and 12 months|3, 6, 12 months|,Minor amputation (below the ankle excluding the toes) of the trial leg at 3, 6 and 12 months.|3, 6, 12 months|,Infrapopliteal surgical bypass of the trial leg at 3, 6 and 12 months.|3, 6, 12 months|,Infrapopliteal endovascular re-intervention of the trial leg at 3, 6 and 12 months.|3, 6, 12 months|,Peri-procedural (within 30 days) complications.|30 days|,Death.|3, 6, 12 months|,Clinical assessment primarily by Rutherford score for peripheral arterial disease|2, 3, 4 and 5 years after treatment|,Target lesion patency by means of duplex sonography|2, 3, 4 and 5 years after treatment|,Major amputation (at or above the ankle) of treated limb|yearly up to 10 years after treatment|,Minor amputation (below the ankle excluding the toes) of the trial leg at 3, 6 and 12 months.|yearly up to 10 years after treatment|,Endovascular or surgical re-intervention of target lesion|3, 6, 12 months, 2,3,4 and 5 years after inclusion|,||||arm_group_count:2||arm_group_list:1|PTA with primary placement of Drug (paclitaxel) Eluting Stent,2|PTA,||||inclusion_exclusion: Inclusion Criteria: - Written informed consent - Age > 18 years - If female patient with child bearing potential, patient may not be pregnant at the study entry and must utilize reliable birth control for the duration of her participation into the study - Patient is willing and able to comply with the specified follow-up evaluation - Critical Limb Ischaemia, this is Fontaine stage III (ischaemic rest pain) and IV (ischaemic ulcers or gangrene) or Rutherford category 4 (ischaemic rest pain), 5 (minor tissue loss) or 6 (major tissue loss) - Stenotic (>50% luminal loss) or occluded infrapopliteal artery, including the tibiofibular trunk, the anterior tibial artery, the posterior tibial artery and the peroneal artery, with a lesion length ≤ 60 mm - Artery to be treated with a diameter more tham or equal to 2mm and less than or equal to 4mm - Patent common iliac, external iliac, superficial femoral and popliteal artery on the ipsilateral side prior to randomisation, possibly after treatment during the same session - At least one patent crural (anterior tibial, posterior tibial or peroneal) artery with expected unobstructed runoff to ankle level after treatment Exclusion Criteria: - Acute limb ischaemia - Subacute limb ischaemia which requires thrombolysis as first treatment modality - Active bleeding or bleeding diathesis - Recent (less than 3 months) hemorrhagic stroke or other any other CNS abnormality with increased risk of haemorrhage, such as intracranial neoplasm, arteriovenous malformation, intracranial aneurysm or aneurysm repair - Gastrointestinal or genitourinary bleeding of clinical significance within the previous 6 weeks before treatment - Aneurysm in common femoral, superficial femoral or popliteal artery on the ipsilateral side - Revascularization involving the same limb within 30 days prior to the index procedure or planned revascularization of the same limb within 30 days of the index procedure - Previous implanted stent at the index site - Life expectancy of less than 6 months or other factors making clinical follow-up difficult - Known allergy to acetylsalicylic acid (aspirin), clopidogrel, heparin or paclitaxel - Known allergy to contrast media - Known heparin induced thrombocytopenia (HIT type 2) - Patient unable or unwilling to tolerate anticoagulant, anti-platelet therapy or contrast media - Creatinine clearance < 20 ml/min (as derived from Cockcroft-Gault or MDRD formula)unless patient is on hemodialysis - Aneurysm in common femoral, superficial femoral or popliteal artery on the ipsilateral side - Severely calcified lesions with expected resistance to stenting - Poor inflow due to ipsilateral stenoses or occlusions of the iliac or femoropopliteal arteries that cannot be treated during the same session - Significant vessel tortuosity or other parameters prohibiting access to the lesions and/or delivery of the stent - Patients without (expected) distal runoff to the index site - Previous implanted stent at the index site ||mesh_term:Vascular Diseases,Peripheral Vascular Diseases,Peripheral Arterial Disease,Ischemia,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT01083394||dmc_oversight:No||primary_outcome_count:1||primary_outcome_list:Percentage diameter stenosis|6 months|,||||secondary_outcome_count:5||secondary_outcome_list:All-cause mortality|6 and 24 months|,Major adverse peripheral events (MAPE) defined as acute thrombosis of SFA or ipsilateral amputation or revascularization (PTA or bypass surgery)|6 Months|,Time to onset of any of MAPE|3-24 months|,Binary restenosis rate|6 months|,Percentage diameter stenosis in duplex ultrasound|6 and 24 months|,||||arm_group_count:2||arm_group_list:conventional PTA|In stent restenosis is treated with PTA using a conventional balloon.,PTA with PEB|In stent restenosis is treated with PTA using a paclitaxel eluting balloon.,||||inclusion_exclusion: Inclusion Criteria: - Symptomatic ≥ 70% in-stent restenosis of the AFS, (Rutherford stage 2-6) - Written, informed consent by the patient or her/his legally-authorized representative for participation in the study Exclusion Criteria: - Acute ischemia and/or acute thrombosis of the SFA - Untreated ipsilateral iliac artery stenosis >70% - Not at least one vessel run-off - Popliteal involvement with stenosis >70% - Severe renal insufficiency (GFR <30 ml/min/m2) - Malignancies or other comorbid conditions (for example severe liver, renal and pancreatic disease) with life expectancy less than 12 months or that may result in protocol non-compliance. - Pregnancy (present, suspected or planned) or positive pregnancy test. - Previous enrollment in this trial. - Patient's inability to fully cooperate with the study protocol. ||mesh_term:Vascular Diseases,Peripheral Vascular Diseases,Peripheral Arterial Disease,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT03206762||dmc_oversight:Yes||primary_outcome_count:2||primary_outcome_list:Target Lesion Revascularization|1 year|,Major Adverse Events|30 Days|,||||secondary_outcome_count:0||secondary_outcome_list:||||arm_group_count:2||arm_group_list:Jetstream Atherectomy+Ranger DCB or Medtronic IN.PACT DCB|Jetstream Atherectomy used in conjunction with the Ranger DCB or Medtronic IN.PACT DCB,POBA+DCB (Ranger or IN.PACT)|POBA and then DCB treatment (Ranger or IN.PACT),||||inclusion_exclusion: Inclusion Criteria: Subject must meet all of the following general inclusion criteria. 1. Has a Rutherford Clinical Category of 2 - 4. 2. Is willing and capable of complying with all follow-up evaluations at the specified times (including an angiogram at the 1-year follow-up visit). 3. Is ≥ 18 years old. 4. Is able and willing to provide written informed consent prior to study specific procedures. Angiographic Inclusion Criteria: Subject must meet all of the following angiographic inclusion criteria. Unless otherwise specified, the Investigator performing the procedure bases all angiographic inclusion criteria on visual determination at the time of the procedure. 1. Has evidence at the target lesion of ≥ 70% de novo stenosis of a. ≥ 10 cm length, or b. any chronic total occlusion (> 1 month by history or known by conventional or CT angiography or arterial duplex ultrasound) in the SFA (at least 1 cm from the bifurcation of the profunda) and/or popliteal artery, or 3. at least grade 2 or higher calcification as defined by the peripheral arterial calcium scoring system (PACCS)26 2. Has evidence of at least one runoff vessel to the ankle/foot of the limb to be treated that does not have significant (< 70%) stenosis during the index procedure. 3. Has a reference vessel diameter of 4 - 7 mm. 4. Has a target lesion an exchangeable guidewire can cross via the true lumen (without using a re-entry device or a subintimal approach). General Exclusion Criteria: The subject must not meet any of the following general exclusion criteria. 1. Has one or more of the contraindications listed in the JetStream or Ranger IFUs. 2. Has a contraindication or known untreated allergy to antiplatelet therapy, anticoagulants, thrombolytic drugs or any other drug anticipated to be used (that cannot be reasonably substituted). 3. Is expected to require cilostazol (Pletal) during the one-year follow-up period. 4. Has a hypersensitivity to contrast material that cannot be adequately pretreated. 5. Has known hypersensitivity to treatment device materials including paclitaxel or nitinol. 6. Has known uncontrollable hypercoagulable condition, or refuses blood transfusion. 7. Has life expectancy of less than 24 months. 8. Is pregnant, of childbearing potential not taking adequate contraceptive measures, or nursing. 9. Has surgical or endovascular procedure of the target vessel within 30 days prior to the index procedure. 10. Has any planned surgical intervention (requiring hospitalization) or endovascular procedure within 30 days after the index procedure. 11. Is currently participating in an investigational drug or another device study that may clinically interfere with the study outcomes. 12. Has any co-morbid condition that in the judgment of the physician precludes safe percutaneous intervention. 13. Has had a previous peripheral bypass affecting the target vessel (allowable for physician to pass through bypass graft in aorta-iliac region to get to the target lesion). 14. Has chronic renal insufficiency (eGFR < 30 ml/min or creatinine ≥ 2.5 including dialysis patients). 15. Has planned laser, cryo, TurboHawk or any other treatment except study treatment within 30 days after the index procedure. 16. Has had superficial thrombophlebitis or deep venous thrombus within 30 days prior to index procedure. 17. Has had a stroke within 3 months prior to index procedure. 18. Has had a myocardial infarction within 1 month prior to index hospitalization 19. Has history of significant gastrointestinal bleeding in the past 2 months prior to index procedure, or any history of hemorrhagic diathesis. 20. Has a known or suspected systemic infection at the time of the index procedure. 21. Patients with ipsilateral Iliac and CFA disease are allowed in the study but these lesions have to be treated successfully first (<30% residual) before patient can be enrolled. Treatment as per investigator's preference. 22. Aneurysm located in the target vessel or aneurysmal vessel Angiographic Exclusion Criteria: The subject must not meet any of the following angiographic exclusion criteria. The Investigator performing the procedure bases all angiographic exclusion criteria on visual determination at the time of the procedure. 1. Has < 70% stenosis prior to treatment of the target lesion. 2. Has in-stent restenosis of the target lesion. 3. Has an acute intraluminal thrombus within the target lesion. 4. Has an aneurysmal target vessel 5. Patient has already been enrolled in the study or any other study that by the investigator judgment may interfere with the outcome of this trial 6. Has two or more lesions that require treatment in the target vessel. Lesions have to be separated by > 5 cm in order to be considered different lesions. Only one lesion per target vessel can be enrolled during the index procedure 7. Has disease that precludes safe advancement of the JS device to the target lesion. 8. P3 segments of the popliteal vessel. ||mesh_term:Vascular Diseases,Peripheral Vascular Diseases,Peripheral Arterial Disease,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT01952457||dmc_oversight:n/a||primary_outcome_count:1||primary_outcome_list:Primary patency at 12 months|12 months|,||||secondary_outcome_count:1||secondary_outcome_list:Proportion of subjects who experience device malfunction or serious device-related or serious adverse events within 30 days post-procedure|30 days|,||||arm_group_count:2||arm_group_list:Zilver PTX|Patients in the Zilver PTX arm have to be treated by placement of the Zilver PTX drug-eluting stent (Cook), according to standard procedures based on the Instructions for Use. The only pre-treatment allowed prior to placement of the Zilver PTX drug-eluting stent (Cook) is standard PTA. Diameter measurements must be performed of the healthy vessel proximal and distal to the previously stented area. Diameter selection of the Zilver PTX drug-eluting stent (Cook) should result in minimal oversizing. The target lesion needs to be completely covered by using as few stents possible. Post-dilatation can be performed according to the Instructions of Use.,prosthetic bypass|Patients in the bypass arm have to be treated with a prosthetic bypass graft according to the institution's standard of care and the Instructions for Use of the prosthetic bypass graft.,||||inclusion_exclusion: Inclusion Criteria: - Patient presenting with lifestyle-limiting claudication, rest pain or minor tissue loss (Rutherford classification from 2 to 5) - Patient is willing to comply with specified follow-up evaluations at the specified times - Patient is >18 years old - Patient understands the nature of the procedure and provides written informed consent, prior to enrollment in the study - Patient has a projected life-expectancy of at least 24 months - Noninvasive lower extremity arterial studies (resting or exercise) demonstrate ankle-brachial index ≤0.8 - Patient is eligible for treatment with the Zilver PTX paclitaxel-eluting stent (Cook) or with surgical bypass placement - Male, infertile female, or female of child bearing potential practicing an acceptable method of birth control with a negative pregnancy test within 7 days prior to study procedure - Stenotic or occlusive de novo lesion located in the femoropopliteal arteries, suitable for endovascular therapy and for bypass surgery - Total target lesion length is at least 15cm - Minimum of 1.0cm of healthy vessel (non-stenotic) both proximal and distal to the treatment area - P2 and P3 are patent and there is angiographic evidence of at least one vessel-runoff to the foot, that does not require intervention (<50% stenotic) - Target vessel diameter visually estimated to be >4mm and <9mm at the proximal and distal treatment segments within the SFA Exclusion Criteria: - Untreated flow-limiting aortoiliac stenotic disease - Any previous surgery and/or endovascular procedure in the target vessel - Severe ipsilateral common/deep femoral disease requiring surgical reintervention - Perioperative unsuccessful ipsilateral percutaneous vascular procedure to treat inflow disease just prior to enrollment - Femoral or popliteal aneurysm located at the target vessel - Non-atherosclerotic disease resulting in occlusion (e.g. embolism, Buerger's disease, vasculitis) - No patent tibial arteries (>50% stenosis) - Prior ipsilateral femoral artery bypass - Severe medical comorbidities (untreated CAD/CHF, severe COPD, metastatic malignancy, dementia, etc.) or other medical condition that would preclude compliance with the study protocol or 2-year life expectancy - Serum creatinine >2.5mg/dL within 45 prior to study procedure unless the subject is currently on dialysis - Major distal amputation (above the transmetatarsal) in the study or non-study limb - Any previously known coagulation disorder, including hypercoagulability - Contraindication to anticoagulation or antiplatelet therapy - Known allergies to stent or bypass graft components (nickel-titanium, Dacron, ePTFE, etc.) - Known allergy to contrast media that cannot be adequately pre-medicated prior to the study procedure - Currently participating in another clinical research trial - Angiographic evidence of intra-arterial thrombus or atheroembolism from inflow treatment - Any planned surgical intervention/procedure within 30 days of the study procedure - Target lesion access in the Zilver PTX stent arm not performed by transfemoral approach ||mesh_term:Vascular Diseases,Peripheral Vascular Diseases,Peripheral Arterial Disease,||||
NCTID:NCT00986752||dmc_oversight:No||primary_outcome_count:1||primary_outcome_list:Percentage diameter stenosis|6 months|,||||secondary_outcome_count:6||secondary_outcome_list:All-cause mortality|6 and 24 months|,Major adverse peripheral events (MAPE) defined as acute thrombosis of SFA or ipsilateral amputation or revascularization (PTA or bypass surgery)|6 months|,Time to onset of any of MAPE.|3-24 months|,Binary restenosis rate|6 months|,Percentage diameter stenosis in duplex ultrasound|6 and 24 months|,Change from baseline in functional status and health related quality of life (Walking Impairment Questionaire)|3 and 6 months|,||||arm_group_count:3||arm_group_list:Stenting|Due to randomization one nitinol stent will be implanted after dilation with a conventional balloon.,Stenting after PEB|Due to randomization one nitinol stent will be implanted after dilation with a Paclitaxel eluting balloon.,Atherectomy|The third randomization arm is Atherectomy.,||||inclusion_exclusion: Inclusion Criteria: - Symptomatic ≥ 70% stenosis of the SFA (Rutherford stage 2-6) - Written informed consent Exclusion Criteria: - Acute ischemia and/or acute thrombosis of the SFA - Untreated ipsilateral iliac artery stenosis >70% - Previous stenting of the SFA - Popliteal stenosis >70% - Severe renal insufficiency ||mesh_term:Vascular Diseases,Peripheral Arterial Disease,Peripheral Vascular Diseases,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT01298947||dmc_oversight:Yes||primary_outcome_count:1||primary_outcome_list:Target Lesion Percent Stenosis|at 1 Year|,||||secondary_outcome_count:1||secondary_outcome_list:Procedural Success|at 1 year|,||||arm_group_count:2||arm_group_list:Laser atherectomy and drug-coated balloon|Laser atherectomy and Paclitaxel-coated balloon angioplasty in treatment of instent lesions of femoropopliteal arteries,Drug eluting Ballon PTA|Paclitaxel-coated balloon angioplasty,||||inclusion_exclusion: Inclusion Criteria: - Subject must meet all of the following general inclusion criteria. 1. Has a Rutherford Clinical Category Score of 1 - 5. 2. Is willing and capable of complying with all follow-up evaluations at the specified times. 3. Is ≥ 18 years old. 4. Provides written informed consent prior to study specific procedures. Exclusion Criteria: - The subject must not meet any of the following general exclusion criteria. 1. Has contraindications listed in any study device IFUs. 2. Has a contraindication or known untreated allergy to antiplatelet therapy, anticoagulants, thrombolytic drugs or any other drug anticipated to be used. 3. Has a hypersensitivity to contrast material that cannot be adequately pretreated. 4. Has known hypersensitivity to treatment device materials including Paclitaxel. Has known uncontrollable hypercoagulable condition, or refuses blood transfusion. 6. Has life expectancy of less than 12 months. 7. Is pregnant, of childbearing potential not taking adequate contraceptives, or nursing. 8. Has surgical or endovascular procedure of the target vessel within 14 days prior to the index procedure. 9. Has any planned surgical intervention (requiring hospitalization) or endovascular procedure within 30 days after the index procedure. 10. Is currently participating in an investigational drug or another device study that may clinically interfere with the study outcomes. 11. Any co-morbid condition that in the judgment of the physician precludes safe percutaneous intervention. 12. Has had a previous peripheral bypass affecting the target vessel. 13. Has chronic renal insufficiency with creatinine > 2.5 mg/L (except patients under chronic renal replacement therapy). 14. Is unable or unwilling to receive dual anti-platelet therapy. 15. Equipment is unavailable to fulfill study treatments. ||mesh_term:Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT03625830||dmc_oversight:Yes||primary_outcome_count:1||primary_outcome_list:Late lumen loss in segment section at M9|9 months|,||||secondary_outcome_count:0||secondary_outcome_list:||||arm_group_count:2||arm_group_list:Paclitaxel-eluting PTCA-Balloon Catheter(SeQuent® Please)|,Rapid exchange PTCA Balloon Catheter (SeQuent® Neo)|,||||inclusion_exclusion: Inclusion Criteria: Criteria related to subjects - Patients with stable angina pectoris, or unstable angina pectoris, or old myocardial infarction, or documented silent ischemia; - At the age of 18-80; - Women of childbearing potential may not be pregnant nor have the desire to becoming pregnant during the study. Hence, patients will be advised to use an adequate birth control method up to (including) the end of follow-up; - Patients must agree to undergo the 9-month angiographic follow-up and the clinical follow-up at 30 days, 6 months, 9 months and 12 months after operation; - Patients who are psychologically and linguistically able to understand the purpose of the study, and show sufficient compliance with the study protocol; - Patients who have expressed acknowledgment of the risks and benefits described in the informed consent document by providing informed consent; Criteria related to lesions - The target lesion is primary, in situ coronary artery lesion located in 1 or 2 different coronary arteries, with no more than 1 target lesion in each coronary artery; - The reference vessel diameter is within the range of 2.0 mm - 2.75 mm; (visually measured) - Interventional treatment should be conducted on lesion(s) of non-target vessel(s) in advance (which must be concurrent treatment), and management of random and target lesions should be performed after successful treatment of non-target lesion(s); - The pre-operative diameter stenosis must be either ≥ 70% or ≥ 50% with ischemia; (visually measured) - Each target lesion should be treated with only one SeQuent® Please or SeQuent® Neo. Exclusion Criteria: Criteria related to subjects - Patients with recent myocardial infarction (within one week), or patients with myocardial infarction over one week but whose troponin level has not recovered to normal; - Patients with severe congestive heart failure or NYHA class IV heart failure; - Patients with severe valvular heart disease; - Women who are pregnant or lactating; - Patients with remaining life expectancy of no more than 1 year or with factors causing difficulty in clinical follow-up; - Patients who had cerebral stroke within 6 months before operation; - Patients who are currently involved in any other clinical trial; - Patients with presence or history of severe hepatic failure and therefore are not eligible for angiography; - Patients with presence or history of severe renal failure (GFR < 30 ml/min) and therefore are not eligible for angiography; - Patients who have received heart transplant; - Patients with cardiogenic shock; - Patients with left ventricular ejection fraction less than 30%; - Patients suffering from coronary artery spasm without significant stenosis; - Patients considered as ineligible by the investigator for other reasons; Criteria related to lesions - Evidence of extensive thrombosis in target vessel before intervention; - Percutaneous coronary intervention of venous graft; - Chronic total occlusion (TIMI 0 flow before operation); - Left main disease and/or triple vessel disease needed to be treated, bifurcation lesion with branch vessel diameter ≥ 2.5 mm, and bypass graft lesion; - There is non-target lesion(s) in the proximal large vessel and target lesion(s) in the distal small vessel of the same vessel (eligible if there is non-target lesion(s) in proximal large vessel and a target lesion in the bifurcated small vessel); - The target vessel is distorted or has calcified lesion(s); - Lesion within 5 mm away from the coronary artery ostium; - Lesion that cannot be treated with PTCA or other interventional techniques; - After pre-dilation of target lesion, the residual stenosis is ≥ 30% or TIMI flow is < 3, and/or type C or above dissection appears; Exclusion criteria related to concomitant medication - Patients prone to bleeding and contraindicated for anticoagulant or antiplatelet drugs; - Patients who are intolerant to aspirin and/or clopidogrel or have a history of neutrophilopenia or thrombocytopenia, or patients with severe hepatic insufficiency and contraindicated for clopidogrel. - Patients who are known to be intolerant or allergic to heparin, contrast agent, paclitaxel, iopromide, rapamycin, polylactic acid - glycolic acid polymer, stainless steel; - Patients with a history of leukopenia (leukocyte count < 3 × 109/L for more than 3 days), neutrophilopenia (ANC < 1,000 neutrophils/mm3 for more than 3 days), or thrombocytopenia (< 100,000 platelets/mm3); - Patients with a history of peptic ulcer or gastrointestinal bleeding in the past 6 months ||mesh_term:Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT02891005||dmc_oversight:n/a||primary_outcome_count:1||primary_outcome_list:Late lumen loss|at 9 months|,||||secondary_outcome_count:4||secondary_outcome_list:Incidence of Device Success|at 9 months|,Incidence of Operation Success|at 9 months|,Incidence of the target lesion in-segment restenosis (%) at 9mm|at 9 months|,Clinical-driven target lesion revascularization (TLR) and target vessel revascularization (TVR)|at 9 months|,||||arm_group_count:2||arm_group_list:paclitaxel controlled release balloon catheter|Patients treated with paclitaxel controlled release balloon catheter,common balloon catheter|Patients treated with common balloon catheter,||||inclusion_exclusion: Inclusion Criteria: Subject need 18 to 80 years of aged male or non-pregnant women; Subject has stable anina pectoris, or unstable anina pectoris, or old myocardial infarction patients, or ischemia with evidence but without symptom; Subject has a life expectancy of more than 2 years; Lesion vessel reference diameter is less than or equal to 2.5mm, target lesion length is less than or equal to 40mm; Target lesion stenosis is equal or greater than 70% or 50% and with ischemia; Single or two coronary small vessel lesions in situ; Subject can understand the trail purpose, sign informed consent voluntarily, agree to accept clinical telephone follow-up and angiographic follow-up at 9 months; Target lesion can be pre-expanded successfully (Guide wire can get through lesion, balloon pre-expand the remnant stenosis of vessel lumen is less or equal to 50%, without current limiting interlayer and thrombosis). Exclusion Criteria: Patient that in the opinion of the investigator is not appropriate for this trail; Pregnancy and lactation female patients; Patient has a life expectancy of less than 2 years; Severe congestive heart failure or NYHA IV heart failure; Patient who have bleeding constitution, cannot use antithrombotic and antiplatelet drugs; Patient that happened acute myocardial infarction within a week; Patient who happened stroke within six months; Patient who with severe renal failure (GFR≤30ml/Min); Patient has received heart transplantation; Patient who cannot tolerate aspirin and / or P2Y12 receptor inhibitor drugs; Patient who has allergy to paclitaxel, PLGA or contrast agent; Peptic ulcer or gastrointestinal bleeding within the prior 6 months; Patients who are participating in another drug or device clinical trail, which have not completed the primary endpoint follow- up period. Angiographic relevant： Merge three or more coronary small vessel lesions; Target vessel with extensive thrombosis evidence; Restenosis of vein graft after bypass surgery; Target lesion proximal exist seriously distorted or severe calcified lesion. ||mesh_term:Constriction, Pathologic,Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT00766129||dmc_oversight:No||primary_outcome_count:1||primary_outcome_list:Neointima hyperplasia volume by Intravascular Ultrasound|9 months|,||||secondary_outcome_count:5||secondary_outcome_list:All cause mortality|5 years|,Cardiovascular mortality|5 years|,Stent thrombosis|5 years|,Target lesion revascularization|5 years|,Angiographic late loss|9 months|,||||arm_group_count:2||arm_group_list:T|Implantation of Taxus stent into saphenous vein graft,C|Implantation of Luc-Chopin stent into saphenous vein graft,||||inclusion_exclusion: Inclusion Criteria: 1. Atherosclerotic lesion in saphenous vein grafts causing angiographic stenosis ≥70% 2. Stable coronary artery disease or non ST segment elevation acute coronary syndrome 3. Reference segment diameter in range of 2.5-4.5mm Exclusion Criteria: 1. Cardiogenic shock 2. Contraindications to prolonged dual antiplatelet therapy 3. Female of child birth potential unless on effective contraception 4. Other medical condition that may limit survival ||mesh_term:||||
NCTID:NCT03149913||dmc_oversight:n/a||primary_outcome_count:1||primary_outcome_list:Occlusion rate of the target lesion at 6 months|6 +/- 1 months|,||||secondary_outcome_count:1||secondary_outcome_list:target lesion revascularization|3, 6, 12 and 24 months|,||||arm_group_count:2||arm_group_list:Drug coated balloon|SeQuentPlease OTW paclitaxel coated balloon catheter,uncoated PTA balloon catheter|Standard of care uncoated BTK balloon catheter,||||inclusion_exclusion: Inclusion Criteria: - >18 years of age - Chronic stenotic or occlusive atherosclerotic disease of the infrapopliteal arteries - Rutherford 2-5 patients - Patients with ≤ 2 BTK lesions (≥ 70% diameter stenosis) - Lesion length limited to 5-25 cm Exclusion Criteria: - Planned or foreseeable amputation - Previous amputation at the index limb - Index vessel with no run-off to the foot distal to the index lesion - Prior treatment of the index lesion with a drug coated balloon - In-stent restenosis - Life expectancy <1 year - Known creatinine >1.4 mg% if patient is not on dialysis - Acute thrombus in the index limb - Aneurysm in the index leg - Known hypersensitivity or contraindication to aspirin, heparin, clopidogrel, abciximab, paclitaxel - Patients with concomitant medical illnesses that require cytostatic or radiation therapy ||mesh_term:Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT03332264||dmc_oversight:No||primary_outcome_count:1||primary_outcome_list:Percent diameter stenosis at 1 year post intervention in successfully treated patients|12 +/- 2 months|,||||secondary_outcome_count:3||secondary_outcome_list:Late Lumen Loss|12 months|,Binary restenosis|6,12, 24, 36 months|,Target lesion revascularization|6, 12, 24, 36 months|,||||arm_group_count:3||arm_group_list:Drug coated balloon catheter|PTA with paclitaxel coated "SeQuent Please OTW",Drug coated stent|PTA with paclitaxel coated "Eluvia Vascular Stent System",Uncoated stent|PTA with bare nitinol stent (as commonly used in site),||||inclusion_exclusion: Inclusion Criteria: - PAOD and Rutherford classes 2 - 4 (pain-free walking distance <500 m) - eligible for peripheral revascularization by means of PTA - peripheral lesions in the superficial femoral artery (SFA) and / or the PI-segment of the popliteal artery (A.pop.) - minimum diameter stenosis of ≥70% - treatment length at least 15 cm (lesion length at least 13 cm) - maximum of lesions to be treated should be 2 (all treated lesions should be treated within the randomization to the study group, i.e. either coated balloon catheters or coated stents or bare nitinol stents); in case of two lesions matching the eligibility criteria, the one presenting the worst attributes (length and stenosis degree) should be chosen as target lesion - long diffuse stenosis with or without occlusions may only be divided in separate lesions if non-stenotic (i.e. <50% stenosis) segments in between the lesions extent to >2 cm, otherwise vessel segments will be treated as a single extended lesion - eligible for an operative vascular intervention in case of complications during the PTA Exclusion Criteria: - Rutherford class 1,5 or 6 - more than two stenotic lesions in the target vessel requiring treatment - inflow lesion (proximal to the study lesion) with flow limitation not being successfully treated prior to the study lesion - in-stent restenosis of the study lesion - strongly calcified lesions with circumferential presence of calcifications and a lesion calcification length of >4 cm - reference vessel diameter <4 mm and >6 mm - guide wire could not be successfully advanced across the lesion - lesions below the knee requiring treatment - target lesion is located in the PII-segment of the popliteal artery (A.pop.) or within a bypass graft - acute thrombosis of the study lesion requiring lysis or thrombectomy prior to the treatment of the study lesion - potential loss of leg due to critical or acute ischemia - no patent distal run-off vessel - medical reason against double anti-platelet therapy in anti-coagulated patient, e.g., receiving coumarine or conditions which prevent the intake of the double anti-platelet therapy for two months - female patient who is pregnant or lactating - under 18 years of age - patients under administrative or judicial custody (§20 Act on medical Devices, Germany) - expected life span of less than 24 months ||mesh_term:Paclitaxel,Albumin-Bound Paclitaxel,||||
NCTID:NCT01970579||dmc_oversight:Yes||primary_outcome_count:1||primary_outcome_list:Late Lumen Loss|6 months|,||||secondary_outcome_count:0||secondary_outcome_list:||||arm_group_count:2||arm_group_list:Paclitaxel coated balloon|,uncoated PTA catheter|,||||inclusion_exclusion: Inclusion Criteria: - Willingness to treat the target lesion according to the DCB only concept - Patients in Rutherford classes 2 through 4 (corresponding to Fontaine stage IIb to III) - Patients eligible for peripheral revascularization by means of PTA - Patients must be ≥ 18 years of age - Patients who are mentally and linguistically able to understand the aim of the study and to show sufficient compliance in following the study protocol - Patients must agree to undergo the 6-month angiographic and clinical follow-up - Patients must agree to undergo the 1 and 2 year clinical follow-up - Patient is able to verbally acknowledge an understanding of the associated risks, benefits, and treatment alternatives to therapeutic options of this trial. The patients, by providing their informed consent, agree to these risks and benefits as stated in the patient informed consent document. - Peripheral lesions in the native SFA or popliteal artery with reference vessel diameters between ≥ 4.0 and ≤ 7.0 mm, lesions lengths ≥ 4 cm and ≤ 27 cm as angiographically documented - Diameter stenosis pre-procedure must be ≥ 70% - Target lesion in the SFA or popliteal artery (first two proximal segments)*. * as far as applicable distance of the target lesion to a previously implanted stent should be about 1cm - Vessels must have adequate runoff with at least one vessel to the foot. - Treatment of max. two lesions is permitted. Exclusion Criteria: - Patients with Rutherford class 5 or 6 - Women who are known or suspected to be pregnant. Hence, patients will be advised to use an adequate birth control method up to and including the 6-month follow-up. - Patients with an expected life span of less than 24 months - Patients with bleeding diathesis in whom anticoagulation or anti-platelet medication is contraindicated - Patients who had a cerebral stroke < 6 months prior to the procedure - Patients with unstable angina pectoris - Patients with acute myocardial infarction within the past 2 weeks - Patient participates in other clinical trials involving any investigational device or drug that interfere with the effects to be studied in this trial. - Interventional treatment at the contralateral leg within 2 weeks prior to or after the study intervention - Untreated hyperthyroidism - Patient has presence or history of severe renal failure (GFR < 30ml/min) and is therefore not eligible for angiography. - Post transplantation of any organ or immune suppressive medication - Other disease to jeopardize follow-up (e.g. malignoma) - Addiction to any drug or to alcohol (WHO definition) - Patients with clinically significant aneurysmal disease of the popliteal, femoral or iliac artery and patients with history of clinically significant abdominal aortic aneurysm - Patients with any type of surgical/interventional procedures within 4 weeks prior to or planned after study intervention (if those may interfere with the peripheral study intervention and/or patient's ability to perform the follow up examinations) - Conditions which prevent the intake of the double anti-platelet therapy for two months - Patients with contraindication for drug-eluting balloon angioplasty given in the instruction for use - Patients under administrative or judicial custody (§20 Act on Medical Devices, Germany) - Strongly calcified lesions with circumferential presence of calcifications and a lesion length of > 4 cm - Chronic total occlusions longer than 10 cm - Lesion below the knee requiring treatment - Target lesion within a bypass graft - In-stent restenosis - Lesions treated with DCB - Concomitant use of atherectomy, cryoplasty or laser therapy - Inflow lesion (proximal to the study lesion) with flow limitation not being successfully treated prior to the study lesion ||mesh_term:Paclitaxel,Albumin-Bound Paclitaxel,||||
